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General Introduction 
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Posttraumatic Stress Disorder (PTSD)
After exposure to actual or threatened death, serious injury or sexual violence, some people 
may develop a posttraumatic stress disorder (PTSD). The life time prevalence of PTSD is 
estimated at 7-10 % (de Vries & Olff, 2009; Kessler, Petukhova, Sampson, Zaslavsky, & 
Wittchen, 2012). PTSD is characterized by recurrent intrusions of the traumatic event(s), for 
instance in involuntary, intrusive distressing memories, dissociative reactions (e.g. flashbacks) 
or distressing dreams. Furthermore, PTSD is marked by persistent avoidance of thoughts, 
emotions and feelings closely associated with the traumatic events and external reminders 
(e.g. people and places) that prompt these thoughts, emotions and feelings. Patients suffering 
from PTSD also experience negative alterations in mood and cognitions associated with the 
traumatic event. By example, they blame themselves for causing the traumatic event, hold 
exaggerated negative beliefs about themselves, others or the world, or experience persistent 
fear or anger. Lastly, PTSD is characterized by alterations in arousal and reactivity in relation 
with the traumatic event, for instance shown by hypervigilance, exaggerated startle response 
or sleep disturbance (American Psychiatric Association, 2013).
 PTSD is a highly burdening disorder for both the individual and society (Kessler, 2000). 
What is more, 80-90% of PTSD patients suffer from at least one co-morbid disorder, such as 
depression, anxiety disorder, substance abuse or personality disorder (van Minnen, Zoellner, 
Harned, & Mills, 2015). Some have even proposed that PTSD mediates the relationship 
between negative life events and these co-morbid disorders (Mueser, Rosenberg, Goodman, & 
Trumbetta, 2002). All in all, PTSD is a prevalent and severely disturbing disorder and effective 
treatment is of paramount importance. 
Prolonged Exposure (PE) therapy for PTSD
In guidelines across the world (Comittee on Treatment of Posttraumatic Stress Disorder & Board 
on Population Health and Public Health Practice, 2008; NICE, 2005; Van Balkom et al., 2013), 
exposure therapy is considered first-line treatment for PTSD. Prolonged exposure (PE) therapy, 
as originally developed by Foa and Rothbaum (1998) encompasses both imaginal exposure and 
exposure in vivo. In imaginal exposure the patient recounts the traumatic memory aloud, in the 
present tense as if the trauma is happening in the here and now. The therapist encourages the 
patient to recall the memory as vivid and detailed as possible. After repeating this for a couple 
of times, the patient is prompted to focus on the most difficult moments in the memories. 
The recounts are audiorecorded, and the patient listens to this audio-recording several times 
in-between sessions. Exposure in vivo encompasses exposure to safe, but anxiety provoking 
stimuli in real-life. For instance, visiting the place of the traumatic incident. 
 Extinction learning is thought to be one of the mechanisms of action of PE. From a 
Pavlovian conditioning model, fear is first acquired via the pairing of a neutral stimulus (e.g. a 
motor cycle helmet, CS) with an aversive stimulus (e.g. a sexual assault by someone wearing a 
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motor cycle helmet, US). Once fear is acquired, the previously innocuous stimulus (CS) alone 
elicits fear. Repeated (prolonged) exposure to the CS without occurrence of the US leads to 
the loss of fear reactions. The learning of this new contingency (CS-no US) is referred to as 
extinction learning (Bouton, 1993). In PE, fear extinction is aimed at both by exposure in vivo to 
trauma related stimuli (CS) and imaginal exposure to traumatic memories (as representations 
of the CS).
            A       B
Figure 1. A) Graphical representation of experimental fear acquisition and extinction. A neutral stimulus (CS; 
presentation of a rectangular shape) is paired with an aversive stimulus (US; electric shock). After several pairings, 
presentation of the CS alone, elicits fear. During the extinction phase, the CS is repeatedly presented in absence 
of the US, leading to a loss of fear reactions. B) In exposure therapy, a PTSD patient is exposed to a motor cycle 
helmet (CS) that reminds her of the sexual assault (US). After several exposures, the motor cycle helmet (CS) does 
not longer elicit fear. Note the similarity between the extinction and exposure curves. 
Efficacy of prolonged exposure therapy for PTSD
The efficacy and (cost) effectiveness of PE therapy for PTSD is well established (Bradley, 
Greene, Russ, Dutra, & Westen, 2005; Le, Doctor, Zoellner, & Feeny, 2014; Powers, Halpern, 
Ferenschak, Gillihan, & Foa, 2010; Watts et al., 2013). The first studies examined its efficacy 
for single-event trauma survivors (for instance, Foa, Dancu, et al., 1999), but since then many 
more studies in different trauma survivors and treatment settings have verified its first-line 
status (e.g. Eftekhari et al., 2013; Foa et al., 2005). Although the efficacy of PE therapy for PTSD 
is beyond doubt, not all PTSD patients profit from treatment. 
 First, despite its status as first-line treatment for PTSD, not all PTSD patients receive PE (or 
any other evidence based treatment; Cahill, Foa, Hembree, Marshall, & Nacash, 2006; Ehlers, 
Gene-Cos, & Perrin, 2009; Kessler, 2000; Shin, Greenbaum, Jain, & Rosen, 2014). Therapists 
perceive all kind of impediments for exposure therapy delivery, especially in the case of co-
morbidity (Becker, Zayfert, & Anderson, 2004; van Minnen, Hendriks, & Olff, 2010). Often they 
fear symptom exacerbation during PE (Becker et al., 2004), even though empirical work has 
shown this fear to be ungrounded (Foa, Zoellner, Feeny, Hembree, & Alvarez-Conrad, 2002; 
Jayawickreme et al., 2014; van Minnen et al., 2015). 
Acquisition
CS + US
Extinction
CS - no US
Time
Fe
ar
Exposure treatment
CS - no US
Time
Fe
ar
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 Second, not all patients that receive PE derive benefit from it. Even though most patients 
show a positive response to treatment, only half of the patients actually lose their diagnosis 
after a full course of therapy (Bradley et al., 2005). For decades now, researchers have tried to 
identify who is likely to benefit from PE, and perhaps even more importantly, who is not. Despite 
several attempts, not one stable predictor of PE outcome has been identified, besides initial 
PTSD symptom severity (van Minnen, Arntz, & Keijsers, 2002). As a matter of fact, most studies 
showed that variables that are clinically assumed to hinder good exposure therapy outcome, 
actually lack empirical support for impeding treatment outcome. For instance, comorbid 
anxiety or depressive disorders do not impede positive treatment outcome (Hagenaars, van 
Minnen, & Hoogduin, 2010; van Minnen, Harned, Zoellner, & Mills, 2012). Thus, while we know 
that not every patient will benefit from PE, so far, we have no empirical support of a predictor 
whom to exclude from PE. There are indications that patients with higher pretreatment PTSD 
symptoms may have suboptimal treatment outcome, and tentatively, for these patients 
additional treatment strategies may be warranted. 
 Third, dropout rates tend to be high. Large clinical trials have shown drop-out rates for 
PE up to 38% (Schnurr et al., 2007), and meta-analyses demonstrated drop-out rates around 
20% percent (Hembree et al., 2003; Imel, Laska, Jakupcak, & Simpson, 2013). Although 
disheartening, these high dropout rates are not exclusive to PE. Meta-analyses repeatedly 
show that drop-out rates do not differ between active treatments (such as Eye Movement 
Desenzitization and Reprocessing (EMDR) or Cognitive Processing Therapy; Bisson, Roberts, 
Andrew, Cooper, & Lewis, 2013; Imel et al., 2013)). Nonetheless, the high drop-out rate is a 
serious problem in effectively treating PTSD symptoms. As with non-response, researchers 
have tried to identify those patients likely to dropout from PE, but across studies no consistent 
predictors for premature treatment termination have been found (Rizvi, Vogt, & Resick, 2009; 
van Minnen et al., 2002). 
 In sum, PE is a well-established proven effective therapy for PTSD. Following guideline 
recommendations, all treatment seeking PTSD patients should receive PE therapy or another 
established therapy, such as EMDR or CPT. Notwithstanding the efficacy of PE therapy there is 
room for improvement, given that not all patients benefit from treatment, remission rates are 
relatively low, and drop-out levels tend to be high. 
Can we improve PE therapy efficacy for PTSD?
Attempting to improve PE therapy efficacy, some have tried to boost effects by combining PE 
therapy with other psychological interventions. For most anxiety disorders, effective cognitive 
behavioral treatment (CBT) protocols comprise both cognitive and exposure therapy, while 
in PTSD they contain either cognitive therapy (CPT) or exposure therapy (PE). The sensible 
idea that the addition of cognitive interventions might augment PE effects, fitted well within 
the CBT tradition, but unfortunately, proved disappointing in enhancing remission rates. For 
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instance, Foa and colleagues (2005) compared PE with and without cognitive restructuring 
in a large patient sample, and did not find any enhancement effects. In line, a meta-analysis 
over six studies with cognitive interventions added to exposure, demonstrated no clinically 
significant superiority (Kehle-Forbes et al., 2013). One possible explanation might be that both 
interventions (exposure and cognitive therapy) modify the same underlying dysfunctional 
cognitions, granted that exposure therapy also reduces negative beliefs without explicitly 
addressing them (Hagenaars, van Minnen, & de Rooij, 2010; McLean, Yeh, Rosenfield, & Foa, 
2015; Nacasch et al., 2015; Zalta et al., 2014).
 Another way to improve treatment efficacy, might be to combine exposure therapy with 
psychopharmacological treatment. Stand-alone treatment with antidepressant drugs (more 
specifically, Selective Serotonin Reuptake Inhibitors; SSRI’s) is an effective (second line) 
treatment strategy for PTSD (see for review: Watts et al., 2013). In clinical practice, many PTSD 
patients receive a combination of psychotherapeutic and SSRI treatment, although there is 
no stable evidence that this combination is more effective than either treatment strategy 
alone. When provided from the beginning of treatment, the combination of PE and a SSRI 
(paroxetine) was more efficacious than PE plus placebo in a small civilian sample (Schneier 
et al., 2012). In contrast, a large three-armed clinical trial that compared PE with paroxetine 
and their combination, showed no beneficial effect of the combination strategy (Popiel, 
Zawadzki, Praglowska, & Teichman, 2015). In treatment resistant patients, the addition of a SSRI 
(paroxetine) to PE did not enhance PE effects (Simon et al., 2008), nor the other way around, the 
addition of PE to SSRI (sertraline) treatment did not improve treatment effects for those who 
did not respond to medication (Rothbaum et al., 2006). 
 All in all, while combining two proven effective treatment strategies might have face 
validity in improving efficacy, the effects of such combination strategies are disappointing. 
A novel route to augment exposure therapy efficacy
In the classical pharmacotherapy, treatment is aimed at symptom reduction, hypothetically by 
correction of neurochemical abnormalities. A new way of treatment efficacy enhancement was 
born with the idea that pharmacological enhancement might also be targeted at the underlying 
learning mechanisms of exposure therapy. Given that extinction learning is thought to be at 
the base of exposure therapy effects, and that extinction learning can be modeled very well 
in animals, preclinical designs could establish the potential of pharmacological enhancers as 
exposure therapy facilitators. In this respect, the pharmacological agent d-cycloserine (DCS) 
was the first drug that was systematically studied as a potential exposure therapy facilitator. 
d-cycloserine enhancement of extinction learning in animals
d-cycloserine (D-4-amino-3-isoxazolidone; DCS) is a partial agonist that acts at the glycine side 
of the N-methyl-D-aspartate (NMDA) receptor complex. The NMDA receptor is critically involved 
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in extinction learning, and animal studies showed that infusion with NMDA antagonists blocked 
extinction learning (Myers & Davis, 2002). This sparked the idea that the opposite might also 
be true: NMDA agonists might enhance extinction learning. Indeed, Walker and colleagues 
(2002) were the first to demonstrate that systematic administration or infusion of DCS into 
the basolateral nucleus of the amygdala prior to extinction training enhanced the extinction 
of learned fear in rats. In these studies, rats first received 10 pairings pairing of a light (CS) 
with an electrical foot shock (US; i.e. the conditioning). Forty-eight hours later, some rats were 
given extinction training wherein the light (CS) was presented for 30 times but never followed 
by the foot shock (noUS). Thirty minutes prior to extinction training (or mere exposure to the 
test chamber without extinction training), rats were injected with either DCS or saline solution. 
All rats were then tested 24 hours later to assess fear responses to the CS (the light). The rats 
treated with DCS prior to extinction training demonstrated less fear to the CS than rats treated 
with saline. Importantly, this effect was only observed in the rats that had received extinction 
training. For the rats that had not received extinction training (but were injected with DCS or 
saline), there were no differences in fear reactions to the CS. In other words, DCS does not 
reduce fear by itself, it exerts it effects solely by enhancement of extinction learning. Note that 
it specifically enhances the consolidation of extinction learning, i.e. it augments stabilization of 
the memory of the extinction training in the hours after learning. These first and very promising 
findings were soon replicated by others (Ledgerwood, Richardson, & Cranney, 2003, 2004; 
Richardson, Ledgerwood, & Cranney, 2004). Interestingly, DCS could also enhance extinction 
when administered 3 hours after extinction training (Richardson et al., 2004), which is within 
the memory consolidation time window, and thus underlines the idea that DCS specifically 
enhances the consolidation of the extinction memory. 
d-cycloserine enhancement of exposure therapy: clinical studies
Given the similarities between extinction training and exposure therapy, the question arose 
whether these findings could be translated to humans. Because DCS was already approved for 
human use in the treatment of tuberculosis it could be relatively easily tested as an adjunct 
to exposure therapy. In a proof-of-principle trial, Ressler and colleagues (2004) examined 
whether DCS could enhance extinction learning in 27 acrophobic patients. All participants 
received two sessions of virtual reality exposure to heights within a virtual glass elevator. Prior 
to each session participants ingested either DCS (50 or 500 mg) or placebo, and drug allocation 
was double blind. Those who received DCS (either dose) had better outcome on all outcome 
measures: after exposure therapy, they experienced less fear when confronted with heights, 
and reported lower acrophobia symptoms on self-report measures. Importantly, these effects 
were maintained up until three months follow-up.
 These exciting pilot findings asked for replication. Indeed, Hofmann and colleagues (2006) 
demonstrated DCS enhancement effects in a truncated exposure protocol for 28 patients with 
 Chapter 1
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social anxiety disorder Those who received 50 mg of DCS one hour prior to four sessions of 
exposure therapy, showed superior outcome compared to those who received placebo, a 
finding that was later replicated in a parallel design with a larger sample (Guastella et al., 2008). 
Similarly, a first trial in patients suffering from panic disorder demonstrated augmentation 
effects of 50 mg of DCS given one hour prior to three interoceptive exposure sessions (Otto 
et al., 2010). Yet, a second RCT in a similar population failed to show overall beneficial effects 
for the same dose taken one hour before exposure in vivo. It did however show a statistical 
trend towards enhanced outcome in the more severely ill patients (Siegmund et al., 2011). For 
obsessive-compulsive disorder (OCD), treatment gains were less pronounced, with one study 
reporting no enhancement at all with 250 mg DCS given four hours prior to 12 exposure and 
response prevention sessions (Storch et al., 2007). A subsequent DCS study with OCD patients 
also failed to find any posttreatment or follow-up gains for 125 mg taken two hours before 
sessions (Kushner et al., 2007). However, at midtreatment, the patients in the DCS group did 
show lower subjective fear levels during exposure than the patients in the placebo group, 
indicating faster treatment results. Another RCT (Wilhelm et al., 2008) likewise found that their 
DCS group receiving 100 mg one hour before sessions showed better treatment results after 
five sessions, but not at treatment completion (10 sessions) or follow-up. In a reanalysis of this 
study, slopes of improvement during exposure therapy were evaluated, and it was found that 
DCS initiated treatment effects sooner in treatment (Chasson et al., 2010). Combined, these 
findings in OCD patients suggested that DCS might not always enhance therapy effects, but 
may accelerate results instead. 
 All in all, DCS showed promise as an innovative treatment strategy for the anxiety 
disorders either by speeding up or enhancing exposure therapy effects. However, whether DCS 
could also enhance PE effects in PTSD had yet to be established. Furthermore, if DCS indeed 
facilitated PE efficacy in PTSD, there were open questions regarding its mechanism of action 
and the conditions for effective application in PTSD. Lastly, this novel strategy of combining 
exposure therapy with learning enhancing agents raised the question whether there were 
other drugs that might also show promise in augmenting PTSD treatment outcome.
Outline of the dissertation
Given the exciting findings of DCS enhancement in other anxiety disorders and the suboptimal 
outcome of Prolonged Exposure (PE) for PTSD, the first aim of this dissertation was to test the 
augmentation effects of DCS for PE in PTSD. Chapter 2 describes the results of a double blind 
randomized clinical trial investigating the augmentation effects of DCS (50 mg) given one hour 
prior to weekly PE sessions for PTSD. In chapter 3, prescriptive variables for DCS enhancement 
of exposure therapy in PTSD patients were examined. As in non-enhanced exposure therapy, it 
is likely that not all patients will benefit from DCS enhancement. Ideally, prescriptive variables 
would identify those patients who may merit from DCS enhancement, which could guide 
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clinicians in the effective application of DCS. In chapter 4, one of the conditions for successful 
DCS administration is investigated. Reasoning from the proposed working mechanism of 
DCS – enhancement of extinction learning consolidation - it is logical to assume that good 
extinction learning during a therapy session is conditional for successful DCS enhancement. 
Indeed, in animal studies it was found that enhancement effects of DCS were exclusive to 
rats that showed fear extinguish during extinction training (Bouton, Vurbic, & Woods, 2008; 
Weber, Hart, & Richardson, 2007). Hence, in the fourth chapter it is investigated whether the 
degree of extinction learning (as indexed by subjective fear decline) during PE predicted DCS 
enhancement effects. In chapter 5, it is further explored what defines good extinction learning 
during PE. Subjective fear levels are commonly used (both in practice and science) to establish 
the success of an exposure session. The simple and intuitive idea is that lower fear levels in and 
between exposure sessions reflect extinction learning and indicate success. However, there is a 
growing body of work suggesting that fear levels during extinction training or exposure therapy 
do not necessarily point to successful learning and good treatment outcome (see for review 
Craske et al., 2008; Craske, Treanor, Conway, Zbozinek, & Vervliet, 2014). Extinction learning is 
thought to be cognitively mediated by changes in harm expectancies (i.e. from CS-US to CS-
noUS). Instead of fear decline, changes in harm expectancies might better indicate new learning 
and index exposure session success. Thus, in the fifth chapter, harm expectancies during PE 
and their relation to treatment outcome is investigated. The idea that pharmacological agents 
can enhance treatment mechanisms has sparked researchers to test various drugs as potential 
treatment facilitators. In the sixth chapter all candidate agents to enhance exposure therapy 
effects in PTSD are reviewed. We specifically reviewed whether these agents indeed improve 
treatment outcome for PTSD patients (as compared to standard treatment), and what might be 
clinical barriers for the implementation of these enhancers in routine clinical care.
 Chapter 1
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A Randomized Placebo-
Controlled Trial of d-cycloserine 
to Enhance Exposure Therapy 
for Posttraumatic Stress Disorder
Based on: de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. 
(2012). A Randomized Placebo-Controlled Trial of d-cycloserine to Enhance Exposure Therapy 
for Posttraumatic Stress Disorder. Biological Psychiatry, 71(11), 962-968. 
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Abstract
Posttraumatic stress disorder (PTSD) is a complex and debilitating anxiety disorder, and, although 
prolonged exposure therapy has been proven effective, many patients remain symptomatic 
after treatment. In other anxiety disorders, the supplementary use of d-cycloserine, a partial 
agonist at the glutamatergic N-methyl-D-aspartate receptor, showed promise in enhancing 
treatment effects. We examined whether augmentation of prolonged exposure therapy for 
PTSD with d-cycloserine enhances treatment efficacy.
 In a randomized, double-blind, placebo-controlled trial we administered 50 mg 
d-cycloserine (50 mg) or placebo one hour before each exposure session to 67 mixed trauma 
patients, recruited from regular referrals, with a primary PTSD diagnosis satisfying DSM-IV 
criteria. Although d-cycloserine did not enhance overall treatment effects, the participants 
having received d-cycloserine did show a stronger treatment response. Exploratory session-
by-session analyses revealed that d-cycloserine yielded higher symptom reduction in those 
participants that had more severe pretreatment PTSD and needed longer treatment. The present 
study found preliminary support for the augmentation of exposure therapy with d-cycloserine, 
specifically for patients with more severe PTSD needing longer treatment.
 Chapter 2
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Introduction
Posttraumatic stress disorder (PTSD) is an anxiety disorder with a lifetime prevalence of 
about 8% (Kessler et al., 2005; Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995). PTSD is 
often accompanied by comorbid psychiatric disorders (Kessler et al., 1995) and sufferers are 
frequently impaired in daily life and work functioning. There are various effective treatment 
strategies available. Several controlled studies demonstrated the efficacy and effectiveness 
of prolonged exposure therapy (PE), a cognitive behavioral therapy for the treatment of 
PTSD (see for an overview Powers et al., 2010). Consequently, PE is considered a first-line 
treatment for PTSD (Foa, Keane, Friedman, & Cohen, 2009; NICE, 2005). In PE, patients are 
asked to vividly recount the traumatic experience and to confront fear evoking trauma-related 
stimuli (Foa & Rothbaum, 1998). The proposed working mechanism of PE is fear extinction 
by effective emotional processing of the traumatic memory. Notwithstanding the efficacy of 
PE, improvements are needed, given that many patients remain symptomatic after treatment 
(Bradley et al., 2005; Schnurr et al., 2007). With studies reporting rates of 20 - 35%, dropout 
also is an important issue (Bisson & Andrew, 2007; Hembree et al., 2003; Simon et al., 2008).
 To improve treatment efficacy in anxiety disorders, researchers are focusing on the 
pharmacological enhancement of the mechanisms of extinction-based (exposure) therapies. 
Fear extinction has been linked to N-methyl-D-aspartate (NMDA) glutamatergic receptor 
activity in the basolateral amygdala (see Norberg, Krystal, & Tolin, 2008). Animal research 
suggested that NMDA receptor agonists, such as the partial agonist d-cycloserine (DCS), can 
enhance extinction effects (Walker et al., 2002). Clinical studies that subsequently examined 
whether fear extinction is indeed facilitated by supplementing exposure therapy with DCS 
found augmentation effects in patients with specific phobia (Ressler et al., 2004), social phobia 
(Guastella et al., 2008; Hofmann et al., 2006), panic disorder (Otto et al., 2010; Siegmund et al., 
2011) and obsessive compulsive disorder (Kushner et al., 2007; Storch et al., 2007; Wilhelm et 
al., 2008). Even though the findings of some studies were less pronounced (e.g. Wilhelm et al. 
(2008) and Siegmund et al. (2011) respectively found enhancement effects at midtreatment 
and for severely disordered patients only), overall, DCS showed promise in augmenting 
exposure-based therapy (see for a review Norberg et al. (2008)). Findings in studies using a 
single prolonged stress paradigm in rats as an animal model of PTSD (Yamamoto et al., 2008; 
Yamamoto et al., 2010) suggested that DCS might also be effective in the treatment of this 
disorder, but to our knowledge the exposure-enhancing properties of DCS have to date not 
been systematically investigated in this population. 
 One pilot study did test DCS in PTSD patients, but as a stand-alone therapy, i.e., without 
additional exposure or other emotional learning treatment techniques (Heresco-Levy et 
al., 2002), despite the general assumption that DCS as such does not positively influence 
treatment outcome, but does so solely by augmentation of exposure effects. The trial was also 
limited in that it included only 11 patients. Moreover, DCS was administered on a daily basis, 
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while chronic use –as opposed to acute use for the facilitation of exposure sessions– is known 
to lead to negative effects (Ressler et al., 2004; Richardson et al., 2004). It was therefore not 
surprising that no beneficial effects were found. 
 In conclusion, in patients with anxiety disorders augmenting exposure-based therapies 
with DCS appears promising in improving treatment outcome, but controlled PTSD studies are 
lacking. With the present study we aimed to test the efficacy of DCS in combination with PE 
for PTSD in a randomized, double-blind, placebo-controlled design. We hypothesized that the 
patients receiving DCS would profit more from PE than those receiving placebo. In addition, we 
explored the effects of DCS over the course of the treatment by analyzing weekly changes in 
PTSD symptoms. 
Methods and Materials
Participants
All participants were regular referrals to two Dutch outpatient clinics specializing in the 
treatment of anxiety disorders. Participants were enrolled between March 2008 and March 
2010, with final follow-ups completed in June 2010. After regular pretreatment screening a 
member of the research team invited eligible patients to participate in the study. Inclusion 
criteria were (I) age between 18 and 65 years, and (II) current PTSD DSM-IV diagnosis (American 
Psychiatric Association, 2000) confirmed by a structured diagnostic interview (see Measures). 
Exclusion criteria were (1) (current or past) psychosis or delusional disorders, (2) acute 
suicidal tendency, (3) mental retardation, (4) substance abuse or dependence, (4) pregnancy 
or lactation, (5) a serious and unstable medical condition (e.g., pacemaker, renal disease or 
porphyria), (6) a history of epileptic seizures, (7) medication use that might interfere with DCS 
(e.g., anticoagulants), (8) insufficient ability to speak and write Dutch. Written informed consent 
was obtained from all volunteer participants. The study protocol was approved by the medical 
ethics committee of the Radboud University Nijmegen Medical Centre. 
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Table 1. Sample characteristics
Characteristic d-cycloserinea Placeboa p-value (2-sided)
Sample size N = 33 N = 34 NA
Age, mean (SD) in yrs 36.27 (11.56) 40.26 (11.05) .15 †
Female 29 (87.9) 25 (73.5) .14 ‡
Married or cohabitating 11 (33.3) 14 (41.2) .51 ‡
Post-high-school education 23 (69.7) 23 (67.6) .86 ‡
Trauma history .42 ‡
Sexual assault 14 (42.2) 21 (61.8)
Violent non-sexual assault 12. (36.4) 8 (23.5)
Accident 1 (3.0) 2 (5.9)
Warzone experiences 1 (3.0) 1 (2.9)
Miscellaneous 5 (15.2) 2 (5.9)
Axis-I comorbidity (current) 22 (66.7) 25 (73.5) .54 ‡
Comorbid anxiety disorder 14 (42.2) 14 (41.2) .92 ‡
Comorbid depressive disorder 15 (41.7) 21 (58.3) .18 ‡
Receiving psychotropic medication 13 (39.4) 15 (44.1) .70 ‡
a Values are expressed as numbers (percentages) unless otherwise indicated. 
† Value obtained by t test.
‡ Values obtained by χ² test.
Abbreviation: NA, not applicable
Of the 751 eligible participants randomly assigned in double-blind fashion to the treatment 
conditions, eight participants dropped out before the first exposure session, leaving 67 
participants receiving the allocated intervention. The treatment protocol was completed by 45 
participants, 24 receiving exposure plus DCS and 21 receiving exposure plus placebo, while 
40 completers and five dropouts completed the 3-month follow-up assessment. No significant 
differences between completers and dropouts were found for any sample characteristic or 
baseline symptom severity measures.
 The sample characteristics are presented in table 1. The majority of the patients (80.6%) 
was female and the sample’s mean (SD) age was 38.3 (11.4) years. The traumatic events 
underlying PTSD were mixed and comprised sexual assault including childhood sexual abuse 
(N = 35), violent non-sexual assault (N = 20), a road traffic or other accident (N = 3), warzone 
experiences (N = 2), and miscellaneous (N = 7). Less than half of the participants (41.8%), who 
1  For administrative reasons, participants were randomized before the baseline assessments. Consequently, 16 
patients received a randomization number but never entered the study, because they were excluded or withdrew 
before completion of the baseline assessment.
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were equally distributed across the two groups, were taking psychotropic medication: 11 a 
benzodiazepine, eight an antidepressant, and nine both benzodiazepines and antidepressants. 
All had been on a stable dose before allocation and agreed to maintain the regular dose 
throughout the trial. All participants met the DSM-IV criteria for PTSD, and diagnostic interviews 
(M.I.N.I. (Sheehan et al., 1998)) revealed that 70.1% (N = 47) had at least one additional 
diagnosis (mean 2.0). The most common axis-I disorders were depressive disorder (31.9%), 
panic disorder with agoraphobia (13.8%), and social phobia (10.6%). 
 No significant group differences were found for gender, age, education, trauma type, 
comorbidity and psychotropic medication use. 
Measures
The DSM-IV axis-I diagnoses of PTSD and any comorbid conditions were established with 
the Mini-International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al., 1998), a valid and 
reliable structured interview to assess axis-I psychiatric diagnoses. 
 The primary outcome measure was PTSD symptom severity as assessed with the Clinician-
Administered PTSD Scale (CAPS-1; Blake et al., 1995), a clinician-rated structured interview 
developed to test for the presence of the 17 DSM-IV-TR criteria for PTSD. The interrater 
diagnostic agreement was shown to be excellent (Blake et al., 1990), as was the internal 
consistency (α = .94; Blake et al., 1995), while the concurrent validity was adequate (Blake 
et al., 1995; Blake et al., 1990). PTSD symptoms were also assessed with the Posttraumatic 
Stress Symptom Scale, Self Report (PSS-SR; Foa, Riggs, Dancu, & Rothbaum, 1993), a 17-item 
questionnaire with which patients rate the frequency of PTSD symptoms. Analyses showed a 
high internal consistency (α = .91; Foa et al., 1993). The Dutch version also shows good internal 
consistency (Mol et al., 2005).
 As secondary measures, we assessed general anxiety, depression and general 
psychopathology. General anxiety was evaluated with the state subscale of the State and Trait 
Anxiety Inventory (STAI; Spielberger, Gorsuch, & Lushene, 1970; Van der Ploeg, Defares, & 
Spielberger, 1980). The STAI-state comprises 20 items regarding state anxiety and gauges the 
level of anxiety the respondent experiences at the time of assessment. The internal consistency 
of the Dutch version is between .86 and .95 (Van der Ploeg et al., 1980). Depression was assessed 
using the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), a 21-
item self-report questionnaire measuring the severity of depressive symptoms. The internal 
consistency is high for both psychiatric and non-psychiatric samples (α coefficients range from 
.76 to .95 and .73 to .92, respectively; Beck, Steer, & Garbin, 1988). General psychopathology 
was quantified using the Symptom Checklist (SCL-90; Arrindell & Ettema, 1986; Derogatis, 
Rickels, & Rock, 1976), a frequently used outcome measure containing 90 items regarding 
psychopathologic abnormalities with good psychometric properties (α =.89; Arrindell & 
Ettema, 1986). All interviews and questionnaires were Dutch translations.
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 All assessments were conducted by trained, independent assessors who were blind to the 
treatment condition. The assessments were performed pre- and posttreatment, and 3 months 
after treatment completion (follow-up), while all participants completed the PSS-SR before 
every treatment session.
Medication
d-cycloserine was originally approved by the US Food and Drug Administration as an antibiotic 
for the treatment of tuberculosis. Generally, it is dosed at 500 to 1000 mg twice daily. Peak 
blood levels occur within four to eight hours after oral dosing, with a half-life time of ten hours 
(Hardman & Limbird, 2001). The compounding chemist purchased DCS from Duchefa Farma 
(Haarlem, the Netherlands) to make the 50 mg DCS capsules along with the identical-looking 
placebo. We opted for 50 mg/d because this dose had proven effective in previous extinction 
studies (Hofmann et al., 2006; Ressler et al., 2004). DCS or placebo was taken one hour prior to 
the start of an exposure session. We weekly checked adverse events with a self-report measure.
 Using standard software, an independent statistician generated a randomization list using 
random blocks with a maximum of ten numbers each. The active and placebo capsules were 
dispensed by the pharmacist in numbered containers in accordance with the randomization 
list. Everyone involved in the study (i.e., researchers, participants, therapists and assessors) 
were blind to the treatment condition until all follow-up assessments were completed. 
Treatment 
Both treatment groups received a standardized PE program originally developed by Foa and 
Rothbaum (1998). In the first session participants were educated about PTSD symptoms and 
the treatment rationale. Based on the research by Van Minnen and Foa (2006), which showed 
that extinction and treatment efficacy was not affected by exposure duration, the subsequent 
weekly sessions comprised 30 minutes of prolonged imaginal exposure rather than the 
original 45-60 minutes. During exposure the participants were instructed to close their eyes 
and to recount aloud the traumatic event in the first person and in the present tense. They 
were further instructed to imagine the traumatic event as vividly as possible and to recount 
as many sensory details as possible. Each exposure session was audiotaped and participants 
were asked to listen to the relevant recording five times a week at home. From the third session 
onwards, participants were given in-vivo exposure assignments that included real-life exposure 
to fearful stimuli related to the trauma (e.g., visiting the trauma place or watching a trauma-
related movie). Homework compliance was good, the mean (SD) of between session exposure 
was 5.26 (2.79) and did not differ between groups (t (64) = -1.26, p = .21).
 In a previous PTSD study of PE we found that several participants terminated treatment 
early, because they had reached (full) recovery (Hagenaars, van Minnen, & Hoogduin, 2010). A 
study on the augmentation of exposure therapy with DCS in OCD patients had also reported 
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early completers (Kushner et al., 2007). In accordance with Foa et al. (2005), we hence defined 
stopping rules to allow for early termination: if a patient’s PSS-SR scores had dropped below 15 
in two subsequent sessions and if there was patient-therapist agreement on the improvement, 
the patient was allowed to end treatment. Since most PE protocols prescribe eight or more 
exposure sessions (Bryant et al., 2008; Powers et al., 2010), all participants who completed 
treatment before the eighth session were considered early completers and those who received 
eight to ten sessions regular completers. 
  The therapists delivering the treatment were psychologists trained in PE therapy for 
PTSD. All weekly sessions were supervised. Twenty-one percent of all treatment sessions 
(N = 99) were randomly selected and rated by graduate-level research assistants according 
to an adherence protocol. Competence was scored on a 3-point scale (1 = inadequate, 2 = 
good, mostly adequate, 3 = adequate or better). Overall competence was good (M = 2.60, SD 
= 0.16, range = 2.25-2.88). Adherence was also good, 98.8% of prolonged exposure sessions 
was performed in accordance with the protocol. There were no between-group differences in 
competence or adherence (t (97) = 0.36, p = .72 and t (78) = 1.15, p = .26, respectively). 
Statistical analysis
All analyses were conducted using PASW version 18.0.3 statistic software package (SPSS 
Inc, Chicago, Ill). Differences between the treatment groups on frequency variables were 
analyzed using chi-square or Fisher’s exact test. To compare group differences on other 
variables independent sample t- tests were performed.
 Continuous outcome variables were analyzed using the Mixed Models procedure 
for repeated measure analysis with group (DCS vs. placebo) and time (pre-, 
posttreatment, and follow-up assessments) as the main fixed effects and an unstructured 
covariance matrix for the repeated factor time. Weekly changes in self-reported 
PTSD symptoms were explored with the same model, with group (DCS vs. placebo), 
completer status (early vs. regular), and sessions (1-10) as the main fixed effects and an 
unstructured covariance matrix for the repeated factor sessions.
 The PASW mixed-model procedure provides Estimated Marginal Means (EMM), which 
are model-predicted means comparable to LSMEANS in SAS. We report EMMs in the tables 
and figure. Univariate tests of the EMMs were done with Sidak’s correction for multiple 
comparisons.
 Dichotomous outcome data on the CAPS (response and remission) were analyzed using 
chi-square analysis. Response was defined as a decrease from baseline ≥10 points on CAPS 
score (Schnurr et al., 2007; Weathers, Keane, & Davidson, 2001), and remission was defined 
as a CAPS severity score <20 (Schnurr et al., 2007; Weathers et al., 2001). For the analyses 
on the dichotomous outcome data missing values were substituted by the last observation 
available. 
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Results
Adverse effects
Upon breaking the blind, we found no difference between participants reporting adverse 
effects with placebo and those reporting adverse effects with DCS (χ²1 = 1.89, p = .17).
2
Blindness check
At posttreatment, all participants were asked whether they believed to have received DCS 
or placebo. There were no statistical differences between the two treatment groups (DCS 
vs. placebo) in the percentages of participants believing to have received DCS (12.5 % vs. 
17.4%, p = .26 Fisher’s exact test). The percentages of therapists believing the patient had 
received DCS were also similar for the two groups (7.1% vs. 15.4%, respectively; p =.41 
Fisher’s exact test). 
Primary measures
Intent-to-treat analysis
The groups differed with respect to their pretreatment CAPS scores (F (1,65) = 8.66, p =.01). The 
mixed model analysis revealed a main effect of time (F (2,46) = 28.44, p <.001). There was a pre-
to-post decrease in CAPS scores, reflecting a drop in clinician-observed PTSD symptoms, which 
reduction was maintained at follow-up (see table 2). No significant group × time interaction 
was found, indicating that the treatment effect did not differ between groups across time (F 
(2,46)= 0.49, p =.62). As to the baseline PSS-SR scores the groups did not differ (F (1,64) = 1.27, 
p =.26), with the mixed model analysis revealing a main effect of time (F (2,42)= 36.16, p <.001). 
Self-reported PTSD symptoms improved over time in both groups. Similar to the clinician-rated 
scores, there was no interaction effect of group by time (F (2,42) = 1.41, p =.26).3 
2 Fourteen participants receiving DCS reported one or more adverse events that they related to DCS including: 
increased anxiety (n =2), headache (n =3), dizziness (n =3), drowsiness (n =2). Nine participants on placebo reported 
drug-induced depressed mood (n =3), headache (n=2), drowsiness (n=2) and bowel pain (n =2). In both groups one 
patient was excluded on account of adverse effects. One patient from the DCS group was admitted to hospital 
during the study, presenting with loss of motor function, disorientation and severe headache. Extensive neurological 
examination failed to reveal any neurological or other physical abnormality and a suspected relationship with DCS 
or placebo was ruled out. However, at the request of the patient, the randomization code was broken, after which 
she was excluded from the study. In the placebo group, one patient reporting persistent dizziness was excluded 
from the study on the advice of an independent physician, without the randomization code being broken.
3  Interaction with concomitant antidepressants use and comorbid depressive and anxiety disorders 
A mixed model analysis, with group, time and antidepressants (yes vs. no) as fixed factors and participants as 
a random factor nested within the time factor, revealed a non-significant interaction effect of group by time 
by antidepressants (CAPS: F (7,56) = 0.72, p =.66; PSS-SR: F (7,46) = 1.14, p =.35), indicating that concomitant 
antidepressant use was not associated with group differences in PTSD symptoms across time. Similarly, no 
interaction effects were found for comorbid depressive or anxiety disorders (all p-values >.05).
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 Thirty-four participants (50.7%) showed posttreatment response according to the CAPS 
(see table 3). A response (response vs. non-response) × group (DCS vs. placebo) chi-square 
detected a between-group difference (χ²1 = 4.32, p =.04). The participants in the DCS group 
were more likely to show response than the participants in the placebo group (odds ratio = 
2.83, 95% confidence interval [CI] = 1.05-7.61). A remission (remission vs. no remission) × 
group chi-square failed to identify posttreatment group differences (χ²1 = 1.38, p =.24). The 
follow-up analyses did not reveal any group differences (response: p =.10, remission p =.11). 
Table 2. Estimated means for all measures for the two treatment groups.
d-cycloserine (N = 33) Placebo (N = 34)
Outcomea Pretreatment Posttreatment Follow-up Pretreatment Posttreatment Follow-up
CAPS 61.75 
(2.92)
34.33
(6.46)
30.28
(6.26)
73.82 
(2.88)
53.65 
(6.55)
43.52 
(6.22)
PSS-SR 26.05 
(1.43)
11.80
(2.59)
12.40 
(2.68)
28.34 
(1.43)
18.41 
(2.59)
15.28 
(2.63)
BDI 22.88
(1.56)
14.35
(2.31)
13.72
(2.73)
27.91 
(1.53)
21.27
(2.35)
19.02 
(2.69)
STAI 48.16
(1.46)
42.70
(2.42)
43.77
(2.87)
52.30 
(1.44)
52.17 
(2.42)
48.55 
(2.77)
SCL90 217.13 
(10.67)
156.80 
(14.42)
166.73 
(15.63)
248.13 
(10.58)
211.68 
(14.42)
193.28 
(15.36)
a All values are given as the estimated model mean (SE). 
Abbreviations: CAPS, Clinician-Administered PTSD Scale; PSS-SR, Posttraumatic Stress Scale – Self-Report; 
BDI, Beck Depression Inventory; STAI; State and Trait Anxiety Inventory; SCL90, Symptom Checklist 90.
Table 3. Numbers (percentages) for the dichotomous outcomes on the Clinician-Administered 
PTSD Scale (CAPS)
Intent-to-treat sample (N = 67)
d-cycloserine (N = 33) Placebo (N = 34)
Outcomea Posttreatment Follow-up Posttreatment Follow-up
CAPS responseb 21 (63.6) 23 (69.7) 13 (38.2 ) 17 (50.0)
CAPS remissionc 11 (33.3) 15 (45.5) 9 (26.5 ) 7 (20.6)
Completers sample (N = 45)
d-cycloserine (N = 24) Placebo (N = 21)
Outcomea Posttreatment Follow-up Posttreatment Follow-up
CAPS responseb 21 (87.5) 23 (95.8) 13 (61.9) 15 (71.4)
CAPS remissionc 11 (45.8) 15 (62.5) 7 (33.3) 9 (42.9)
a Missing values imputed by the “last observation carried forward” method
b Response reflects a decrease from baseline of 10 points or more(Schnurr et al., 2007; Weathers et al., 2001) 
c Remission defined as total CAPS score < 20 (Schnurr et al., 2007; Weathers et al., 2001) 
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Secondary measures analysis
None of the mixed analyses of the secondary measures yielded a time × group interaction: 
depression: F (2,44) = .32, p =.73, self-reported anxiety: F (2,45) = 1.60, p =.21, and general 
psychopathology: F (2,47) = 3.16, p =.052. 
Completers analysis
Treatment was completed by 24 participants in the DCS group and 21 participants in the 
placebo group. The results were similar to those of the intent-to-treat-analyses and we hence 
only report the CAPS and PSS-SR here. The mixed analyses found a main effect of both time 
and group for both PTSD symptom scales (CAPS: F (2,40) = 40.82, p <.001 and F (1,42) = 4.50, p 
= .04, respectively; PSS-SR: F (2,37) = 41.48, p < .001 and F (1,42) = 4.09, p = .05, respectively). 
However, neither scale showed a time-by-group interaction effect (CAPS: F (2,40) = .45, p =.64; 
PSS-SR: F (2,37) = .84, p = .44). The posttreatment response data showed that the participants 
in the DCS group were more likely to show response than the participants in the placebo group 
(χ²1 = 3.97, p =.05; odds ratio = 4.31, 95% CI = 0.97-19.24). This effect was maintained at 
follow-up (p = .04, Fisher’s exact; odds ratio = 9.20, CI = 1.01 -84.26). No group differences 
were found for remission (posttreatment: p =.39; follow-up p =.19). 
PTSD-symptom course analysis
To explore the effects of DCS over treatment course, we ran session-by-session analyses for 
the completers. The mixed model analysis did not yield a group × session interaction effect 
(F (9,31)= 1.54, p = .18). Nineteen participants (42.2%) were classified as early completers, 
having attained recovery before session 8. Exploratory analysis revealed that the course 
of PTSD symptoms over time of the early completers differed from that recorded for the 
regular completers. To better understand the data, we analyzed the two subgroups. The 
regular completers showed more severe self-reported PTSD symptoms at session 1 than the 
early completers (F (1,44) = 4.94, p = .03). The subsequent mixed model analysis revealed 
a significant interaction effect of group by session by completer status (F (22,49) = 2.28, p 
= .01). As can be seen in Figure 1, the regular completers receiving DCS reported a greater 
reduction across sessions than the regular completers on placebo. Follow-up univariate 
tests showed the between-subgroup difference to be significant from session 5 to session 
10 (p-values ranging between .001 and .01). As to the early completers, the DCS and 
placebo subgroups showed no such session differences in symptom reduction. Here, PSS-SR 
scores did not differ significantly at the last session (i.e., session 7) or any previous session 
(p-values ranging between .16 and >.99). 
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Figure 1. Estimated model means for self-reported PTSD-symptom scores (PSS-SR) per completed 
session for the completer subgroups, with errors bars indicating standard errors.
In line with this, a mixed model analysis revealed a significant interaction effect of group (DCS 
vs. placebo), completer status (early vs. regular completers), and time (pre, post, FU) for both 
clinician- and self-rated PTSD symptoms (CAPS: F (7,48) = 3.20, p = .01; PSS-SR: F (7,41) = 
2.62, p = .03). The follow-up univariate tests showed that the between-group difference was 
significant both at treatment completion (CAPS: F (1,41) = 10.99, p = .002; PSS-SR: F (1,42) = 
11.99, p = .001) and at follow-up (F (1,37) = 4.24, p = .05, F (1,34) = 5.66, p = .02, respectively). 
Compared to the regular completers receiving placebo, the regular completers taking DCS 
showed fewer PTSD symptoms at both assessments (see table 4). The early completers showed 
no such subgroup differences (all p-values >.10). 
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Table 4. Estimated means of the primary measures for the two completer groups.
Early completers (N = 19)
d-cycloserine (N = 11) Placebo (N = 8)
Outcomea Pretreatment Posttreatment Follow-up Pretreatment Posttreatment  Follow-up
CAPS 55.46 
(4.32)
20.27 
(7.48)
21.90 
(8.94)
65.19 
(5.07)
11.25
(8.77)
18.86 
(10.25)
PSS-SR 21.21 
(2.08)
6.91 
(3.17)
11.15
(3.9)
24.88 
(2.36)
4.25 
(3.72)
6.08 
(4.59)
Regular completers (N = 26)
d-cycloserine (N = 13) Placebo (N = 13)
CAPS 68.23 
(3.97)
38.31
(6.88)
28.69 
(8.13)
76.52 
(3.97)
70.54 
(6.88)
51.77 
(7.71)
PSS-SR 27.62
(1.85)
12.21
(2.97)
9.70
(3.44)
32.08
(1.85)
26.77 
(2.97)
21.05 
(3.31)
a All values are given as the estimated model mean (SE). 
Abbreviations: CAPS, Clinician-Administered PTSD Scale; PSS-SR, Posttraumatic Stress Scale – Self-Report
Dropout
There were no significant differences in participants dropping out in the DCS group (N = 9 
[27,3%]) and in the placebo group (N =13 [38,2%]), (χ²1= 0.91, p =.34).
Discussion
In this study we presented the first results on the augmentation of prolonged exposure 
therapy for PTSD with d-cycloserine. The standardized treatment program effectively reduced 
PTSD symptoms, regardless of whether patients received placebo or DCS. In contrast to our 
hypothesis and previous clinical studies we did not find an overall enhancement effect for (50 
mg/d) DCS.
 Despite the lack of an overall augmentation effect, what did become evident is that the 
patients taking DCS were more likely to show response at the end of the treatment than those 
having received placebo. For the completers, this effect was maintained at follow-up. More 
specifically, our session-by-session analyses showed that DCS enhanced outcomes in the 
subgroup of regular completers only, i.e., exclusively in those patients who had completed all 
planned sessions. These patients reported a greater symptom reduction over sessions than 
the patients receiving placebo. The early completers did not show such a DCS-related gain. 
Clinically, this is a highly relevant finding. Apparently, and consistent with previous studies 
(Foa et al., 2005; Hagenaars, van Minnen, & Hoogduin, 2010), some PTSD patients respond 
well and fast to exposure and, given potential ceiling effects, for them there seems no need 
to augment the therapy with pharmacological treatment. In contrast, some patients who 
apparently fail to respond to psychotherapy may benefit from pharmacological augmentation. 
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Our study demonstrated that for these patients the addition of DCS was indeed effective. 
A previous review of PTSD outcome studies did not yield stable and reliable predictors based on 
pretreatment patient characteristics, except for symptom severity (van Minnen et al., 2002). In the 
current trial we again found that, compared to the early completers, the patients who had needed 
all treatment sessions had similar pretreatment characteristics (e.g., trauma type or comorbidity), 
but did report more severe PTSD symptoms in the first treatment session. 
 As ours is the first study to examine the effects of DCS in combination with exposure therapy 
in PTSD patients, we can only compare our results with findings obtained in patients with other 
anxiety disorders. Our findings are in contrast with previous studies in patients with specific 
phobia (Ressler et al., 2004), social phobia (Guastella et al., 2008; Hofmann et al., 2006) and panic 
disorder (Otto et al., 2010), in which strong DCS augmentation effects were found with truncated 
exposure protocols (2-4 sessions). However, they are in line with studies in OCD (Kushner et al., 
2007; Storch et al., 2007; Wilhelm et al., 2008) and panic disorder patients (Siegmund et al., 2011), 
in which less strong augmentation effects were found with longer protocols (10-12 sessions).
 A possible explanation of the overall lack of enhancement effect in our study is the length 
of our study protocol. Animal data suggest that the NDMA receptor can become desensitized after 
frequent DCS exposure (Quartermain, Mower, Rafferty, Herting, & Lanthorn, 1994). Also, previous 
clinical studies demonstrated that DCS perhaps does not always enhance treatment effects per 
se, but instead initiates response sooner (Kushner et al., 2007; Norberg et al., 2008; Wilhelm et 
al., 2008). With a full exposure protocol, all patients are likely to respond, making it more difficult 
to demonstrate posttreatment DCS effects (see Storch et al., 2007). However, this explanation is 
not supported by our session-by-session analyses which showed augmentation effects for regular, 
but not for early completers; which rather points in the direction of the earlier mentioned ceiling 
effect. The baseline differences on the CAPS (Clinician-Administered PTSD Scale), with the total 
DCS group receiving lower scores, may also have contributed to this effect, making it more difficult 
to distinguish DCS effects. A previous study similarly reported enhancement effects for patients 
with severe symptoms only (Siegmund et al., 2011), and another study found no effects of DCS 
on subclinical fear (Guastella, Dadds, Lovibond, Mitchell, & Richardson, 2007). In future studies 
the optimal dose of DCS should be established, taken into account the possible ceiling effects for 
patients with less severe baseline symptom levels.
 A limitation of our study is the high dropout rate: in both groups approximately one in three 
patients ended treatment prematurely. Although this is not unusual in PTSD treatment studies, this 
may have introduced a bias in our results. The mixed model analysis we used is the recommended 
procedure in case of missing data and may limit this bias (Gueorguieva & Krystal, 2004). Eight 
participants never received any exposure treatment and were not included in our analysis, which 
hence was not a true ITT analysis. Another point of criticism is the fact that when the patients 
completed the homework assignments they were not taking DCS, which may have diluted DCS-
related effects. 
 Chapter 2
| 29RCT of DCS to enhance exposure therapy 
  Although exposure therapy is the treatment of choice for PTSD (Foa et al., 2009; 
NICE, 2005) and its efficacy and effectiveness well established (Powers et al., 2010), many 
patients remain symptomatic after initial treatment, while little is known about “next-step” 
interventions. Simon et al. (2008) found no additional effect of paroxetine on exposure therapy 
for patients who had shown to be refractory to the initial eight sessions. Our study tentatively 
suggests that combining DCS and exposure improves treatment outcome for initial (more 
severely affected) non-responders. Extending the number of exposure sessions has been 
shown to enhance outcomes (Foa et al., 2005), and, given that DCS is usually well tolerated 
and inexpensive, additional use of the drug would make extended psychotherapy more cost-
effective. In our view, the exposure-DCS combination is well worth exploring as an effective 
next-step intervention for PTSD. 
 In conclusion, our PTSD study contributes to the existing research on the use of 
d-cycloserine in anxiety disorders to augment exposure-based treatments. We found partial 
evidence of DCS-related gains in that the patients given 50 mg of DCS prior to each session 
were more likely to show response than the patients receiving placebo. Subsequent analyses 
yielded preliminary support for the use of DCS in patients with more severe PTSD needing 
longer treatment. Our findings warrant replication in other PTSD populations, as does the 
supposition that DCS might be a next-step intervention for patients who do not initially 
respond to exposure therapy. 
39  Allocated to exposure and placebo
34  Received allocated intervention
5  Did not receive allocated intervention
 (dropped out before first exposure session)
1  Lost to follow-up (lost contact)
13  Discontinued intervention (dropout)
36  Allocated to exposure and D-cycloserine
33  Received allocated intervention
3  Did not receive allocated intervention
 (dropped out before first exposure session)
4  Lost to follow-up (lost contact)
9  Discontinued intervention (dropout)
33  Analysed
0  Excluded from analysis
34  Analysed
0  Excluded from analysis
75 Randomized
279 Assessed for eligibility 204  Excluded after pre-screening
65  Did not speak Dutch
51  Declined to participate
37  Psychiatric exclusion
26  Medical exclusion
16  Late exclusion or withdrawal
9  Other reasons
Supplementary Figure. Progress of participants in the study.
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Prescriptive Variables for 
d-cycloserine Augmentation 
of Exposure Therapy for 
Posttraumatic Stress Disorder
Based on: de Kleine, R. A., Hendriks, G. J., Smits, J. A., Broekman, T. G., & van Minnen, A. (2014). 
Prescriptive Variables for d-cycloserine Augmentation of Exposure Therapy for Posttraumatic 
Stress Disorder. Journal of Psychiatric Research, 48(1), 40-46. 
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Abstract
In recent years, several studies have demonstrated efficacy of d-cycloserine (DCS) enhanced 
exposure therapy across anxiety disorders. In this study we examined person-level variables 
that predicted response to DCS enhanced exposure therapy in a chronic, mixed trauma PTSD 
sample. The sample consisted of 67 treatment-seeking individuals, randomly allocated 
to receive exposure therapy augmented with DCS (50 mg) or identical looking placebo. 
We examined the following baseline predictors of treatment response: (1) demographic 
characteristics (age, gender, marital status, and education); (2) clinical characteristics (initial 
PTSD symptom severity, Axis I comorbidity, depression symptom severity, and antidepressants 
use); (3) personality characteristics (openness, conscientiousness, extraversion, agreeableness, 
and neuroticism). Outcome was measured with the PTSD Symptom Scale, Self-Report, 
which was assessed weekly during treatment. Two prescriptive variables were identified: 
conscientiousness and extraversion. For high conscientious participants, those who received 
DCS showed better outcome than those who received placebo. And for low extraversion, DCS 
showed superior outcome relative to placebo. Education was identified as a prognostic variable, 
it predicted response across both groups: higher education was related to worse outcome. Our 
results provide support for the influence of personality traits on DCS augmented exposure 
outcome and give more insight into possible working mechanisms of this novel treatment 
strategy. Ultimately, this may contribute to treatment matching strategies in order to improve 
treatment efficacy of exposure therapy for PTSD. 
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Introduction
Exposure therapy, a form of cognitive behavioral therapy (CBT), is an effective treatment for 
PTSD (see for review Powers et al., 2010). In exposure therapy, PTSD patients are repeatedly 
exposed to the traumatic memory (imaginal exposure) and to safe, but anxiety provoking, 
trauma-related stimuli (in vivo exposure). A proposed working mechanism of exposure therapy 
is fear extinction by effective emotional processing of the traumatic memory and incorporation 
of corrective information, namely the absence of anticipated harm (Foa & Kozak, 1986). Even 
though the efficacy and effectiveness of exposure therapy for PTSD are widely established, 
there is room for improvement, since loss of diagnosis rates tend to be around 40 to 65 percent 
(Bradley et al., 2005; Schnurr et al., 2007).
 Attempting to improve treatment efficacy of exposure treatment for anxiety disorders, 
researchers have focused, among other strategies, on pharmacological enhancement of fear 
extinction. Augmentation of exposure therapy with the cognitive enhancer d-cycloserine (DCS), 
a partial agonist of the N-methyl-d-Aspartate (NMDA) glutamate receptor, has shown efficacy in 
the treatment of several anxiety disorders (see for meta-analyses: Bontempo, Panza, & Bloch, 
2012; Norberg et al., 2008), although several studies have failed to demonstrate efficacy 
(Guastella, Dadds, et al., 2007; Litz et al., 2012; Tart et al., 2013). To date, two studies have 
examined the efficacy of DCS enhanced exposure treatment in PTSD patients and found mixed 
results. Our group (de Kleine, Hendriks, Kusters, Broekman, & van Minnen, 2012) observed 
an effect of DCS on treatment response in a mixed-trauma population. More importantly, we 
found DCS to be beneficial in a subgroup of patients, namely those who needed all treatment 
sessions and had higher pretreatment PTSD symptoms. This finding suggests that DCS may be 
beneficial for a specific subsample of patients. Litz et al. (2012) examined DCS and exposure 
treatment in a male Veteran population and found that placebo outperformed DCS. Closer 
inspection of their data suggested that lack of within-session extinction resulted in the 
unfavorable outcome for DCS, considering the data suggesting that end-of-exposure fear is 
predictive of DCS enhanced exposure therapy outcomes (Smits, Rosenfield, Otto, Marques, et 
al., 2013; Smits, Rosenfield, Otto, Powers, et al., 2013). Based on these studies it appears that 
DCS enhancement might have differential effects in PTSD patients. 
 Overall, hypotheses on why outcomes of DCS enhancement differ across studies are 
mainly of methodological nature - e.g. studies differed in treatment protocol length and 
DCS dosage (see for instance: Hofmann, Smits, Asnaani, Gutner, & Otto, 2011). In addition, 
it has been suggested that person-level variables, such as baseline symptom severity and 
antidepressant use, may influence DCS efficacy (de Kleine et al., 2012; Guastella, Dadds, et 
al., 2007; Rodebaugh, Levinson, & Lenze, 2013; Siegmund et al., 2011). Most recently, Smits 
et al. (2013) examined predictive factors of DCS enhanced exposure therapy in a large sample 
of social phobic patients. They found certain personality traits, namely agreeableness and 
conscientiousness, to be related to DCS augmentation effects. Specifically, DCS augmentation 
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was evident only among individuals low in conscientiousness and among individuals high in 
agreeableness. 
 To gain more insight into variables associated with outcome of DCS-enhanced exposure 
therapy for PTSD, we examined prescriptive variables of DCS efficacy outcome in our 
randomized clinical trial (de Kleine et al., 2012). Here, a prescriptive variable is an individual 
characteristic that predicts differences in outcome between DCS- and placebo- enhanced 
exposure therapy, and thus requires, statistically, demonstration of a significant interaction 
between the individual characteristic and treatment condition (DCS vs. placebo; Kraemer, 
Wilson, Fairburn, & Agras, 2002). Attempting to replicate and extend the findings reported by 
Smits et al. (2013) we examined the potential prescriptive effects of personality traits, while 
also considering and controlling for demographic and clinical characteristics. 
 In addition to prescriptive variables we examined prognostic variables, or individual 
characteristics that are predictive of treatment outcome irrespective of experimental 
condition (i.e. DCS vs Placebo; Fournier et al., 2009). Prognostic variables therefore require 
demonstration of a statistically significant main effect of the individual characteristics. Our 
selection of candidate prognostic variables was guided by previous findings of exposure 
therapy outcome prediction studies in PTSD patients. Clinicians often believe that exposure 
therapy is contraindicated for PTSD patients with comorbid disorders (Becker et al., 2004; 
van Minnen et al., 2010), but empirical evidence is lacking (see van Minnen et al., 2012 for 
overview). In fact, a recent meta-analysis showed a positive relationship between general 
comorbidity and treatment outcome (Olatunji, Cisler, & Tolin, 2010), and some studies have 
documented better exposure treatment outcome for those with more depressive symptoms 
(Feeny, Zoellner, Mavissakalian, & Roy-Byrne, 2009; Rizvi et al., 2009). Of note, van Minnen, 
Artnz and Keijsers (2002) examined a range of possible predictors, including comorbidity 
and trauma characteristics, but found baseline PTSD symptom severity to be the only stable 
and reliable predictor of exposure therapy outcome. At the time of this writing, little research 
exists on the clinical predictors of DCS efficacy for enhancing exposure therapy outcomes. 
Given these observations, we examined the prescriptive and prognostic effects of initial PTSD 
symptom severity, while also considering the possible influence of depressive symptoms, and 
DSM-IV axis I comorbid disorders. 
 In sum, enhancing treatment efficacy of exposure therapy for PTSD with DCS appears a 
promising strategy. However, it is likely that, as in non-enhanced exposure therapy for PTSD, not 
all patients benefit from this treatment strategy. By identifying prescriptive variables, we hope 
to direct clinicians in the effective application of DCS and gain more insight into mechanisms 
of exposure therapy efficacy. 
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Material and Methods
Participants
A full description of the sample characteristics and study procedures can be found elsewhere 
(de Kleine et al., 2012). Briefly, all 67 participants were regular referrals to two outpatient 
clinics, satisfying DSM-IV criteria for PTSD, confirmed by a structured diagnostic interview 
(Clinician Administered PTSD Scale (CAPS; Blake et al., 1990). Trauma-type was mixed and 
comprised sexual assault including childhood sexual abuse (52%), violent non-sexual assault 
(30%), a road traffic or other accident (4%), warzone experiences (3%), and miscellaneous 
(10%). Exclusion criteria were (1) (current or past) psychosis or delusional disorders, (2) current 
suicidal intent, (3) mental retardation, (4) satisfying DSM-IV criteria for substance abuse or 
dependence, (4) pregnancy or lactation, (5) a serious and unstable medical condition (e.g., 
pacemaker, renal disease or porphyria), (6) a history of epileptic seizures, (7) medication use 
that might interfere with DCS (e.g., anticoagulants), (8) insufficient ability to speak and write 
Dutch. The study protocol was approved by the medical ethics committee of the Radboud 
University Nijmegen Medical Centre and written informed consent was obtained from all 
volunteer participants.
Treatments
Participants were randomly assigned in double-blind fashion to receive exposure therapy 
and DCS (N = 33) or exposure therapy and placebo (N = 34). Both treatment groups received 
a standardized prolonged exposure therapy program (see Foa & Rothbaum, 1998), with 
a maximum of 10 sessions (M = 7.22 [2.58]). Twenty-two participants (33%) dropped out 
prematurely, leaving 45 protocol completers. There was no statistical significant difference in 
drop-out rate between groups (DCS: N = 9 (27%); placebo: N = 13 (38%); χ²1 = 0.913, p = .339). 
Prior to the start of each exposure session, DCS (50 mg) or placebo (microcrystalline cellulose 
PH-102, identical in appearance) was administered. 
Outcome measure
The primary outcome measure was the Dutch translation of the PTSD Symptom Scale, Self 
Report (PSS-SR; Foa et al., 1993; Mol et al., 2005), a 17-item questionnaire with which patients 
rate the frequency of PTSD symptoms. All participants completed the PSS-SR pretreatment, 
before every treatment session, and posttreatment. Assessments were also conducted at 
3-month follow-up, but data from the follow-up period were not used in this study. 
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Potential predictors 
All potential predictors of treatment outcome were measured during the baseline assessment by 
trained independent assessors blind to treatment condition (Axis I comorbidity, antidepressants 
use), or self-report (demographic characteristics, PSS-SR, BDI, NEO). Each potential predictive 
variable was assigned to one of the following domains:
 Demographic characteristics: The following variables composed this domain: age, gender, 
marital status (single vs. married or cohabitating), educational level (based on the Dutch school 
system: 1 = primary school; 2 = high school; 3 = vocational education; 4 = higher vocational 
education; 5 = university).
 Clinical characteristics: This domain comprised: PTSD symptom severity (PSS-SR); 
comorbidity (the presence (yes, no) of at least one DSM-IV axis-I diagnoses other than PTSD 
as established with the Mini-International Neuropsychiatric Interview (M.I.N.I.) (Sheehan et al., 
1998)); depressive symptom severity assessed with the Beck Depression Inventory (BDI; Beck 
et al., 1961) and antidepressants use (yes, no).4
 Personality characteristics: Openness; Conscientiousness; Extraversion; Agreeableness 
and Neuroticism of the Five Factor model of personality (Costa & McCrae, 1992) were assessed 
with the Dutch translation of the 60-item version of the Neuroticism-Extraversion-Openness 
Five Factor Inventory (NEO-FFI; Hoekstra, Ormel, & de Fruyt, 2003).
Data analytic strategy  
Our primary statistical analyses investigated the association between possible prescriptive or 
prognostic variables and the pre- to posttreatment change in self-reported PTSD symptoms. We 
followed the data analytic strategy developed by Fournier et al. (2009), guided by the conceptual 
work of Kraemer et al. (2002). This approach was later used by Amir et al. (2011), and Smits et 
al. (2013). We analyzed continuous data from the PSS-SR using mixed model regressions. Using 
this approach, for each participant (i.e. a full intent-to-treat analysis) a linear slope and intercept 
was estimated from a collection of parameters. We included random effects for intercepts and 
slopes and an unstructured covariance matrix was used for these random effects. Following 
Fournier and colleagues (2009) we centered the time variable at posttreatment, so that intercept 
estimations represent PSS-SR scores at posttreatment. Continuous predictor variables were 
converted to z-scores and categorical predictors were coded -.5 and .5. Degrees of freedom for 
4  In our previous paper on the outcome of our RCT we conducted post-hoc analyses to examine the relation 
between outcome and comorbid depressive disorder and concomitant antidepressant use. These mixed-model 
analyses involved testing a group (DCS vs placebo) by time (pre, post, follow-up) by depressive disorder/
concomitant antidepressant use interaction effect, which did not yield any significant results. We would like to 
note that, in the current study, we modeled treatment outcome by examining both the intercept (i.e., outcome at 
posttreatment) as well as the slope of change (i.e., session-to session improvement) and therefore it is possible 
that significant interactions between group and these prescriptive variable candidates emerge in these analyses.  
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the regression coefficients were estimated with Satterthwaite approximation. We performed all 
analyses using SPSS version 19.0 (IBM).
 The model was built to assess simultaneously whether a variable was prescriptive or 
prognostic. As previously described, a prescriptive variable predicts differential outcome 
between the treatment groups (i.e., DCS versus placebo). So, to determine whether a 
variable was prescriptive, we examined the predictor and group interaction on the intercept 
(posttreatment PSS-SR scores, represented in the model by the predictor × group term) and 
linear slope (estimated change over time, represented in the model by predictor × time × 
group). A prognostic variable would predict outcome irrespective of treatment. To determine 
whether a variable was prognostic, we examined the effect of the predictor on the intercept 
(predictor term) and linear slope (predictor × time). Our smallest, simple model included the 
following variables: time, group, and time × group. To examine the effect of possible prescriptive 
or prognostic variables, for each of these variables their main effect and interaction with time, 
group, and time × group was added to the simple model.
 We classified our potential predictors into three different domains: demographic 
characteristics, clinical characteristics, and personality characteristics. Following prior research 
with this data analytic approach (Amir et al., 2011; Fournier et al., 2009; Smits, Hofmann, et al., 
2013), we first conducted a step-wise procedure for each domain. In step 1, we tested a model 
with all potential predictors and their interaction with time, group, and time × group. The terms 
that were significant at p <.20 retained in step 2. In step 3 and 4, all terms that were significant 
at respectively p <.10 and p <.05 at the previous step were retained. In all these steps, a main 
effect was retained, regardless of its significance, if an interaction term with group (predictor × 
time or predictor × time × group) proved significant. Finally, all terms that were significant at p 
<.05 at step 4 within a domain, were included in a final model assessing the predictors across 
all three domains. 
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Results
Baseline differences
Despite randomization, we found a between-group difference on BDI baseline scores. For this 
variable, t-tests for continuous variables revealed that the mean in the placebo group was 
significantly higher than the mean in the DCS group: BDI baseline, placebo: M = 27.91, SD = 
6.99; DCS: M = 23.13, SD = 10.38, t (62) = -2.17, p = .034. For all our other predictive variables, 
chi-square analyses for categorical and independent t-tests for continuous variables revealed 
no between group differences. 
Stepwise analysis of each domain of predictor domains
The form and interpretation of each significant effect will be discussed in the paragraph on the 
Final Model. Table 1 presents the descriptive statistics of the predictor variables and tables 
2-5 present the results of the stepwise analyses for each domain of predictors. Variables were 
considered to be predictive if they were significantly associated with both linear slopes and 
posttreatment PSS-SR scores. 
Table 1. Descriptive statistics of predictor variables for the total sample (N=67).
M SD
Demographic characteristics
Age 37.81 11.37
Gender (% woman) 79.1
Single (%) 61.2
Education (level) 2.79 1.00
Clinical characteristics
PSS –SR baseline 27.22 8.18
Axis I comorbidity (%) 70.1
BDI baseline 25.59 9.05
Antidepressants use (%) 25.4
Personality characteristics (NEO-FFI)
Openness 24.05 5.78
Conscientiousness 28.29 6.45
Extraversion 22.67 6.38
Agreeableness 29.77 5.84
Neuroticism 31.68 6.40
Abbreviations: PSS-SR = PTSD Symptom Scale, Self-Report; BDI = Beck Depression Inventory; NEO-FFI = 
Neuroticism-Extraversion-Openness Five Factor Inventory 
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Demographic characteristics. In the demographic characteristics no prescriptive variable 
emerged. One prognostic variable (see table 2), education, was associated with the slope, t 
(45) = 2.17, p = .035, 0.32 ± 0.15, as well as PSS-SR scores at posttreatment, t (58) = 3.01, p = 
.004, 5.53 ± 1.77. No prescriptive variable emerged from this domain. 
Table 2. Stepwise analysis of Demographic Characteristics domain
Demographic Characteristics
Change over time Posttreatment scores
Predictor ba SE p ba SE p
Step 1
Age  -0.55 0.16 2.64 1.79 ‡
Gender -0.14 0.38 -3.16 4.36
Single -0.42 0.31 ‡ -4.08 3.43
Education 0.28 0.15 † 5.82 1.69 **
Age × Group -0.04 0.32 -4.83 3.58 ‡
Gender × Group 0.07 0.77 1.13 8.72
Single × Group 0.92 0.61 ‡ 6.80 6.85
Education × Group -0.15 0.30 -8.83 3.39 *
Step 2, 3 and 4 (retain effects at p <.20; p <.10 and p <.05)
Education 0.32 0.15 * 5.39 1.79 *
Note. M = mean; SD = standard deviation; SE = standard error. a b-values represent unstandardized beta 
coefficients predicting PTSD Symptom Scale, Self-Report (PSS-SR) at the end of treatment. For lower order terms, 
values represent effects averaged across the two groups. Negative values represent more favorable outcome, 
i.e. lower PSS-SR scores. For interaction terms, values represent the difference between the two groups in the 
magnitude of the effect. 
‡ p <.20 †p <.10. * p < .05. ** p <.01.
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Clinical characteristics. Table 3 displays the results of the analysis of this domain. No prescriptive 
or prognostic variable was identified in this domain. 
Table 3. Stepwise analysis of Clinical Characteristics domain
Clinical Characteristics 
Change over time Posttreatment scores
Predictor ba SE p ba SE p
Step 1
PSS-SR baseline -0.24 0.21 4.92 2.15 *
Comorbidity 0.78 0.36 * 7.62 3.87 †
BDI baseline 0.28 0.22 4.25 2.40 †
Antidepressants -0.16 0.38 -0.99 4.06
PSS-SR baseline × Group -0.30 4.30 0.06 0.41
Comorbidity × Group -0.64 0.72 -8.88 7.74
BDI baseline × Group -0.50 0.45 -9.28 4.80 †
Antidepressants × Group -0.85 0.76 -10.84 8.13 ‡
Step 2, 3, 4 (retain effects at p <.20; p <.10 and p <.05)
Comorbidity 0.57 0.34 † 9.01 4.14 *
Note. M = mean; SD = standard deviation; SE = standard error. a b-values represent unstandardized beta coefficients 
predicting PTSD Symptom Scale, Self-Report (PSS-SR) at the end of treatment. For lower order terms, values 
represent effects averaged across the two groups. Negative values represent more favorable outcome. i.e. lower 
PSS-SR scores. For interaction terms, values represent the difference between the two groups in the magnitude of 
the effect. Abbreviations: PSS-SR = PTSD Symptom Scale Self Report; BDI = Beck Depression Inventory.
‡ p <.20 †p <.10. * p < .05. ** p <.01.
Personality characteristics. Of the five variables in this domain, two variables, extraversion 
and conscientiousness, were identified as prescriptive factors (see table 4). Both predicted 
differential effect of treatment on slopes: conscientiousness t (54) = -2.14, p = .037, -0.66 ± 
0.31; and extraversion, t (56) = 2.34, p = .023, 0.81 ± 0.35; as well as posttreatment PSS-SR 
scores – conscientiousness t (62) = -2.39, p = .020, 10.42 ± 4.18 and extraversion, t (69) = 2.49, 
p = .015, 10.49 ± 4.18.
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Table 4. Stepwise analysis of Personality Characteristics domain
Personality Characteristics
Change over time Posttreatment scores
Predictor ba SE p ba SE p
Step 1 
Openness 0.13 0.16 3.24 1.92 †
Conscientiousness 0.06 0.15 2.04 1.85
Extraversion 0.29 0.18 ‡ 0.54 2.12
Agreeableness -0.18 0.15 -3.19 1.86 †
Neuroticism 0.28 0.16 † 4.87 1.89 *
Openness × Group 0.41 0.32 -1.21 3.83
Conscientiousness × Group 0.57 0.31 † -8.86 3.70 *
Extraversion × Group 0.58 0.36 ‡ 8.69 4.23  *
Agreeableness × Group 0.22 0.31 -0.17 3.71
Neuroticism × Group -0.41 0.32 -5.91 3.77 ‡
Step 2 (retain effects at p < .20).
Conscientiousness 0.06 0.15 0.97 1.85
Extraversion 0.35 0.18 * 1.64 2.12
Neuroticism 0.27 0.16 ‡ 4.63 1.97 *
Conscientiousness × Group -0.63 0.30 * -8.59 3.72 *
Extraversion × Group 0.78 0.34 * 9.61 4.04 *
Step 3 and 4 (retain effects at p <.10 and p <.05).
Conscientiousness 0.05 0.15 0.89 1.93
Extraversion 0.27 0.17 ‡ 0.03 2.09
Conscientiousness × Group -0.66 0.31 * -9.25 3.86 *
Extraversion × Group 0.81 0.35 * 10.42 4.18 *
Note. M = mean; SD = standard deviation; SE = standard error. a b-values represent unstandardized beta 
coefficients predicting PTSD Symptom Scale Self Report (PSS-SR) at the end of treatment. For lower order terms, 
values represent effects averaged across the two groups. Negative values represent more favorable outcome. 
i.e. lower PSS-SR scores. For interaction terms, values represent the difference between the two groups in the 
magnitude of the effect. 
‡ p <.20 †p <.10. * p < .05. ** p <.01.
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Final model with all significant predictors
After the stepwise analyses of our three predictor domains, we included all the significant 
predictors in one final model. This allowed us to test the effect of each predictor on PSS-SR 
change, while controlling for the other variables. The final model contained the two prescriptive 
variables, conscientiousness and extraversion, and the prognostic variable, education (see 
table 5). 
Table 5. Final model with all significant predictors from the domain models
Final Model
Change over time Posttreatment scores
Predictor ba SE p ba SE p
Education 0.39 0.14 ** 6.03 1.70 **
Conscientiousness 0.00 0.15 -0.01 1.82
Extraversion 0.33 0.16 * 0.83 1.92
Conscientiousness × Group -0.77 0.30 * -10.70 3.63 **
Extraversion × Group 0.76 0.33 * 9.80 3.81 *
Note. M = mean; SD = standard deviation; SE = standard error. a b-values represent unstandardized beta 
coefficients predicting PTSD Symptom Scale Self Report (PSS-SR) at the end of treatment. For lower order terms, 
values represent effects averaged across the two groups. Negative values represent more favorable outcome, 
i.e. lower PSS-SR scores. For interaction terms, values represent the difference between the two groups in the 
magnitude of the effect. 
‡ p <.20 †p <.10. * p < .05. ** p <.01.
 With respect to the prescriptive variables, conscientiousness remained a significant 
prescriptive variable in the final model for both change over time as well as posttreatment 
PSS-SR scores (respectively: t (48) = -2.59, p = .013,- 0.77 ± 0.30) and t (58) = -2.95, p = .005, 
-10.70 ± 3.63). Thus, conscientiousness predicted a differential effect of treatment on PTSD 
symptom change over time and posttreatment PSS-SR scores. Using the Aiken and West (1991) 
approach, we examined the nature of this interaction by evaluating the model-based predicted 
effects of group for high conscientious (+ 1 SD) and low conscientious (-1 SD) participants. 
As illustrated in Figure 1, there was no difference between the two conditions in change of 
predicted PSS-SR scores for low conscientious participants (group × time: t (55) = -0.10, p = 
.921, -0.05 ± 0.46). However, for those high in conscientiousness, predicted improvement on 
the PSS-SR was higher for those in the DCS group than for those in the placebo group (group 
× time: t (51) = -2.36, p = .022, -1.04 ± 0.44), with predicted end of treatment PSS-SR scores of 
respectively 8.02 and 24.40.
 Extraversion also remained a significant predictor in the final model for both change over 
time as well as posttreatment PSS-SR scores (respectively: t (50) = 2.33, p = .024,- 0.76 ± .33 
and t (65) = 2.57, p = .012, 9.80 ± 3.81). Like we did with conscientiousness, we examined this 
interaction by evaluating the model-based predicted effects for groups for low (-1 SD) and high 
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(+1SD) extraversion. For those low on extraversion, participants who received DCS showed 
better outcome, than those who received placebo (group × time: t (50) = -2.83, p = .007, -1.27 ± 
0.45), with predicted end of treatment PSS-SR scores of respectively 7.98 and 23.46. For those 
high on extraversion, there were no differences between groups (group × time: t (55) = 0.06, p 
= .956, 0.03 ± 0.49 ).
 Finally, education remained a prognostic variable of both slope and PSS-SR scores at 
posttreatment, respectively: t (45) = 2.79, p = .008, 0.39 ± 0.14 and t (58) = 3.56, p = .001, 
6.03 ± 1.70. For the lower order effects, the unstandardized b-estimates can be interpreted as 
representing the change in estimated posttreatment PSS-SR scores per unit of the predictor 
above the sample mean. Thus, individuals with education levels one unit above the sample 
mean can be expected to score 6.03 points higher on the PSS-SR at the end of treatment. 
 Because of our between group differences at baseline on BDI scores, we fitted an 
additional model with BDI and all its interactions with time and group. The results of this 
additional model were consistent with the final model reported above.
Figure 1. Predicted PSS-SR scores for the two treatment groups for participants low in 
conscientiousness. Low conscientiousness is defined as NEO-FFI conscientiousness 1 SD below 
the grand mean. Abbreviations: PSS-SR = PTSD Symptom Scale, Self-Report; DCS = d-cycloserine.
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Figure 2. Predicted PSS-SR scores for the two treatment groups for participants high in 
conscientiousness. High conscientiousness is defined as NEO-FFI conscientiousness 1 SD above 
the grand mean. Abbreviations: PSS-SR = PTSD Symptom Scale, Self-Report; DCS = d-cycloserine. 
Figure 3. Predicted PSS-SR scores for the two treatment groups for participants low in extraversion. 
Low extraversion is defined as NEO-FFI extraversion 1 SD below the grand mean. Abbreviations: 
PSS-SR = PTSD Symptom Scale, Self-Report; DCS = d-cycloserine. 
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Figure 4. Predicted PSS-SR scores for the two treatment groups for participants high in extraversion.
High extraversion is defined as NEO-FFI extraversion 1 SD above the grand mean. Abbreviations: 
PSS-SR = PTSD Symptom Scale, Self-Report; DCS = d-cycloserine. 
Discussion
In this study, we aimed to identify individual characteristics that (1) predict outcome of DCS 
enhanced exposure therapy in PTSD patients and (2) predict outcome of exposure therapy 
for PTSD irrespective of DCS enhancement. By using an explorative approach, we aimed to 
generate hypotheses regarding potential matching strategies for DCS augmented exposure 
therapy in PTSD patients. 
 We identified two personality traits as prescriptive variables: conscientiousness and 
extraversion. For those high in conscientiousness, participants who received DCS showed 
better outcomes compared to those who received placebo. Our findings are largely in line 
with the findings of Smits et al. (2013) who also identified conscientiousness as a prescriptive 
factor. However, in contrast to our findings, they found enhancement of DCS only to be evident 
in persons low in conscientiousness. Because conscientiousness encompasses different facets 
(for instance, dutifulness, order and self-discipline), and there are some data suggesting that 
different facets have very different effects on fear conditioning (Pineles, Vogt, & Orr, 2009), 
one explanation might be that our sample differed from Smits et al.’s on facets level of 
conscientiousness. Unfortunately, we used the short version of the NEO and were unable to 
explore conscientiousness at facet level. Nonetheless, the work of Smits and colleagues and 
our findings suggest that there is an interaction between conscientiousness and extinction 
learning enhancement with DCS; future studies should investigate this relationship in more 
detail in order to identify the specific elements of conscientiousness that may contribute to 
this effect. 
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 We also identified extraversion as a prescriptive factor for DCS enhanced exposure 
outcome in PTSD patients. Specifically, only for those low in extraversion, participants who 
received DCS showed better outcomes compared to those who received placebo. This 
finding comports well with research in healthy subject samples, which has positively related 
extraversion to extinction learning (Rauch et al., 2005), and negatively to renewal (i.e. a return 
of fear after a successful extinction learning session; (Martinez et al., 2012), thus suggesting 
that low extraversion may point to (be a correlate of) an extinction learning deficit that may 
be reversed by DCS. It has also been shown that extraversion is related to thickness of the 
medial orbitofrontal cortex part of the ventromedial prefrontal cortex (vmPFC) (Rauch et al., 
2005). The vmPFC down regulates the amygdala, which is hyperactive in PTSD patients (e.g. 
Shin et al., 2005), and vmPFC activation and thickness have been related to extinction learning 
(Milad et al., 2005; Milad et al., 2007). Accordingly, low extraversion may point to extinction 
deficits explained by reduced vmPFC activation and thickness, which may be reversed by DCS 
administration. Although extraversion did not emerge as a moderator in the Smits et al. (2013) 
study, it is likely that the range in extraversion in their sample of social phobic patients was 
restricted, suggesting that extraversion as a prescriptive variable for DCS enhancement may be 
specific to certain patient populations. 
 Aside from personality traits, neither Smits et al. (2013) nor our study observed any 
prescriptive variables of DCS enhancement. The analyses of the parent trial of the current 
study suggested that DCS was beneficial especially for a subgroup of participants who did not 
initially respond to exposure therapy, this subgroup was characterized by more baseline PTSD 
symptoms (de Kleine et al., 2012). Importantly, initial PTSD severity alone (thus apart from the 
initial reaction to exposure treatment) did not emerge as a prescriptive variable in the present 
analyses nor did antidepressant use, which had been related to poorer DCS responding in 
an initial preclinical study (Werner-Seidler & Richardson, 2007) and an analogue study with 
humans (Rodebaugh et al., 2013).
 Consistent with previous work, we did not identify many prognostic variables of treatment 
outcome, regardless of DCS enhancement (van Minnen et al., 2002). In fact, education was the 
only prognostic variable in this study. Surprisingly, higher education levels predicted worse 
treatment outcome in the present study. Indeed, the relation between education and (non-
enhanced) exposure treatment outcome was not significant in previous work from our group 
(van Minnen et al., 2002) and others (Rizvi et al., 2009), and in line with that finding, Ehlers 
and colleagues (2005) found lower education to be related to better outcome in cognitive 
therapy for PTSD patients. If replicated, the findings of our analyses may lessen concerns about 
patients with low educational levels responding well to CBT for PTSD. 
 The fact that we did not identify any prognostic clinical characteristics is in line with 
studies that have failed to observe a relation between exposure therapy outcome and 
comorbidity in general (see van Minnen et al., 2012) or depressive symptoms specifically 
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(Hagenaars, van Minnen, & Hoogduin, 2010). Whereas patients who present with greater 
PTSD symptom severity prior to treatment sometimes evidence greater PTSD symptoms at 
posttreatment (van Minnen et al., 2002), we did not observe a relation between initial PTSD 
severity and symptom change over time in the present study. These findings add to the extant 
literature by showing that, while patients who present with greater severity may show worse 
end state functioning, their response to treatment is no different from patients who present 
with less severe symptoms.
 There are a number of limitations that deserve mentioning. First of all, even though our 
sample size can be considered large when compared to most DCS trials, for the purpose of 
predictor identification we had a relatively small sample. This may have limited our power 
to identify predictors, or inflated the risk of false positive findings. Thus, our findings need 
to be replicated in a larger trial. Second, because we examined predictors in a sample of 
chronic mixed-trauma PTSD patients randomized to receive either 8-10 sessions of exposure 
therapy plus DCS (50 mg) or placebo, our findings may not generalize to treatment protocols 
with a different duration (e.g. shorter protocols), different DCS dosages, or other PTSD (e.g. 
veterans instead of civilians) and other anxiety disorder populations. Third, we only examined 
psychological factors, while, especially given the nature of this treatment study, it would have 
been very interesting to examine biological factors. Ideally, future studies would combine 
both psychological and biological measures in treatment outcome prediction studies. Finally, 
a limitation of this study is that we did not investigate interactions among predictors. Even 
though we deliberately did not include these interactions into our model, because we already 
conducted a large number of tests, investigation of more complicated relationships can 
contribute to our understanding of prescriptive factors of DCS augmented exposure therapy 
(Fournier et al., 2009).
 Despite these limitations, this study provided support for the possible influence of 
person-level variables on DCS enhanced exposure therapy. Taken together with the findings 
of Smits et al. (2013) in patients suffering from social anxiety disorder it appears that some 
personality factors may influence DCS augmented exposure therapy outcome. Interestingly, 
there are indications that these personality factors may reflect extinction learning capacity. 
Subsequently, there are some data suggesting that process variables - i.e. indicators of 
extinction learning in the initial treatment phase - can have predictive value for DCS enhanced 
exposure therapy (Smits, Rosenfield, Otto, Marques, et al., 2013; Smits, Rosenfield, Otto, Powers, 
et al., 2013). We hypothesize that the combination of baseline variables and in-session signs of 
extinction learning may have better predictive significance than solely baseline variables, and 
suggest that future studies focus more on how these two sets of variables interact to explain 
therapy outcomes. 
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Extinction Learning as a 
Moderator of d-cycloserine 
Efficacy for Enhancing Exposure 
Treatment in Posttraumatic 
Stress Disorder
Based on: de Kleine, R. A., Smits, J. A., Hendriks, G. J., Becker, E. S., & van Minnen, A. (2015). 
Extinction Learning as a Moderator of d-cycloserine Efficacy for Enhancing Exposure 
Therapy in Posttraumatic Stress Disorder. Journal of Anxiety Disorders, 34, 63-67.
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Abstract
Augmentation of exposure therapy with d-cycloserine (DCS) has proven efficacious across 
anxiety disorders, although results in PTSD have been mixed. Work in animals and anxiety-
disordered patients suggest that the potentiating effects of DCS are dependent on the level 
of extinction learning during extinction training and exposure treatment, respectively. The aim 
of the current study was to replicate and extend previous work by examining the association 
between the degree of extinction learning and DCS efficacy in our randomized clinical trial 
on DCS (50 mg) versus placebo enhancement of exposure therapy in a chronic mixed-trauma 
PTSD sample (N = 67; de Kleine et al., 2012). The decline in subjective units of distress ratings 
collected during and across exposure sessions were evaluated as indices of extinction learning. 
First, we examined whether extinction learning during an exposure session moderated DCS 
effects on self-reported PTSD symptoms at the next session. Second, we examined whether 
averaged extinction learning over the course of treatment interacted with group assignment 
to predict change over time and posttreatment outcome. We did not find evidence that DCS 
effects were moderated by the degree of extinction learning, although, extinction learning 
was related to outcome regardless of group assignment. In PTSD, not one extinction-learning 
index has been consistently linked to DCS enhanced exposure treatment outcome. More 
(experimental) work needs to been done to unravel the complex interplay between extinction 
learning and DCS enhancement, especially in PTSD patients. 
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Introduction
d-cycloserine (DCS), a partial agonist of the NMDA receptor, has been tested as an augmentation 
strategy for exposure therapy effects because it is thought to enhance the consolidation of 
extinction learning (Davis, Ressler, Rothbaum, & Richardson, 2006), a key mechanism of action 
of exposure therapy. Accumulating evidence points to the efficacy of this novel augmentation 
strategy (see for meta-analyses: Bontempo et al., 2012; Norberg et al., 2008; Rodrigues et al., 
2014), but results of these clinical studies have been mixed, especially in the treatment of 
posttraumatic stress disorder (PTSD). Difede and colleagues (2014), who investigated DCS 
enhanced virtual reality exposure therapy (VRET) for civilian PTSD patients following the WTC-
attacks, showed faster and greater symptom decline for those who received DCS. De Kleine 
and colleagues (2012) investigated the DCS enhancement effects of prolonged exposure (PE) 
in a civilian chronic, mixed-trauma sample, and observed no overall improvement in outcome, 
although DCS did augment effects in a subgroup of more severe patients that needed longer 
treatment. Similarly, Rothbaum and colleagues (2014) failed to find overall enhancement 
effects of DCS compared to placebo and alprazolam in a large veteran population using VRET, 
but did show that DCS reduced physiological reactivity to trauma relevant cues. In a mixed 
trauma sample of 7 to 18 year-old youth, Scheeringa and Weems (2014) found no evidence of 
DCS facilitation using a cognitive behavioral therapy program, including exposure exercises. 
Importantly, Litz et al. (2012) actually observed negative effects for DCS augmentation of 
exposure treatment albeit in a small veteran PTSD sample.
 There are a number of possible explanations for the observed inconsistencies across 
studies. First, it has been put forward that methodological differences across studies could 
account for the different outcomes (Hofmann et al., 2011). For instance, dose, timing and 
number of DCS administrations have differed among studies. Second, it has been suggested 
that person-level variables, such as symptom severity (Guastella, Dadds, et al., 2007; Siegmund 
et al., 2011), antidepressant use (Werner-Seidler & Richardson, 2007) or personality traits 
could influence DCS effects. In support, De Kleine et al. (2014) found that personality traits 
(conscientiousness and extraversion) influenced DCS effects in PTSD patients. Third, in line 
with the proposed working mechanism of DCS, it has been stipulated that enhancement effects 
may be influenced by the amount of (extinction) learning during treatment (for instance Litz et 
al., 2012). Indeed, in preclinical paradigms it has been found that DCS was especially beneficial 
for animals that showed more within-session extinction during training (Bolkan & Lattal, 2014; 
Bouton et al., 2008; Weber et al., 2007). When the amount of extinction learning during training 
was experimentally restricted, DCS was found to have no augmentation (Bouton et al., 2008) 
or even detrimental effects (Lee, Milton, & Everitt, 2006). This suggests that when there is 
not sufficient extinction learning, DCS might potentiate reconsolidation of the fear memory, 
which has been translated clinically into “DCS might make a good exposure better, and a bad 
exposure worse” (Litz et al., 2012, p. 1189).
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 Recent reanalyses of clinical trial data on DCS enhanced exposure treatment support 
this hypothesis. Smits and colleagues (2013) found that fear levels at the end of an exposure 
session interacted with DCS effects in their trial on DCS enhanced virtual reality treatment in 
acrophobic patients. That is, compared to placebo, those who received DCS and had low fear 
at the end of the exposure session improved more in the following week, while those with 
relatively high end fear improved less. A similar pattern was found in a large social phobic 
sample. In addition to the per session effects, DCS enhancement effects at posttreatment were 
only evident among those who had low end fear during the sessions that were augmented with 
DCS (Smits, Rosenfield, Otto, Marques, et al., 2013). In this latter study, Smits and colleagues 
examined additional indices of extinction learning, namely peak fear levels and decrement of 
fear within-session (i.e. peak fear minus end fear), but found the strongest moderating effects 
for end fear. 
 Whether extinction learning moderates DCS efficacy for enhancing PE for PTSD is unclear. 
Litz and colleagues (2012) found less within-session extinction in some (but not all) exposure 
sessions for those receiving DCS compared to placebo, and suggested that these differences 
were related to their negative outcome for DCS, but did not report on the test of this 
hypothesized effect. Rothbaum and colleagues (2014) found that DCS enhancement effects 
were stronger among patients who showed greater between-session extinction learning over 
the course of treatment, but did not report on the moderator effects of end fear or within-
session extinction.
 To conclude, the aim of the present study is to further investigate whether DCS 
enhancement effects are moderated by the degree of extinction learning during exposure 
therapy in PTSD. Specifically, we hypothesize that DCS enhancement effects are specific 
to sessions that are successful or associated with low end fear levels. Extinction learning 
consolidation is thought to occur hours after the end of exposure sessions, and when DCS is 
administered just before or immediately after exposure sessions, peak blood levels of DCS 
overlap with this consolidation window. Accordingly, if we observed the expected moderation 
effect in our study, our findings would suggest that learning process are indeed underlying DCS 
efficacy, and imply that clinicians should be judicious in applying DCS in conjunction with PE.
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Materials and methods
This study is a reanalysis of clinical trial data on DCS enhancement of PE in PTSD (trial 
registration: www.trialregister.nl, NTR1184). For a full description of the trial methods and 
materials we refer to the parent trial (de Kleine et al., 2012).
Participants
Sixty-seven participants were recruited in two Dutch regular mental health care facilities. The 
sample consisted predominantly of women (88%), and trauma-type was mixed, with most of the 
participants being survivors of sexual violence, including childhood sexual abuse. Participants 
who fulfilled any of the following criteria were excluded: (1) (current or past) psychosis or 
delusional disorders, (2) current suicidal intent, (3) mental retardation, (4) satisfying DSM-
IV criteria for substance abuse or dependence, (4) pregnancy or lactation, (5) a serious and 
unstable medical condition (e.g., pacemaker, renal disease or porphyria), (6) a history of epileptic 
seizures, (7) medication use that might interfere with DCS (e.g., anticoagulants), (8) insufficient 
ability to speak and write Dutch. Co-morbidity rates were high, with over 70 percent suffering 
from at least one comorbid Axis I disorder. During treatment, 22 participants (33%) dropped 
out prematurely, leaving 45 treatment completers. The drop-out rate between groups did not 
differ significantly (DCS: N = 9 (27%); Placebo: N = 13 (38%); χ²1 = 0.913, p = .339).
Treatment 
All participants received manualized PE treatment (see Foa, Hembree, & Rothbaum, 2007), with 
a maximum of 10 sessions. In the first session, participants received psychoeducation on PTSD 
symptoms and the treatment rationale. Based on the prior work by Van Minnen and Foa (2006), 
the subsequent weekly exposure sessions comprised 30 minutes of imaginal exposure (rather 
than the 45 to 60 minutes of the original PE protocol). Patients were instructed to imagine 
the traumatic event as vividly as possible and to repeatedly recount it aloud in the present. 
Throughout imaginal exposure, fear levels were monitored by subjective units of distress 
(SUD; Wolpe, 1958) ratings on a scale of 0 (no fear) to 100 (maximum fear). SUD ratings were 
obtained right before the start of imaginal exposure every 5 minutes, and immediately at the 
end of imaginal exposure. All therapists (N = 25) were psychologists trained in PE treatment for 
PTSD, and all weekly sessions were supervised. In a previous study (Hagenaars, van Minnen, 
& Hoogduin, 2010), we had found that a proportion of patients terminated treatment early, 
because they had reached (full) recovery. To allow for early termination, we defined stopping 
rules: if the PSS-SR score was below 15 on two subsequent sessions, and if there was patient-
therapist agreement on improvement, patients could end treatment. The mean number of total 
sessions received was 7.22 (SD = 2.58). 
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Design 
After enrollment, participants were randomly allocated in double blind fashion to receive 
prolonged exposure plus placebo (microcrystalline cellulose PH-102; N = 34) or prolonged 
exposure plus d-cycloserine (50 mg; N = 33). Study drugs (identical in appearance) were 
dispensed by an independent pharmacist in numbered containers in accordance with a 
computer generalized randomization list. Participants ingested the study drug 60 minutes prior 
to each prolonged exposure session. The study protocol was approved by the medical ethics 
committee of the Radboud University Nijmegen Medical Centre and written informed consent 
was obtained from all volunteer participants.
Instruments
Outcome measure
PTSD symptom severity was measured by means of a self-report at baseline, at each 
prolonged exposure session (i.e. weekly), and at posttreatment. The weekly assessment 
took place at the treatment location, just before the beginning of each treatment session. 
Participants filled out the Dutch translation of the Posttraumatic Stress Symptom Scale, Self 
Report (PSS-SR; Foa et al., 1993). Both the original and translated version have shown good 
internal consistency (Foa et al., 1993; Mol et al., 2005), as has the version employed in this 
study (α =.94).
Extinction learning indices
The primary analyses followed those described by Smits and colleagues (2013; 2013) and 
tested the moderator effects of end fear level (as an indicator of extinction learning). First, we 
examined whether end fear moderated the effect of group (Placebo versus DCS) on PSS-SR 
scores at the next session. Second, we examined the moderating effect of averaged end fear 
levels over the course of treatment (i.e. the mean of the last SUD scores obtained at every 
session) on group on PSS-SR score change and posttreatment scores. As alternative measures 
of extinction learning, we explored the effects of within- and between-session extinction. 
Within-session extinction was calculated by subtracting end fear from peak fear (i.e. Peaksn – 
Endsn), and we tested (1) the moderating effects of within-session extinction on PSS-SR scores 
at the next session and (2) the moderating effects of the average within-session extinction 
(Mean of Peaksn – Endsn) on PSS-SR change and posttreatment scores. Lastly, following 
Rothbaum and colleagues (2014), we tested whether the average between-session extinction 
level moderated the effect of DCS vs. Placebo on PSS-SR score change and posttreatment 
scores. Here, between-session extinction was calculated as the mean of change in peak fear 
levels (i.e. the highest SUD score obtained during a session) between successive sessions 
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(Mean of Peaksn+1 – Peaksn). We collected SUDs data in 93.7% of the DCS/placebo enhanced 
sessions (N = 385; total sum of sessions = 406), with rates of missing values per session 
ranging from 0 (session 3 and 10) to a maximum of 12.9% (session 7). Most participants 
(77.6%; N = 52) provided SUDs data for all sessions, 16.4% (N = 11) had missing data for 
one session, and 5.9% (N = 4) had missing SUDs data for more than two sessions. Note, that 
in mixed model analyses, subjects with missing data are not necessarily excluded from the 
analysis (in contrast to, for instance, repeated measures).
Data analytic strategy  
We analyzed continuous data from the PSS-SR using mixed model regressions. First, to 
determine if end fear moderated the effect of group (Placebo versus DCS) on PSS-SR scores 
at the next session our model included the following predictors: end fear, group (DCS versus 
Placebo), and end fear × group. We included several variables to control for potential third 
variables (see also Smits, Rosenfield, Otto, Marques, et al., 2013): beginning fear, beginning fear 
× group, baseline PTSD symptom severity (as assessed with the PSS-SR), PSS-SR score from the 
previous session and education (based on de Kleine et al., 2014). This analysis included data 
from all DCS/placebo enhanced sessions (session 2-9).
 Second, we examined whether the mean level of end fear across all augmented exposure 
sessions (session 2-9) interacted with group assignment on both change over time and 
posttreatment PTSD symptoms. This model included linear time (centered at posttreatment), 
group (DCS versus Placebo), averaged end fear and all interactions as predictors of weekly 
PSS-SR scores. In line with the per session analysis, we included averaged beginning fear 
and its interactions with time and group, baseline PTSD symptom severity and education 
as control variables. The models examining the moderating effects of within- and between-
session extinction included the same variables, but all end fear terms were replaced by within 
or between-session extinction, respectively. For all analyses, we used maximum likelihood 
estimations and an unstructured covariance matrix of the errors of the repeated measures. 
Degrees of freedom for the regression coefficients were estimated with Satterthwaite 
approximation.
Results
Preliminary analyses
At baseline, groups had comparable self-reported symptom severity. PSS-SR scores: Placebo: 
M = 28.28, SD = 8.59; DCS: M = 26.16, SD = 7.73, t (62) = 1.040, p = .302. SUDS data were not 
normally distributed. Mann-Whitney U tests revealed that there were no significant differences 
between groups on any extinction learning index (see table 1).
56 |
Table 1. Means (SDs) for the extinction learning indices for the total sample and both 
treatment groups. 
Total 
N = 67
Placebo
N = 34
d-cycloserine
N = 33
M SD M SD M SD p
End fear 62.17 19.12 66.06 17.81 58.15 19.85 .134
Within-session extinction 17.52 14.03 14.31 10.35 20.83 16.53 .081
Between-session extinctiona 4.53 9.75 3.47 9.48 5.60 10.05 .470
Note.  M = mean; SD = standard deviation; a 3 participants (Placebo: N = 2; DCS N = 1) received only one enhanced 
treatment session, and consequently lack a between session extinction score. 
End fear 
First, we did not find that end fear levels interacted with DCS administration on PSS-SR scores 
at the next session (b = 0.43, t (52) = 0.662, p = .511). Second, average end fear levels did not 
interact with group assignment on PSS-SR change over time (b = 0.33, t (47) = 1.206, p = .234) 
or posttreatment PSS-SR scores (b = 3.01, t (50) = 1.104, p = .275). Irrespective of treatment 
condition, end fear levels predicted PSS-SR scores at the next session (b =1.05, t (41) = 3.207, p 
= .003), symptom decline over treatment (b =0.39, t (48) = 2.847 p = .006), and posttreatment 
PSS-SR scores (b = 4.98, t (47) = 3.677, p = .001).
Exploratory analyses: Within- and between session extinction
We did not find significant within-session extinction × group interactions on PSS-SR scores at 
the next session (b = 0.94, t (102) = 0.155, p = .123), nor interaction effects of average within-
session extinction and group on slopes of improvement (b = -0.01, t (54) = -0.056, p = .955) or 
posttreatment PSS-SR scores (b = -1.20, t (60) = -0.472, p = .639). Similarly, between-session 
extinction did not interact with group assignment (change over time: b = -0.11, t (60) =- 0.450, 
p = .654; posttreatment: b = -0.05, t (65) = - 0.020, p = .984). Regardless of group assignment, 
more within-session extinction was related to lower PSS-SR scores at the next session (b = 
-0.96, t (84) = -3.27, p =.002), and both within- and between session extinction were related 
to more improvement over time (b = -0.28, t (54) = -2.298, p = .025; b = -0.32, t (60) = - 2.54, 
p =.014, respectively), and lower posttreatment PTSD symptoms (b = -3.33, t (59) = -2.623, p = 
.011; b = - 4.27, t (66) = -3.369, p = .001, respectively).5
5 In a previous study (de Kleine et al., 2014) we identified two personality traits (NEO Extraversion and 
Conscientiousness) as moderators of DCS enhancement effects in our clinical trial. To examine the effects of 
extinction learning while controlling for these effects, we built models including these variables and their 
interaction with time and group. The results were no different from those presented in the main text, and for the 
sake of clarity, we present the simplest models.
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Discussion
In contrast to previous work and our hypotheses we failed to find moderating effects of the 
degree of extinction learning on DCS administration for symptom improvement in PE for PTSD. 
 Our findings are incongruent with the putative mechanism of action of DCS augmentation 
(i.e., enhancement of extinction learning consolidation), and evidence from preclinical 
and prior clinical research that demonstrated that the degree of extinction learning during 
extinction training/exposure therapy moderated the efficacy of DCS enhancement for several 
anxiety disorders (Bolkan & Lattal, 2014; Bouton et al., 2008; Smits, Rosenfield, Otto, Marques, 
et al., 2013; Smits, Rosenfield, Otto, Powers, et al., 2013; Weber et al., 2007), including PTSD 
(Rothbaum et al., 2014). Interestingly, two additional studies have since documented that the 
efficacy of other cognitive enhancers of exposure therapy (e.g., yohimbine, methylene blue) 
also depends on the level of extinction learning as indexed by low end fear (Smits et al., 2014; 
Telch et al., 2014). In our main trial we failed to establish overall DCS enhancement effects of 
exposure therapy for PTSD (de Kleine et al., 2012). In the current reanalysis, we found evidence 
that (change in) SUDs ratings were related to better outcome regardless of group assignment 
(Bluett, Zoellner, & Feeny, 2014; Rauch, Foa, Furr, & Filip, 2004; van Minnen & Hagenaars, 2002), 
indicating that the range in SUDs ratings in our study was sufficient to moderate treatment 
outcome. However, we found no confirmation for the DCS mechanism of extinction learning 
consolidation enhancement. 
 In order to replicate and extend extant research on extinction learning and DCS interactions 
in exposure therapy we opted to utilize the same extinction learning indices as in the studies 
that guided this paper. However, one explanation of our negative finding may be that in-session 
SUDS ratings are simply not a good index of the learning process that is enhanced by DCS in 
PE for PTSD. There is extensive evidence that DCS does not facilitate extinction learning as 
such, but rather enhances the consolidation of extinction learning (see for instance, Davis et 
al., 2006; Ledgerwood et al., 2003; Ressler et al., 2004; Walker et al., 2002). Although the SUDS 
ratings conceptually map on nicely to the traditional indices of extinction learning in animal 
research on fear extinction, and therefore make a reasonable index of exposure success, it is 
possible that SUDS levels (or their change) not always fully reflect the acquisition of a new 
extinction memory. Principally, SUDS levels gauge fear expression, which is not necessarily 
equivalent to fear extinction learning. Furthermore, SUDs ratings are the result of a subjective 
conscious rating process and therefore subject to cognitive appraisal, while in animal fear 
learning, extinction learning is indexed by automatic physiological or behavioral responding 
(i.e., decrements in freezing or fear potentiated startle (Myers & Davis, 2007). This translational 
obstacle might explain some of the discrepant findings between animal and human studies on 
this topic. Perhaps an end SUDS level or SUDS change score would be a more valid index of 
exposure success (i.e., acquisition of fear extinction memory) and more predictive of treatment 
outcome in PTSD if verified or completed by additional indices of extinction learning (e.g. 
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decreased physiological arousal) or cognitive change (e.g., decreased harm expectancy, see 
also Hofmann, 2008). 
 Even though animal studies provide a solid basis for the extinction consolidation 
enhancement hypothesis of DCS and the central role of the amygdala in this (Ledgerwood et al., 
2003; Walker et al., 2002), the precise underlying mechanism of DCS remains to be determined. 
In an animal model of PTSD, Yamamoto and colleagues (2008) demonstrated that, irrespective 
of its extinction consolidation enhancement effects, DCS might help to reverse hippocampal 
plasticity. The hippocampus is critically involved in new learning, and PTSD has been related 
to reduced hippocampal volume and functioning (see for review Bremner, Elzinga, Schmahl, 
& Vermetten, 2008). In line with the idea that there are several mechanisms of action in PE 
(i.e. extinction learning and cognitive reappraisal), DCS mechanisms may go beyond extinction 
consolidation enhancement, implying that DCS might facilitate auxiliary therapeutic processes 
(e.g. cognitive restructuring) in PE. More studies are needed in this direction to further clarify 
this issue. 
 There are some limitations of the current work that deserve mentioning. First, while we 
assumed a linear relationship between DCS moderation of extinction learning and treatment 
outcome, this may not be necessarily a valid assumption. Following the idea that DCS might 
make “good” exposure sessions better and “bad” exposure sessions worse (Hofmann, 2014; 
Litz et al., 2012), there might be a critical point for successful DCS enhancement, which should 
be established in future work. Second, for the purpose of treatment outcome prediction our 
sample was relatively small. Third, ideally, we would have assessed weekly symptom change 
by both self-report and clinician administered instruments. Fourth, exposure content may have 
differed largely between participants, dependent on their trauma history and index traumas, 
limiting the homogeneity of the results. Last, our predominantly women sample limits the 
generalizibility of our results.
Conclusion
DCS augmentation of exposure therapy shows promise in improving treatment efficacy for 
anxiety disorders, including PTSD. Nonetheless not all studies found positive effects and more 
work needs to be done to elucidate the conditions for successful augmentation. Some have 
suggested that DCS enhancement effects may depend on the “success of an exposure session” 
(Smits, Rosenfield, Otto, Marques, et al., 2013, p. 1455), which was confirmed in several studies 
in anxiety disorders. However, we could not replicate these findings in our mixed-trauma 
PTSD sample. In PTSD, not one extinction learning index has been consistently linked to DCS 
enhancement effects, and more work needs to be done to unravel the complex interplay 
between extinction learning and DCS enhancement in this disorder. 
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Defining the Success of 
Exposure Therapy Sessions: 
Harm Expectancy Violation 
during Exposure Therapy for 
Posttraumatic Stress Disorder 
Based on: de Kleine, R. A., Hendriks, L., Becker, E. S., Broekman, T.B.G., & van Minnen, A. 
(submitted for publication). Defining the Success of Exposure Therapy Sessions: Harm 
Expectancy Violation during Exposure Therapy for Posttraumatic Stress Disorder.
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Abstract
Exposure therapy has proven efficacy for the treatment of posttraumatic stress disorder 
(PTSD). It has been argued that fear habituation, both within and between exposure sessions, 
denotes exposure therapy success. However, studies investigating the predictive value of fear 
habituation for treatment outcome have yielded mixed findings. Alternatively, and in line with 
current theories on extinction learning - one of the proposed mechanisms of action of exposure 
therapy – changes in harm expectancies might be more predictive of favourable treatment 
outcome. We assessed harm expectancies prior to treatment, their violation within and change 
between exposure therapy sessions, and whether this was predictive of PTSD symptom change 
at posttreatment as measured by the Clinician Administered PTSD Scale (CAPS) in 50 patients 
with chronic PTSD who suffered interpersonal childhood trauma enrolled in an exposure 
therapy trial. As hypothesized, harm expectancies were prevalent prior to exposure therapy, 
and were violated within and strongly declined between exposure therapy sessions. However, 
expectancy violation measures were not related to PTSD symptom change. In contrast, fear 
habituation measures were moderately related to PTSD symptom reductions. This is the first 
clinical study examining expectancy violation as a mechanism of change in exposure therapy. 
In line with theory, exposure therapy promotes expectancy violation in PTSD patients. More 
clinical work is warranted to validate expectancy violation as a mechanism of change during 
exposure therapy and to establish valid indices of exposure session success. 
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Introduction
Exposure therapy is an effective treatment strategy for posttraumatic stress disorder (PTSD; 
see for review (Watts et al., 2013)), and involves systematic repeated exposure to traumatic 
memories (imaginal exposure) and to safe, but anxiety provoking trauma related situations 
(exposure in vivo). According to the emotional processing theory (Foa & Kozak, 1986), effective 
exposure to trauma-related stimuli leads to the activation of the pathological fear structure, 
which includes representations of trauma-related stimuli, responses and their meaning, and the 
incorporation of new corrective information within this structure. Importantly, fear habituation 
both within and between exposure sessions are argued to indicate corrective learning, and 
successful treatment outcome, ultimately.
 However, in recent years, there is growing debate whether fear habituation during 
treatment precedes good exposure therapy outcome (Craske et al., 2008; Craske et al., 2014).
Experimental data in both animals and healthy volunteers do not support the role of fear 
decline for successful extinction learning (Plendl & Wotjak, 2010; Prenoveau, Craske, Liao, & 
Ornitz, 2013), nor have clinical analogue studies in anxious samples verified the prerequisite 
of fear habituation for good exposure outcome (Baker et al., 2010; Culver, Stoyanova, & Craske, 
2012; Kircanski et al., 2012). To the contrary, some even found that less fear decrement was 
related to better outcome (Culver et al., 2012). Studies examining the moderating role of 
fear habituation in and over exposure sessions on treatment outcome for PTSD have yielded 
mixed results. Within session fear habituation was unrelated to posttreatment PTSD symptoms 
(Nacasch et al., 2015; Sripada & Rauch, 2015; van Minnen & Hagenaars, 2002), while fear 
habituation over sessions (between sessions habituation) was related to better outcome 
(Bluett et al., 2014; Jaycox, Foa, & Morral, 1998; Nacasch et al., 2015; Rauch et al., 2004; Sripada 
& Rauch, 2015; van Minnen & Hagenaars, 2002), but was by no means a boundary condition 
for beneficial outcome (Bluett et al., 2014). Thus, while fear habituation has been linked to 
exposure success, and consequently is commonly used in clinical practice to guide exposure 
sessions and evaluate their success, there is limited empirical support that it is indeed a key 
mechanism of action.
 Advances in our understanding of learning mechanisms provide alternative ideas 
about mechanisms of change in exposure therapy (Craske et al., 2008; Craske et al., 2014; 
Hofmann, 2008). Extinction learning is thought to be one of the mechanisms of action of 
exposure therapy, and refers to the process wherein a conditioned stimulus (CS; i.e., a trauma 
reminder) is repeatedly presented in absence of the unconditioned stimulus (US; i.e., the 
traumatic experience) thereby leading to reduction of the conditioned response (CR; i.e., fear). 
It is now believed that extinction learning is not so much the unlearning of the original CS-
US association, but rather a new-learning of a CS-noUS relationship (Bouton, 1993; LeDoux, 
1995), referred to as inhibitory learning (Craske et al., 2008; Craske et al., 2014). According to 
the theory of inhibitory learning, extinction is thought to occur after a mismatch between the 
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expectancy of an aversive event and the absence of its occurrence (Gallistel & Gibbon, 2000; 
Rescorla & Wagner, 1972), i.e. violation of the harm expectancy. Translated to exposure therapy 
for PTSD, this means that a PTSD patient learns that confrontation with traumatic stimuli (CS) 
will not lead to the expected hazardous outcome (no-US). 
 In experimental fear conditioning paradigms changes in harm (US) expectancies are often 
used as an index of successful extinction learning (Boddez et al., 2013). There is evidence 
to suggest that PTSD patients are characterized by elevated harm expectancies during 
experimental extinction learning (Blechert, Michael, Vriends, Margraf, & Wilhelm, 2007), and 
that this expectancy bias can predict the onset (Lommen, Engelhard, Sijbrandij, van den Hout, 
& Hermans, 2013) and maintenance (Engelhard, de Jong, van den Hout, & van Overveld, 
2009) of PTSD symptoms. However, to the best of our knowledge, there is no clinical study 
investigating expectancy violations during exposure therapy for PTSD. There is however 
ample evidence that cognitive changes occur during exposure therapy, even without explicitly 
addressing dysfunctional cognitions (Foa & Rauch, 2004; Hagenaars, van Minnen, & de Rooij, 
2010; McLean et al., 2015; Zalta et al., 2014), and that these cognitive changes precede PTSD 
symptom decline (McLean et al., 2015; Zalta et al., 2014). However, in these studies general 
dysfunctional cognitions were studied and not so much expectancy violations. Investigating 
changes in the CS-US relationship could provide us with a better understanding of the 
mechanisms of change during exposure therapy. Hypothetically, and alternatively to the fear 
habituation model, violation of the idea that exposure to trauma related stimuli would lead 
to threat (i.e. If I go to a bar, I will get assaulted) or that recounting the traumatic experience 
is dangerous (i.e. When I recall the trauma, I will go crazy) could index successful extinction 
learning and favorable treatment outcome in the end.
 Given that, up until now, very little is known about expectancy violations during exposure 
therapy in PTSD, the first aim of this study is to gain more insight into PTSD patients’ harm 
(US) expectancies during imaginal exposure. Furthermore, we aim to investigate whether 
harm expectancies are violated and change during imaginal exposure, and if so, whether this 
predicts PTSD symptom change after treatment. Last, we will explore the relationship between 
expectancy violation and fear habituation as indicators of successful learning during exposure 
therapy. 
Methods 
Participants
Participants were 50 treatment seeking patients with chronic PTSD (44 women, 6 men) who 
were treated at a Dutch treatment facility specializing in the treatment of anxiety disorders. 
Specifically, participants were provided with a newly developed brief intensive exposure 
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treatment program for PTSD (see Hendriks, de Kleine, van Rees, Bult, & van Minnen, 2010)
with prolonged exposure (Foa et al., 2007) as main treatment component. All participants 
indicated childhood physical and/or sexual abuse as their index trauma. Prior to enrolment, 
PTSD diagnoses were verified by means of the Clinician Administered PTSD Scale (Blake et al., 
1990), and mean scores indicated severe PTSD symptoms (M= 83.68, SD = 13.83). All volunteer 
participants provided written informed consent.
Measures 
Clinician Administered PTSD Scale. Outcome was assessed with the Clinician-Administered 
PTSD Scale (CAPS-1; Blake et al., 1995), a clinician-rated structured interview developed to test 
for the presence of the 17 DSM-IV-TR criteria for PTSD. The CAPS is considered golden standard 
to establish PTSD diagnosis and symptom severity. The interrater diagnostic agreement was 
shown to be excellent (Blake et al., 1990), as was the internal consistency (α = .94; Blake et al., 
1995), while the concurrent validity was adequate (Blake et al., 1995; Blake et al., 1990). 
 Subjective Units of Distress (SUDs). During each exposure session subjective units of 
distress ratings (SUDs; Wolpe, 1957) were obtained. Participants rated their levels of distress 
on a 0-10 point scale (no anxiety - maximum anxiety). Participants provided SUD scores just 
before imaginal exposure, every 10 minutes during imaginal exposure and at the end of 
imaginal exposure. We used the highest given SUD rating (SUD peak), and the latest SUD rating 
(SUD end) of each imaginal exposure session. Following previous studies (e.g. Rauch et al., 
2004; Rothbaum et al., 2014; van Minnen & Hagenaars, 2002), within session habituation was 
calculated by subtracting SUD end from SUD peak scores and between session habituation 
was calculated as the difference between SUD peak scores from successive sessions. The mean 
of these differences were used as indices of average within- and between session habituation 
over treatment. 
 Harm expectancy and Harm experience ratings. To gain more insight into harm expectancies 
in PTSD patients, at the start of treatment, participants formulated their harm expectancy 
regarding imaginal exposure by completing an open-ended sentence: “Doing imaginal 
exposure, I fear....”. In addition, to assess changes in harm expectancy ratings over sessions, 
participants rated their belief in three commonly expressed harm expectancies regarding 
(imaginal) exposure (Craske et al., 2014; Foa & Kozak, 1986; Foa & Rothbaum, 1998) prior 
to each exposure session on a 0 (totally disagree) to 10-point (completely agree) scale. This 
expectancies were: During imaginal exposure I will get so anxious, that I will: 1) go crazy; 2) 
lose control; 3) panic. Immediately after each session, participants rated their harm experience.
That is, they rated (on a scale from 0 (not at all) to 10 (completely)) whether they actually 
experienced their feared outcome, i.e. had the feeling they went crazy, lost control, or panicked.
Internal consistency of both the harm expectancy and experience questionnaire was deemed 
satisfactory (α =.94 and α =.90, respectively), hence we used mean scores of both measures in 
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all analyses. In analogue to the fear habituation measures, we calculated within and between 
session indices of expectancy violation. Within session expectancy violation was calculated 
by subtracting harm experience from harm expectancy ratings. Between session expectancy 
change was calculated by subtracting harm expectancy scores from successive sessions. The 
mean of these differences were used as indices of average expectancy violation and change 
over treatment. 
Procedure
Prior to treatment all participants completed a baseline assessment, comprising clinician 
administered and self-report instruments. Treatment consisted of brief intensive exposure 
treatment (see Hendriks et al., 2010 for a description), which is largely based on the Prolonged 
Exposure (PE) protocol (Foa et al., 2007). The intensive phase comprised 12 exposure-based 
sessions (90 minutes) provided on four consecutive treatment days. Each day’s first session 
consisted of manualized 60 minute imaginal exposure following the PE protocol. Patients 
were instructed to close their eyes and recount the traumatic memories aloud. Following 
these imaginal exposure sessions, patients engaged each day in two more exposure sessions, 
that included imaginal exposure but also additional exposure-based treatment components 
(exposure in drawings and in-vivo exposure to other trauma-related stimuli, such as trauma-
related pictures and movies). To align with previous studies in this field (Bluett et al., 2014; 
Rauch et al., 2004; van Minnen & Foa, 2006; van Minnen & Hagenaars, 2002) and limit 
variance due to different treatment procedures, we only assessed expectancy violation and 
fear habituation during the imaginal exposure sessions that followed the PE protocol. The 
intensive phase was followed by a maintenance phase, wherein participants received up 
to four weekly exposure-based booster sessions. One week after completion of the total 
treatment program (six weeks), participants (N = 48, 2 missing) completed the posttreatment 
assessment. 
 
Results
Self-reported harm expectancies prior to the first exposure session
At the start of treatment, using the open-ended sentence, almost all participants (96%, N = 48) 
reported harm expectancies related to their responses to exposure, and only two participants 
(4%) reported fear of external threat (i.e. that the offender would re-appear). Examples of the 
reported harm expectancies are listed in table 1. 
 Prior to the first exposure session, mean harm expectancy ratings were 6.45 (SD = 2.43), 
as scored on a 0-10 point scale (see table 2). Harm expectancy ratings prior to the first session 
were not significantly related to pretreatment PTSD symptom severity as measured by the 
CAPS (r = .19, p =.200).
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Table 1. Examples of reported harm expectancies by completion of an open-ended sentence. 
Examples of Reported Harm Expectancies
 “I will go crazy”
“I won’t be able to control my emotions”
“I will lose control”
 “I will lose touch with reality”
“I will freak out”
“I won’t be able to stop crying”
“I will get verbally aggressive”
Harm expectancy changes over treatment 
As can be seen in table 2, harm expectancy ratings declined over the course of treatment. Harm 
expectancy ratings significantly declined to a large extent between imaginal exposure sessions 
on day 1 and 2, t = 5.40, p = .000, r = 0.61, to a medium extent between day 2 and 3, t = 2.995, 
p = .004, r = 0.34, and to a medium extent between day 3 and 4, t = 2.64, p =.011, r = 0.35. 
Table 2. Means (SD’s) of expectancy violation and fear habituation measures per imaginal exposure 
session, and averaged over treatment (N = 50). 
 Day 1 Day 2 Day 3 Day 4 Mean
Expectancy violation measures
Harm expectancy 6.45 
(2.43)
4.35 
(3.05)
3.53 
(2.73)
2.85
(2.78)
4.30 
(2.29)
Harm experience 3.21 
(2.64)
2.61 
(2.55)
1.78 
(2.20)
1.53
(2.21)
2.28 
(2.00)
Within session expectancy violation 3.24 
(2.73)
1.74 
(2.95)
1.75 
(2.08)
1.32 
(1.94)
2.02 
(1.81)
Between session expectancy change - 2.11 
(2.76)
0.82 
(1.94)
0.67
(1.80)
1.20 
(0.93)
Fear habituation measures
SUD peak 8.94 
(1.56)
9.12 
(1.21)
8.70 
(1.33)
8.56 
(1.50)
8.83
(1.15)
SUD end 6.86 
(2.31)
6.06 
(2.95)
6.20 
(2.67)
6.18
(2.59)
6.33 
(2.33)
Within session habituation 2.08 
(2.13)
3.06
(2.62)
2.50 
(2.27)
2.38 
(1.86)
2.51
(1.91)
Between session habituation - -0.18
(1.45)
0.42 
(1.21)
0.14 
(1.07)
0.13
(0.51)
Expectancy violation as a predictor of PTSD symptom reduction following treatment
PTSD symptoms as measured by the CAPS significantly declined over the course of treatment 
(pretreatment: M = 85.79, SD = 15.46; posttreatment M = 61.27, SD =31.05; Cohen’s d = 1.01). 
To control for PTSD symptom severity at baseline, we calculated CAPS residual gain scores 
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(Steketee & Chambless, 1992), and computed correlations between these gain scores and the 
mean expectancy violation measures. In contrast to our expectations, neither within session 
expectancy violation (r = .02, p =.875) nor between session expectancy change (r = -.19, p = 
.185) was significantly related to gains in PTSD symptoms following treatment. 
Exploring the relationship between expectancy violation and fear habituation
Averaged within session expectancy violation and within session fear habituation were not 
significantly related (r = .09, p = .547). As to the between session measures, expectancy changes 
and fear habituation were significantly related (r = .39 p = .002), suggesting that those with a 
greater decline in harm expectancies over treatment sessions also had a greater fear decline 
over sessions (see table 3). 
 Relating the fear habituation measures to CAPS gain scores, both within (r = -.40, p = .005) 
and between session habituation (r = -.30. p = .037) were related to CAPS reduction.
Tentatively, expectancy violation and fear habituation measures are especially predictive of 
treatment response when they occur in synchrony. To test this hypothesis, we ran a stepwise 
regression analysis entering all expectancy violation and fear habituation indices in the first 
step, and these indices plus their interaction (i.e. within session expectancy violation × within 
session habituation; between session expectancy change × between session habituation) in 
the second step. The overall model was marginally significant in the first step (R2 = .19, p = 
.052), with within session habituation being the only significant predictor (ß = -.34, p =.036). 
Including the interaction terms did not improve the overall model (R2 change = .02, p =.644, 
besides within session habituation all ß’s non significant).
Table 3. Correlations between mean expectancy violation and fear habituation 
measures (N = 50).
1. 2. 3. 4. 
1. Within session expectancy violation .08 .09 .20
2. Between session expectancy change .39* .32*
3. Within session fear habituation .38*
4. Between session fear habituation
* p <.05
Discussion
The primary aim of this study was to investigate harm expectancy violation during imaginal 
exposure therapy in PTSD. We showed that: (1) harm expectancies regarding trauma 
recollection were prevalent in PTSD; (2) harm expectancies were violated within sessions 
and strongly declined between sessions; (3) within session expectancy violation nor between 
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session expectancy change was related to PTSD symptom change; (4) between session 
expectancy change and fear habituation were moderately related; and (5) fear habituation 
was moderately related to gains in PTSD symptoms. 
 Prior to treatment, PTSD patients had relative high harm (US) expectancies regarding 
trauma memory recollection, like ‘I am going to lose control’ or ‘I will go crazy’, a finding that 
resembles the previously demonstrated expectancy bias in PTSD patients (Blechert et al., 
2007; Engelhard et al., 2009; Lommen et al., 2013). The strong decline in harm expectancies 
during exposure therapy indicates successful acquisition of a new CS – noUS association, 
i.e. extinction learning. Put simply, patients successfully learned that confrontation with 
their traumatic memories did not lead to the expected danger. This finding is in line with 
previous work showing that exposure therapy promotes cognitive change (Foa & Rauch, 2004; 
Hagenaars, van Minnen, & de Rooij, 2010; McLean et al., 2015; Nacasch et al., 2015; Zalta et 
al., 2014), and adds to this literature by demonstrating specific cognitive changes in the CS-US 
relationship.
 Based on previous findings that changes in harm (US) expectancies during extinction 
training were related to the onset (Lommen et al., 2013) and maintenance of PTSD (Engelhard 
et al., 2009), and the notion that extinction learning underlies exposure therapy effects, we 
expected that changes in harm expectancies during exposure therapy would also be related 
to treatment outcome. Specifically, we expected that those with more expectancy violation 
during exposure therapy would show better treatment response, but we found no evidence in 
this direction. 
 There are several possible explanations for this null finding. First, we used a new, theory-
based PTSD specific instrument to assess harm expectancies during imaginal exposure therapy. 
Although our open-ended sentence completion task verified the relevance of harm expectancies 
related to patients’ responses to imaginal exposure, we cannot rule out that patients would 
have reported different harm expectancies over the course of treatment, or that personalized 
expectancy measures had captured their danger expectancies better. Future research should 
consider refining and personalizing measures of harm expectancies during exposure therapy 
sessions. Second, we only assessed harm expectancies related to recollecting the traumatic 
memories, and not related to exposure to other trauma-relevant cues. It would be interesting 
to learn whether harm expectancies change during exposure in vivo assignments, and how this 
interacts with treatment outcome. Third, this study was conducted in a multiple-traumatized 
PTSD sample and the treatment protocol allowed for changes in exposure content between 
therapy sessions. Although this should be considered a strength in terms of the generalizability 
of the results, it may have also influenced our indices of between session learning. Future 
studies should consider examining the predictive value of both expectancy learning and fear 
habituation for exposure therapy outcome within a more homogenous PTSD sample, in which 
the same US (i.e. trauma related stimulus) is presented during all exposure sessions.
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 Our finding also diverges from previous work demonstrating that changes in trauma 
related cognitions mediate PTSD symptom reduction (McLean et al., 2015; Zalta et al., 2014). 
An explanation for this might be that harm expectancies specifically assess declarative 
knowledge of the CS-noUS association (“I know I won’t go crazy”) and that this type of 
learning might occur independently from corrective learning in PTSD specific dysfunctional 
cognitions (e.g. “I am incompetent”), while change in the latter may be more closely linked 
to PTSD symptom change. Future studies should consider combining expectancy violation 
measures with other measures of cognitive change within and between exposure sessions 
(e.g. the Post Traumatic Cognition Inventory (Foa, Ehlers, Clark, Tolin, & Orsillo, 1999)).
 One of the arguments for examining an alternative index of exposure session success, 
was the unstable evidence that fear habituation during exposure therapy sessions precedes 
good treatment outcome (Craske et al., 2014). However, in the current work we found both 
within and between session fear habituation to be related to PTSD symptom reductions. 
Exemplary for the inconsistent findings with fear habituation as a predictor of therapy 
outcome, we found within session habituation to be the strongest predictor of outcome, 
while previous clinical studies found no relationship between within session habituation 
and treatment outcome (Nacasch et al., 2015; Sripada & Rauch, 2015; van Minnen & Foa, 
2006; van Minnen & Hagenaars, 2002). In line with the idea that fear habituation may be 
linked to outcome, but is not a key mechanism underlying therapeutic change in exposure 
therapy for PTSD (Bluett et al., 2014), the correlations between fear habituation measures 
and PTSD symptom change were in the moderate range. When exploring the relationship 
between expectancy violation and fear habituation measures, between session change 
in harm expectancies was moderately correlated to both within and between session 
fear habituation. Clinically, this makes sense: when expectancies about danger are 
systematically violated, the patient will experience less fear and vice versa. We explored 
whether a simultaneous decline in harm expectancy and subjective fear levels would be 
more predictive of treatment outcome than either index apart, but found no evidence in 
this direction. To sum up, because fear habituation proved to be a hampered indicator of 
success, we examined expectancy violation as an alternative index, but found no additional 
benefits of these measures in defining session success and predicting treatment outcome. 
To guide clinicians in designing and evaluating exposure therapy sessions, we still need 
valid indices of exposure session success. Of note, both harm expectancies and SUDs ratings 
are subjective measures affected by cognitive appraisal. Tentatively, combining these 
measures with more objective fear measures might capture extinction learning processes 
during exposure therapy more validly and better predict treatment outcome. Recently, fear 
potentiated startle was established as a biological outcome of exposure therapy in PTSD 
(Price et al., 2015; Rothbaum et al., 2014), and is it would be interesting to learn whether this 
can also serve as an indicator of exposure session success.
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 To conclude, as an alternative to the fear habituation model, expectancy violation has 
been proposed to indicate successful exposure therapy outcome (Craske et al., 2008; Craske et 
al., 2014; Hofmann, 2008). Although solidly grounded by both theory and experimental work, 
thus far there was no clinical evidence that expectancy violation is indeed a key mechanism of 
change in exposure therapy for PTSD. This is the first study that investigated harm expectancy 
violation during exposure therapy, and we indeed found that harm expectancies were 
prominently present in patients with PTSD and were successfully violated over the course of 
treatment. However, we found no evidence for a relationship between expectancy violation 
measures and PTSD symptom change. More clinical studies are needed to validate expectancy 
violation as a mechanism of change during exposure therapy and to establish valid indices of 
exposure session success. 
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Pharmacological Enhancement 
of Exposure-based Treatment in 
Posttraumatic Stress Disorder: 
A Qualitative Review
Based on: de Kleine, R. A., Rothbaum, B. O., & van Minnen, A. (2013). 
Pharmacological Enhancement of Exposure-based Treatment in PTSD: a Qualitative Review. 
European Journal of Psychotraumatology, 4. doi: 10.3402/ejpt.v4i0.21626
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Abstract
There is a good amount of evidence that exposure therapy is an effective treatment 
for posttraumatic stress disorder (PTSD). Notwithstanding its efficacy, there is room for 
improvement, since a large proportion of patients does not benefit from treatment. Recently, an 
interesting new direction in the improvement of exposure therapy efficacy for PTSD emerged. 
Basic research found evidence of the pharmacological enhancement of the underlying learning 
and memory processes of exposure therapy. The current review aims to give an overview of 
clinical studies on pharmacological enhancement of exposure based treatment for PTSD. The 
working mechanisms, efficacy studies in PTSD patients, and clinical utility of four different 
pharmacological enhancers will be discussed: d-cycloserine, MDMA, hydrocortisone and 
propranolol.
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Introduction
There is a good amount of evidence that (prolonged) exposure therapy is an effective treatment 
for posttraumatic stress disorder (PTSD) (see Powers et al., 2010 for review). It is a first-line 
treatment recommended in guidelines worldwide. Nevertheless, not all patients benefit from 
exposure therapy. Clinical trials have shown that approximately fifty percent of patients lose 
their PTSD diagnosis after exposure therapy and the proportion of patients achieving complete 
remission is even smaller (Bradley et al., 2005; Schnurr et al., 2007).
 In an attempt to improve treatment efficacy, some researchers added other psychological 
interventions to exposure therapy, such as cognitive restructuring (for instance: Foa et al., 
2005; Resick et al., 2008) or imaginal rescripting (for instance: Arntz, Tiesema, & Kindt, 2007). 
Although some studies found support for beneficial effects, overall the effect sizes did not 
exceed those of stand-alone exposure therapy in a clinically significant way (see for review: 
Kehle-Forbes et al., 2013). 
 Another way to improve treatment efficacy that is commonly seen in clinical care is the 
combination of exposure therapy and pharmacological treatment such as antidepressant 
medication. But controlled studies investigating the efficacy of this combined treatment 
strategy are scarce. Rothbaum et al. (2006) examined the effect of adding prolonged exposure 
(PE; Foa & Rothbaum, 1998) for SSRI nonresponders. PTSD patients were provided with 10 
weeks of open label sertraline and those who did not remit were then randomized to either 
receive five additional weeks of sertraline alone or with 10 sessions of twice weekly PE. 
Results show that the addition of 10 sessions of PE led to increased treatment gains but only 
for patients who showed a partial response to phase I sertraline treatment. PE augmentation 
was associated with lower PTSD severity score, more remitters at six month follow up, and 
maintenance of treatment gains. In an almost mirror design, no beneficial effects were found 
for paroxetine enhancement when given in addition to PE to exposure refractory patients 
(Simon et al., 2008). In contrast, however, Schneier and colleagues (2012) found that when the 
combination of exposure therapy and paroxetine (an SSRI) was provided from the beginning of 
treatment, it was more effective than exposure therapy plus placebo, implying additive benefits. 
However, the additive benefits disappeared by follow up. Even though initial treatment with 
exposure therapy and paroxetine may lead to good clinical outcome, there are also some 
important disadvantages of this combination strategy, such as adverse events of medication, 
higher treatment costs, lower treatment acceptability and the risk of relapse after medication 
discontinuation, as was shown with SSRI as a stand-alone treatment for PTSD (Davidson et al., 
2001; Farach et al., 2012). 
 Recently, an interesting new direction in the improvement of exposure therapy efficacy for 
PTSD emerged. Basic research in animals found evidence of the pharmacological enhancement 
of the underlying learning and memory processes of exposure therapy: extinction learning and 
reconsolidation (Debiec & Ledoux, 2004; Walker et al., 2002). Extinction learning refers to the 
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process wherein a conditioned stimulus (CS; i.e. a trauma reminder) is repeatedly presented in 
absence of the unconditioned stimulus (US; i.e. the traumatic experience) thereby leading to 
reduction of the conditioned response (CR; i.e. fear). It is believed that with extinction learning 
a new association (CS-noUS) is formed and consolidated, while the original fear-memory stays 
intact (Bouton, 1993; LeDoux, 1995). In contrast, reconsolidation might change the original fear 
memory. Reconsolidation refers to the process wherein a previously consolidated memory (i.e. 
the fear memory), enters a labile state upon its retrieval, in which it might be susceptible to 
change. Even though it is not perfectly understood if and how extinction and reconsolidation 
inter-relate during exposure therapy (Kindt & Soeter, 2013), both seem to be underlying its 
efficacy. 
 Findings in basic animal research that these memory and learning processes can be 
pharmacologically targeted have been translated to studies in clinical populations (f.i. Ressler et 
al., 2004). In several anxiety disorders it has been examined whether different pharmacological 
agents, often referred to as cognitive enhancers, can optimize exposure treatment efficacy. This 
new line of pharmacological treatment enhancement can be distinguished from traditional 
pharmacotherapy in the following ways: 1) the pharmacological agent is always given in 
supplementary fashion to exposure by administration either shortly before or after an exposure 
session; 2) the enhancer is not expected to positively affect treatment outcome as such, but to 
do so solely by augmentation of exposure effects. 
 The aim of the current review is to give an overview of clinical studies on pharmacological 
enhancement of exposure based treatment for PTSD. Thus far, reviews have focused mainly 
on fundamental research or specific pharmacological backgrounds (Choi, Rothbaum, Gerardi, 
& Ressler, 2010; Dunlop, Mansson, & Gerardi, 2012; Parsons & Ressler, 2013). We were more 
interested in the clinical value of enhancement studies and focused on clinical questions such 
as: what are the proposed working mechanisms of different enhancers? What is known about 
enhancement effects of different pharmacological agents in PTSD patients? What would be 
the feasibility of these enhancers in clinical practice? Therefore, we focused on describing 
pharmacological agents that were studied in PTSD patients and administered in addition 
to (at least one) exposure based treatment session, with the aim to enhance extinction or 
reconsolidation processes. This resulted in reviewing four different pharmacological enhancers: 
d-cycloserine, MDMA, hydrocortisone and propranolol.
d-cycloserine (DCS)
Proposed working mechanism of DCS
Fear extinction has been linked to N-methyl-D-aspartate (NMDA) glutamatergic receptor 
activity in the basolateral amygdala (Norberg et al., 2008). Animal research suggested that 
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NMDA receptor agonists, such as the partial agonist d-cycloserine (DCS), can enhance 
extinction effects (Richardson et al., 2004; Walker et al., 2002). Translating the positive findings 
in animals to humans, clinical studies in diverse anxiety disordered clinical populations (e.g. 
in acrophobia (Ressler et al., 2004), social phobia (Hofmann et al., 2006) and panic disorder 
(Otto et al., 2010)) showed that fear extinction is indeed facilitated by supplementing exposure 
therapy with DCS (see for review: Bontempo et al., 2012; Norberg et al., 2008). The beneficial 
effects of DCS are attributable to extinction enhancement and not to anxiolytic effects of the 
drug, since both animal and human studies showed that fear expression (i.e. freezing in animals 
and subjective fear in humans) during extinction/exposure is not influenced by DCS (Kushner 
et al., 2007; Ressler et al., 2004; Walker et al., 2002). 
DCS enhancement of exposure based treatment in PTSD patients
To date, two studies examined the additional effect on DCS in prolonged exposure therapy 
for PTSD. De Kleine, Hendriks, Kusters, Broekman, and Van Minnen (2012) investigated the 
effect of DCS in a mostly women, mixed-trauma civilian sample. Sixty-seven participants were 
randomized to receive either DCS (50 mg, N = 33, see table 1) or identical looking placebo (N 
= 34) one hour prior to each imaginal exposure session (max. 9 enhanced sessions). Exposure 
therapy was delivered in adherence to the prolonged exposure manual (Foa & Rothbaum, 
1998), and this included imaginal exposure therapy sessions that were enhanced with DCS. 
Overall, no enhancement effects of DCS were found: irrespective of treatment condition, 
symptoms declined over time. Clinician Administered PTSD Scale (CAPS) scores dropped 
on average with 28 (DCS) and 20 (Placebo) points from pre- to posttreatment. Looking at 
treatment response, an effect in favor of DCS was found. In the intent-to-treat sample, 64% 
in the DCS group showed response (defined as a minimum of 10 points decrease on CAPS 
scores (Schnurr et al., 2007)), compared to 38% in the placebo group. In the completers 
group, these numbers were overall higher, but still favored DCS (88% versus 62%). What is 
more, de Kleine et al. found that a large proportion of patients (approximately 40 percent) 
could be considered early completers, i.e. those patients could end treatment before the 
eight session because of remission. When comparing these early completers to those that 
needed all treatment sessions (regular completers) an interesting difference emerged. 
For the early completers, no difference between those who received DCS and those who 
received placebo was found. In contrast, for the regular completers, those who received DCS 
showed better treatment outcome (30 point CAPS decline) than those who received placebo 
(6 point CAPS decline). The two subgroups (early vs. regular completers) did not differ on 
baseline characteristics as trauma type or co morbidity, but, regular completers had more 
PTSD symptoms on baseline compared to early completers. Based on these findings, the 
authors tentatively concluded that DCS seems promising for severe PTSD patients who do 
not initially respond to exposure therapy. 
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 However, a second study on DCS enhancement of exposure therapy in PTSD patients 
showed different outcome. Litz and colleagues (2012) examined the beneficial effects of DCS 
in a male, veteran population. Twenty-six participants were randomized to receive either DCS 
(50 mg; N = 13) or placebo (N = 13) 30 minutes prior to four imaginal exposure sessions. Litz 
and colleagues found that the placebo group had better outcome than the DCS group on both 
self-reported and clinician assessed PTSD symptoms. On average, CAPS scores declined 20 
points in the placebo condition, but increased with 2 points in the DSC condition. For treatment 
response (> 10 points decrease on CAPS scores; Schnurr et al., 2007), a similar pattern was 
found, 70% response in the placebo condition and only 30% in the DCS condition.
Dosing, administration, adverse effects and contra-indications for DCS 
enhancement
DCS was originally approved by the U.S. Food and Drug Administration as an antibiotic for the 
treatment of tuberculosis. Generally, it is dosed at 500 to 1000 mg twice daily. Peak blood 
levels occur within 4 to 8 hours after oral dosing, with a half-life time of 10 hours (Hardman 
& Limbird, 2001). As an enhancer to exposure therapy, DCS is single dosed before exposure 
sessions in low doses (in both PTSD trials 50 mg). Dosage, dose timing or number of doses have 
varied and were not significantly related to outcome in DCS enhancement trials across anxiety 
disorders (Bontempo et al., 2012).
 DCS is orally taken and usually well tolerated. There is no need to physically monitor 
patients after DCS intake. Adverse reactions seem to be related to higher dosages of the drug 
(i.e. more than 500 mg daily). Side effects that have been observed in these high dosages involve 
nervous system symptoms (e.g. convulsions, drowsiness, headache, tremor), cardiovascular 
problems, allergy, and skin rash. However, no serious adverse event was reported in the PTSD 
trials nor in any other clinical trial with DCS as enhancer of exposure therapy (and thus with 
much lower dosages). 
 Looking at contra-indications for DCS enhancement, patients with (a history of) epileptic 
seizures or concurrent alcohol dependence or abuse, were excluded from participation in the 
PTSD trials, because of the risk of epileptic episodes with DCS administration (again, especially 
in higher doses), which is increased with alcohol. Patients who used antidepressants were not 
excluded in both PTSD trials, but they were required to be on a stable dose prior to enrollment. 
In lab-rats it was found that DCS did not facilitate extinction learning in rats previously 
exposed to the tricyclic antidepressant imipramine (Werner-Seidler & Richardson, 2007) but 
no evidence was found for negative interaction effects between antidepressant medication 
and DCS enhancement effects in patients with PTSD (de Kleine et al., 2012) or other anxiety 
disorders (Hofmann et al., 2006; Kushner et al., 2007; Storch et al., 2007).
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Discussion 
Granted that DCS was found to enhance exposure therapy across anxiety disorders (Bontempo 
et al., 2012; Norberg et al., 2008), so far findings in PTSD populations are inconclusive. It is 
difficult to combine the findings of the De Kleine et al. and Litz et al. studies, because the 
studies differed largely with respect to population (e.g. civilian vs. veteran) and methodology 
(e.g. different lengths of treatment protocol and varying times of DCS administration). In line 
with the findings of de Kleine and colleagues (2012), there is some evidence that DCS is 
especially beneficial in severely disordered patients (Guastella, Dadds, et al., 2007; Siegmund 
et al., 2011).
 The proposition that DCS enhances consolidation of extinction learning suggests that 
in case of within session extinction (i.e. good extinction) DCS has beneficial effects, but also, 
that in absence of within session extinction (i.e. no extinction), DCS might have undesirable 
effects by consolidation of the fear memory. Indeed, Smits and colleagues (2013) found in 
an acrophobic sample that DCS was superior to placebo in sessions wherein within session 
extinction occurred, but lead to detrimental effects in sessions without extinction. Likewise, 
in PTSD patients, Litz. et al. (2012) found indicators that those who received DCS showed less 
within session extinction compared to those who received placebo, and Litz and colleagues 
suggest that this may be underlying their finding that placebo outperformed DCS. 
 This raises the questions whether DCS could not be better administered post session 
and only when good extinction learning took place. In animal studies, it was found that post 
extinction training administration of DCS could also enhance extinction effects (Ledgerwood 
et al., 2003). But, the first trials in humans failed to find beneficial effects of post-session 
administered DCS (Tart et al., 2013), except in those patients who showed good within session 
habituation (Smits, Rosenfield, Otto, Powers, et al., 2013). And, despite the apparent logic of 
administering DCS only after successful sessions, research on the predictive value of within 
session extinction for overall treatment outcome is indecisive (Craske et al., 2008; van Minnen 
& Hagenaars, 2002), and the question what exactly defines a successful exposure session has 
yet to be answered.
 Reflecting on the clinical utility of DCS, it seems a good candidate to implement in routine 
clinical care. All in all, DCS seems safe, usually well-tolerated and easy to administer in routine 
clinical care settings. There are no major drug specific contra-indications, although, given the 
high incidence of alcohol abuse in PTSD populations (Mills, Teesson, Ross, & Peters, 2006), 
extra attention should be given to alcohol use during DCS enhanced exposure therapy.
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MDMA
Proposed working mechanism of MDMA enhancement
MDMA (3,4-methylenedioxymethamphetamine) is a substituted phenetylamine and binds and 
reverses monoamine transporters, resulting in serotonin release and activation of the 5-HT 
receptor, and to a lesser extent to the release of norepinephrine and dopamine (Johansen & 
Krebs, 2009; Sessa, 2007). MDMA is known in the public domain as the recreational drug ecstasy. 
The drug has profound subjective effects as feelings of euphoria and well-being, heightened 
senses, and closeness to others (Cami et al., 2000; Kolbrich et al., 2008). Johansen and Krebs 
(2009) suggested that MDMA could enhance extinction learning via three different mechanisms. 
One, MDMA might enhance extinction learning via increased activity in the ventromedial 
prefrontal cortical (vmPFC) and decreased amygdala activity, two interconnected brain regions 
that have been found to be critical for extinction learning (Phelps, Delgado, Nearing, & LeDoux, 
2004). Two, MDMA might enhance extinction learning via enhanced cortisol and norepinephrine 
levels. And a third, more indirect way, may be that MDMA increases oxytocin levels, which may 
strengthen the therapeutic alliance, and thereby facilitate extinction learning. 
 To date, no experimental study examined whether MDMA could enhance extinction 
learning. There is circumstantial evidence for the hypothesis that MDMA strengthens the 
therapeutic alliance via enhanced oxytocin release. In both animal (Thompson, Callaghan, Hunt, 
Cornish, & McGregor, 2007) and human studies (Dumont et al., 2009; Hysek, Domes, & Liechti, 
2012) it was found that MDMA leads to higher blood oxytocin levels, and in humans it was 
shown that blood oxytocin levels were strongly and positively correlated to subjective prosocial 
feelings. 
MDMA enhancement of exposure based treatment in PTSD patients
Three studies examined the augmentation effects of MDMA of exposure-based treatment 
in PTSD patients. Bouso and colleagues (2008) planned to examine the beneficial effects of 
MDMA paired with psychological treatment in 29 patients with chronic PTSD following sexual 
assault, who had failed to respond to previous treatment. But due to political pressure, they 
were forced to close their double-blind randomized placebo-controlled trial after including 
only six participants and no results are available.
 In the first completed study, Mithoefer and colleagues (2011) examined MDMA assisted 
treatment in 20 PTSD patients. All patients had not responded to previous psychotherapy or 
medication. Participants were randomized to receive either MDMA (125mg, with the possibility 
of a supplemental dose of 62.5 mg; N = 12) or pill placebo (N = 8) adjunctive to two 8-10 
hour individual psychotherapy sessions. Prior to the enhanced session, participants engaged 
in two sessions aimed at establishing a therapeutic alliance. As described in the treatment 
manual (available from www.maps.org), the enhanced sessions had a non-directive character: 
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participants were instructed to close their eyes, relax (with the help of music) and to allow 
the inner experience to unfold. Exposure to the traumatic experience occurred spontaneously. 
After each MDMA enhanced session, four integration sessions took place focusing on discussion 
of the experiences in the experimental sessions and further emotional processing of the 
traumatic experience. MDMA enhanced therapy outperformed placebo enhanced therapy on 
both clinician rated and self-reported PTSD symptoms. On average, CAPS scores in the MDMA 
group decreased 50 points from pre- to posttreatment, compared to 13 points in the placebo 
group. Further, over 80% of participants in the MDMA group (10 out of 12 patients) lost their 
PTSD diagnosis, compared to 25% (2 out of 8 patients) in the placebo group. The double blind 
phase of the study was followed up by a cross-over open-label phase, so that in the end 19 
participants received two or three MDMA-enhanced treatment sessions. Long term follow-up on 
16 participants showed that for 14 of them benefits lasted over time (Mithoefer et al., 2013). All 
in all, these appeared to be very promising findings. However, some important methodological 
limitations require noting. First, due to the profound effects of MDMA compared to pill placebo, 
it was impossible to keep participants and therapists blind to treatment condition. Second, 
participants in the MDMA group received more supplementary (exposure) sessions after 
the experimental sessions than participants in the placebo group. Third, the psychotherapy 
component was not an empirically supported treatment delivered in a standard manner.
 In the most recent pilot study (Oehen, Traber, Widmer, & Schnyder, 2013), twelve 
treatment refractory PTSD patients were randomly allocated to receive either MDMA (125 
mg and 62.5 mg 2.5 hours later; N = 8) or active placebo (25 mg and 12.5 mg 2.5 hours later; 
N =4) supplementary to three 8 hour individual psychotherapy sessions. Oehen et al. used 
roughly the same study protocol as Mithoefer and colleagues and exactly the same treatment 
protocol. However, the results of this study were less profound in favoring MDMA over 
placebo. There was a significant interaction of group by time for self-reported PTSD symptoms 
in favor of MDMA, and a trend towards better outcome for the MDMA group in clinician rated 
scores (p =.066). But, compared to the Mithoefer study, change in CAPS scores from baseline 
to posttreatment was small (16 points decrease in the MDMA group and 3 points increase 
in the placebo group), and, notably, all participants still fulfilled PTSD diagnostic criteria at 
posttreatment. 
Dosing, administration, adverse effects and contra-indications for MDMA 
enhancement
A typical (recreational or therapeutic) dose of MDMA is 125 mg, and was also used in the PTSD 
studies. It is orally administered and comes in the form of tablets, capsules or powder. MDMA 
is detectable in the blood within 30 minutes after intake, peak blood levels are 1 to 2 hours 
after intake and MDMA has a half-life of about 6-8 hours (Green, Mechan, Elliott, O’Shea, & 
Colado, 2003).
82 |
 Acute adverse effects are commonly reported, including jaw clenching, grinding of the 
teeth, nausea, tremor and feelings of tension and anxiety (Kolbrich et al., 2008). After MDMA 
usage, there is a period of neurochemical recovery characterized by anhedonia, lethargy and 
depressions. Acute adverse effects were indeed reported in the PTSD trials, but there were 
no serious adverse events. Further, neurotoxicity has been demonstrated in animals, and 
suggested in humans, but functional impairment in humans has not been convincingly related 
to MDMA (Dumont & Verkes, 2006). Importantly, not all neuropharmocological actions of 
MDMA are well comprehended (Green, Marsden, & Fone, 2008).
 The cardiovascular effects of the drug are important to note. MDMA leads to higher blood 
pressure and elevated heart rates (Dumont & Verkes, 2006).Thus, MDMA is unsuitable for PTSD 
patients with cardiovascular problems, requires physical examination before administration 
(stress-electrocardiogram), and physical monitoring and the presence of a physician during 
MDMA enhanced treatment sessions. Further, in the PTSD trials, participants were required to 
taper all psychotropic medication prior to enrollment. Interestingly, empirical data suggests 
that medication that inhibits serotonin (5-HT) and norepinephrine (NE) uptake (respectively 
SSRI’s and SNRI’s), drugs commonly used by PTSD patients, attenuate the effects of MDMA 
(Hysek, Simmler, et al., 2012; Liechti, Baumann, Gamma, & Vollenweider, 2000). 
Discussion
In conclusion, even though the initial findings of MDMA enhancement appear promising, more 
controlled studies on MDMA enhanced treatment are necessary to draw reliable conclusions 
on the efficacy of this combined treatment strategy. In the studies so far, MDMA was not paired 
to a proven effective treatment strategy, i.e. prolonged exposure (Foa & Rothbaum, 1998). 
Critically reflecting on the treatment manual used in MDMA trials, it is questionable whether 
the non-directive, explorative intervention should be considered exposure, as it diverges from 
evidence-based exposure treatments such as prolonged exposure. Preferably, new trials would 
combine MDMA with those established exposure treatments. 
 With respect to one of the proposed working mechanisms of MDMA enhancement, that 
it enhances extinction learning indirectly via improvement of the therapeutic alliance due to 
heightened oxytocin levels, the question arises whether direct administration of oxytocin would 
also enhance exposure therapy. Olff and colleagues (2010) suggest that it might, and may even 
be more powerful than MDMA. Currently, Olff’s group is examining oxytocin enhancement of 
exposure therapy in refugees suffering from PTSD. 
 Reflecting on the feasibility of MDMA enhancement, all together there are questions 
regarding safety and tolerability. Considering the high rate of co-morbid depression in PTSD 
patients (Kessler et al., 2005), the negative mood effects post MDMA intake calls for caution. 
Further, a substantial proportion of PTSD patients use SSRI’s or SNRI’s which appear to be 
incompatible with MDMA enhancement. Implementation in routine clinical care is further 
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complicated by the need for physical monitoring during MDMA enhancement, especially 
with its known cardiac effects. And notably, the use of MDMA as an adjunctive to treatment 
is not without controversy, as its use as a recreational drug (“ecstasy”) is criminalized in 
most countries. The alternative of oxytocin enhancement may have better clinical utility, 
considering that it is easily administered e.g., as a nasal spray and produces little adverse 
effects (MacDonald et al., 2011).
Hydrocortisone
Proposed working mechanism 
Hydrocortisone is a synthetic glucocorticoide that mimics the effects of cortisol. In situations of 
stress, the hypothalamus–pituitary–adrenal (HPA) axis is activated, which results in the release 
of glucocorticoide hormones, i.e. cortisol. It is well-established that cortisol has (complex) effects 
on learning and memory (see for a review on glucocorticoide: de Quervain, Aerni, Schelling, & 
Roozendaal, 2009). First, glucocorticoids play a role in the consolidation of extinction learning. 
It has been shown that administration of glucorticoids facilitates consolidation of extinction 
learning, while suppression of glucorticoid function impairs extinction learning. Second, 
glucorticoids impair the retrieval of emotional memory. In PTSD patients it was found that low-
dose cortisol administration as stand-alone treatment resulted in reduction of re-experiencing 
symptoms, i.e. unwanted retrieval of emotional memories (Aerni et al., 2004). Enhancement of 
exposure therapy with hydrocortisone could be beneficial via both mechanisms: 1) enhanced 
consolidation of extinction learning, and 2) inhibition of emotional memory retrieval. The latter 
may reduce distress after exposure sessions, because retrieval of the emotionally disturbing 
traumatic memory that was targeted during an exposure session is inhibited (Yehuda, Bierer, 
Pratchett, & Malowney, 2010). 
 Two randomized studies provided support for exposure augmentation with hydrocortisone 
in anxiety-disordered patients. Hydrocortisone given prior to exposure sessions proved to 
augment treatment effects in patients suffering from spider phobia (Soravia et al., 2006) and 
acrophobia (de Quervain et al., 2011).
Hydrocortisone enhancement of exposure based treatment in PTSD 
patients
To date, there are no randomized clinical trials on the augmentation effects of exposure 
therapy with hydrocortisone in PTSD patients. Two large scaled clinical studies by Yehuda and 
colleagues are currently including participants (Clinicaltrials.gov identifiers NCT01525680 and 
NCT01090518). Grounding their upcoming trials, Yehuda and colleagues (2010) published a 
case study on hydrocortisone enhancement in two male veterans suffering from severe PTSD 
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and co morbid depressive disorder. Participants were treated with prolonged exposure therapy 
and either hydrocortisone (30 mg, oral, 30 minutes prior to exposure session 3-10) or placebo 
(following the same time schedule). The patient who received hydrocortisone improved more 
over the course of treatment than the patient who received placebo (54 versus 40 points 
reduction on CAPS), specifically with respect to avoidance symptoms. 
 In an experimental design, Suris and colleagues (2010) investigated the effects of 
hydrocortisone in 20 male veterans suffering from PTSD. Participants received either 
hydrocortisone (intravenous, 4mg/kg) or placebo, directly after one exposure based session. 
During this session, participants wrote a description of their two most traumatic events and 
identified from a list bodily sensations they experienced during these events. Afterwards, a 
member of the research team composed a 30-second script portraying each event. A week 
later, scripts were presented to participants while physiological responses (heart rate, 
skin conductance and corrugator and frontalis muscle electromyogram) were measured. 
Subsequently, they filled out questionnaires on PTSD and depressive symptoms. Suris et 
al. found that, compared to placebo, participants who received hydrocortisone had lower 
self reported PTSD avoidance and numbing symptoms at script presentation. There were no 
significant differences on any other PTSD symptom cluster nor on the physiological measures. 
Also, at the one month follow-up assessment, no group differences on any outcome were 
found. In the discussion section of their article, the authors list several limitations of their 
study. Besides the low power, they critically reflect on their study design, and suggest that with 
a higher dose and more enhanced treatment sessions effects may have been larger and more 
lasting. 
Dosing, administration, adverse effects and contra-indications for 
hydrocortisone enhancement
Hydrocortisone can be administered orally, intramuscularly or intravenously. It is used 
in the treatment of inflammation disease, e.g. severe allergies, arthritis or asthma, and as a 
replacement strategy in the chronic endocrine disorder Addisons disease. Therapeutic doses 
vary between 20 mg to 500 mg daily, depending on the specific disease treated. Hydrocortisone 
is well absorbed after oral administration, achieving peak blood concentrations after one 
hour, half-life is approximately 1.5 hours. Dosing and administration of hydrocortisone given 
in supplementary fashion to exposure based treatment in PTSD patients have varied largely 
(eight times, 60 minutes prior to exposure, orally 30 mg (Yehuda et al., 2010) versus one time, 
immediately after exposure, intravenously 4mg/kg (Suris et al., 2010). In the two non-PTSD 
exposure enhancement trials, hydrocortisone was given three or four times, 60 minutes prior 
to exposure, orally and dosed at 10 and 20 mg (de Quervain et al., 2011; Soravia et al., 2006) 
Low doses of hydrocortisone (e.g. 10-30 mg once a week) do not cause major side effects, nor 
do they suppress endogenous cortisol levels (de Quervain et al., 2009). There is no need to 
 Chapter 6
| 85Review on pharmalogical enhancement
physically monitor patients after hydrocortisone intake. Besides the regular exclusion criteria 
for drug trials (e.g. pregnancy, severe medical illness or drug-hypersensitivity) there appear to 
be no major drug specific exclusion criteria for hydrocortisone-enhanced treatment relevant 
to the PTSD population. While participants who used psychotropic medication were excluded 
from non-PTSD trials (de Quervain et al., 2011; Soravia et al., 2006), in upcoming PTSD trials 
participants with (stable) psychotropic medication are included. 
Discussion
The evidence for beneficial effects of hydrocortisone enhancement of exposure therapy in 
PTSD patients is very limited. Efficacy studies in other anxiety disorders showed augmentation 
of exposure effects, but upcoming controlled trials will have to show whether this generalizes 
to PTSD patients. 
 In PTSD patients it appears that hydrocortisone specifically affects avoidance symptoms. 
Avoidance has been implicated in the development and maintenance of PTSD (Foa et al., 2007). 
Hypothetically, decline of avoidance symptoms over the course of treatment could improve 
compliance with exposure sessions and in that way hasten or improve beneficial treatment 
effects. Further, it is of interest to note that hydrocortisone may have acute anxiolytic effects. 
A clinical trial in patients with social phobia showed that hydrocortisone (25 mg) given one 
hour prior to an exposure task reduced self reported fear (Soravia et al., 2006). What the effect 
is of pre-session hydrocortisone on fear levels during exposure therapy in PTSD patients, and 
if and how this influences treatment efficacy, has yet to be established. The proposition that 
hydrocortisone impairs retrieval of the traumatic memory targeted during an exposure session 
may reduce post exposure distress and enhance treatment acceptability. Given the high 
incidence of (early) exposure treatment dropout (Bisson & Andrew, 2007), improving treatment 
acceptability is of great relevance.
 Reflecting on its clinical utility, hydrocortisone seems safe, well-tolerated and easy 
to administer. There are no major drug specific exclusion criteria relevant to the PTSD 
population. So, albeit premature, hydrocortisone appears to be feasible to implement in 
routine clinical care. 
Propranolol
Proposed working mechanism
Propranolol is a synthetic b-adrenergic receptor blocker that crosses the blood brain barrier and 
has both peripheral noradrenergic effects and central inhibitory effects on protein synthesis. 
Protein synthesis is necessary to (re)consolidate new memories and a protein synthesis 
inhibitor, such as propranolol, could interfere with this process (Davis & Squire, 1984). Indeed, 
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experimental studies in non-clinical samples demonstrated that propranolol has effects on 
memory reconsolidation (see for overview: Lonergan, Olivera-Figueroa, Pitman, & Brunet, 
2012). For instance, Kindt and colleagues (2009) found that disruption of reconsolidation 
by oral administration of propranolol resulted in diminished fear responses to conditioned 
stimuli. Even though there is growing interest in (disruption of) reconsolidation processes, 
clinical studies in anxiety-disordered patients are limited to a couple studies in PTSD patients.
Propranolol enhancement of exposure based treatment in PTSD patients
In a randomized clinical trial, Brunet and colleagues (2008) examined the effects of 
propranolol given directly after one exposure based session in 19 chronic PTSD patients 
following mixed trauma. Participants received either propranolol (40 mg short-acting and 
2 hours later 60 mg long-acting; N = 9) or identical looking placebo (following the same 
time schedule; N = 10) immediately after an exposure based session. During this 20-minute 
session, participants described in writing on a standard script preparation form two events 
that caused their PTSD and provided details on request. Afterwards, a member of the 
research team composed and recorded a 30 second during script portraying each event. A 
week later, participants were exposed to the trauma scripts while physiological responses 
(heart rate, skin conductance and left corrugators electromyogram, i.e. facial frowning 
muscle) were measured. Participants who had received propranolol post session responded 
with lower heart rate and skin conductance than participants who had received placebo. 
Unfortunately, information on long-term effects, i.e. PTSD symptoms was not included so 
there is no information regarding the maintenance of these effects and if there was any 
effect on PTSD symptoms. 
 There is support for the efficacy of propranolol as a treatment enhancement strategy 
from three open label studies by Brunet and colleagues (2011). In the first study, 28 patients 
with chronic PTSD following mixed trauma received six propranolol enhanced exposure 
based treatment sessions. Ninety minutes prior to the first session participants received 0.69 
mg/kg short acting (SA) propranolol, after 90 minutes they received a subsequent dose of 1 
mg/kg long acting (LA) propranolol. In this first session, they provided a written account of 
the traumatic event leading to their PTSD. In the subsequent enhanced treatment sessions, 
participants received both SA and LA propranolol 90 minutes prior to the start of the session 
and read aloud their traumatic account to an interviewer, as if the event was happening in 
the here and now. Sessions lasted approximately 15-20 minutes. At posttreatment, PTSD 
symptoms were significantly lower than at pretreatment (mean CAPS decline from pre- to 
posttreatment of 26 points) and twenty participants (71%) no longer met criteria for PTSD.
In the second open study, a similar protocol was followed, only now participants provided 
an oral instead of a written account of the index trauma and propranolol was given in fixed 
doses of 40 mg SA and 80 mg LA. Participants were seven chronic PTSD sufferers with mixed 
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trauma history. Again, there was a significant drop in PTSD symptoms (mean CAPS scores: 68 
at baseline and 36 posttreatment). Comparable to the first study, 71% (5 participants) no 
longer met PTSD diagnostic criteria. In study three, 32 participants self-selected to receive 
propranolol enhanced treatment (N = 7) or no treatment at all (N = 25). Participants all 
suffered from PTSD following the September 2001 industrial disaster in Toulouse, France. 
The protocol was similar to study one, with slight differences in propranolol dosing (see 
table 1) and there was no administration of CAPS interviews. In line with the previous 
findings, for those participants who received propranolol enhanced treatment, self-reported 
PTSD symptoms declined over time. Six of seven treated participants (86%) lost their PTSD 
diagnosis, compared to only two of 25 (8%) in the control group.
Dosing, administration, adverse effects and contra-indications for 
propranolol enhancement
Propranolol lowers heart rate and relaxes blood vessels to improve blood flow and decrease 
blood pressure. As such, it is used for treatment of hypertension, angina pectoris, migraine 
and tremor. In addition, propranolol has anxiolytic effects (it reduces physical anxiety 
symptoms such as trembling and heart pounding) and is used to reduce performance related 
anxiety. Generally, doses vary between 40 mg to 240 mg daily, depending on treatment 
condition. In PTSD trials, propranolol was single dosed directly before or after exposure 
based treatment session(s) with doses varying between 80-120 mg. Propranolol is rapidly 
absorbed. For short acting propranolol peak blood levels occur within one to two hours after 
ingestion and half-life is approximately three to six hours, while for long acting propranolol 
this is respectively five hours and between 10 to 20 hours. 
 Adverse reactions to propranolol appear to be dose related and include light 
headedness, weakness, fatigue, bradycardia, congestive heart failure, hypotension, nausea 
and vomiting. In PTSD patients, when given as a treatment enhancer, no serious adverse 
events were reported and side effects were restricted to mild sedation (Brunet et al., 2011). 
 Propranolol is orally administered. Because propranolol lowers blood pressure, in the 
Brunet trials blood pressure was monitored after the first propranolol intake. If systolic blood 
pressure levels did not drop below a certain point (100 mmHg), participants received the 
subsequent doses. Because of its cardiovascular effects, people with low blood pressure, 
a (family) history of cardiac problems (e.g. heart failure, heart block or certain cardiac 
arrhythmias) were excluded from participation in propranolol studies. Like propranolol, 
alcohol relaxes blood vessels, and simultaneous use may cause problems. In the open label 
trials, participants who used medication that could involve dangerous interactions with 
propranolol were excluded from participation. Notably, this includes antidepressants that 
are cytochrome P450 2D6 inhibitors, such as the SSRI paroxetine. 
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Discussion 
Combined, the findings with propranolol enhancement are promising and we await a placebo 
controlled randomized clinical trial on propranolol enhancement in PTSD patients. However, 
due to the uncontrolled methodology of the propranolol treatment enhancement studies, the 
question of whether the observed benefits were a consequence of propranolol enhancement 
or the psychological intervention in itself remains unanswered. 
 Likewise, regarding the proposed working mechanism, it is unclear from Brunet’s studies 
whether propranolol blocked fear memory reconsolidation or, alternatively, enhanced extinction 
consolidation. Parsons & Ressler (2013) question whether propranolol would succeed in 
reconsolidation blockage in PTSD patients, based on research findings that older memories are 
more difficult to influence after retrieval (Milekic & Alberini, 2002) and that repeated retrieval 
(i.e. re experiences) can strengthen fear memories and make them more resistant to extinction 
and reconsolidation effects (Suzuki et al., 2004). The upcoming controlled trial of Brunet’s 
group (N = 50, six enhanced sessions with 40 mg SA/60 mg LA propranolol, Clinicaltrials.gov 
identifier NCT01127568) will provide us with more information on the potential of propranolol 
as a treatment enhancer in PTSD patients. 
 Considering the feasibility of propranolol for exposure treatment enhancement in 
PTSD patients, propranolol appears to be well tolerated and easy to administer. However, 
its cardiovascular effects require caution in patients with (a family history) of cardiovascular 
problems, and alcohol use should be carefully monitored during propranolol-enhanced 
treatment, especially considering that alcohol abuse is a common problem in PTSD patients (Mills 
et al., 2006). PTSD patients who use SSRI’s have been excluded from propranolol enhancement 
studies (and will be excluded in upcoming trials, see www.clinicaltrials.gov), because of 
potential dangerous drug-drug interactions. This may limit generalizability, considering that 
in routine clinical care many PTSD patients receive psychotropic medication, including SSRI’s, 
prior to the start of psychological treatment. For instance, in a large randomized clinical trial, 
over 75% of the participants were receiving psychotropic medication at baseline (Schnurr et 
al., 2007).
General discussion
In this article we reviewed the clinical data on treatment enhancement of exposure based 
therapies in PTSD patients. Enhancement of learning processes during exposure therapy is an 
emerging research field and shows promise in improving treatment efficacy for PTSD. Reviewing 
the literature to date also revealed some challenges for future research, discussed below.
 Focusing on those enhancers that were given in addition to exposure based treatment 
sessions in patients suffering from PTSD, resulted in the review of four different pharmacological 
enhancers. The early stage of exposure treatment enhancement studies is reflected in the 
reviewed studies, which could largely be considered pilot work. Only a few studies were 
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randomized clinical trials with adequate blinding and sample size (DCS: De Kleine et al., (2012); 
Litz et al. (2012); MDMA: Oehen et al (2013)). All studies differed from one another in greater 
or lesser extent, so that, to date, no study has been fully replicated. Further, the studies on 
MDMA were supported by one association (MAPS, multidisciplinary association of psychedelic 
studies) and the same research group conducted all the studies on propranolol enhancement. 
For most enhancers the empirical evidence is still limited and conclusions on efficacy are 
premature. Similarly, a conclusion about which enhancer has the most potential to enhance 
exposure therapy effects in PTSD patients cannot be drawn. To date, DCS has been studied 
most and proven efficacious across anxiety disorders, but results in PTSD studies were mixed, 
while for the other enhancers efficacy studies are still scarce. 
 Even though all reviewed studies paired the pharmacological agent to an exposure 
based treatment session, studies varied widely in the nature and amount of exposure, and 
only two studies paired the agent to a proven effective treatment strategy. De Kleine and 
colleagues (2012) paired DCS with prolonged exposure therapy (Foa & Rothbaum, 1998), 
and Yehuda and colleagues (2010) added hydrocortisone to prolonged exposure therapy. 
This variation in exposure dose is partly due to differences in proposed working mechanisms, 
extinction consolidation enhancement and/or reconsolidation blockage, which suggests 
respectively longer and shorter duration of trauma memory exposure. Note however, that 
even though extinction and reconsolidation are considered to be two distinct processes, there 
is also some evidence of overlapping properties (Parsons & Ressler, 2013), and it is not yet 
perfectly understood how both processes contribute to exposure therapy effects (Kindt & 
Soeter, 2013). We would like to encourage future enhancement trials to pair the cognitive 
enhancer with an empirically based treatment such as prolonged exposure therapy. Only then 
it can be established whether augmentation with cognitive enhancers is superior to already 
proven effective treatment strategies. In this line, we suggest that authors provide a detailed 
description of the psychological intervention in their enhancement studies reports, so that 
readers may be able to understand exactly what was administered and judge its quality and 
propriety. 
 Almost all reviewed studies reported outcome on the Clinician Administered PTSD Scale 
(CAPS) scores, which allowed us to compare studies on symptom decline over time. In some 
studies, the decline of CAPS scores was spectacular (≥ 50 points; Mithoefer, Wagner, Mithoefer, 
Jerome, & Doblin, 2011; Yehuda et al., 2010), and well exceeded those of non-enhanced 
exposure trials, but note that these enhancement studies were less well controlled. In addition 
to reporting overall CAPS scores, we would like to argue that future enhancement studies report 
scores for PTSD symptom clusters (reexperiencing, hyperarousal and avoidance symptoms) 
separately. The two reviewed studies on hydrocortisone, showed that hydrocortisone appears 
to be beneficial primarily via diminishment of avoidance behavior. It would be interesting 
to learn whether enhancers differ in their effects on different symptom clusters. This would 
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provide us with more information on possible mechanisms of action. Thinking about future 
directions for this field, it would be interesting to explore for which patients augmentation 
with a cognitive enhancer might be especially beneficial. Studies addressing individual 
differences (for instance: dissociative subtype of PTSD (American Psychiatric Association, 
2013), comorbidity, trauma type, personality features) may enhance our understanding of 
treatment efficacy and ultimately contribute to treatment matching strategies.
 Reflecting on the clinical utility of the cognitive enhancers, with the exception of MDMA, 
they seem to be safe and well tolerated. When used as a cognitive enhancer, the doses of 
DCS, hydrocortisone, and propranolol are relatively low and infrequent, while adverse effects 
of these pharmacological agents have been related to higher doses and frequent use. In 
this respect, they show advantage over exposure enhancement with SSRI’s (Schneier et 
al., 2012), with which adverse effects are commonly reported. Given the high incidence of 
alcohol abuse in PTSD patients (Mills et al., 2006), close monitoring of alcohol intake during 
enhanced exposure treatment is advised. Although alcohol abuse is not considered to be a 
contra-indication for exposure treatment in PTSD patients (Mills et al., 2012; van Minnen et al., 
2012) the potential hazardous drug-drug interactions call for caution. Additionally, the use of 
concurrent psychotropic medication, specifically SSRI’s, deserves extra attention in the light of 
exposure treatment enhancement. Considering that a large proportion of PTSD patients receive 
psychotropic medication, and that use of antidepressants (SSRI’s) is an exclusion criterion for 
enhancement studies with propranolol and MDMA, generalizability of findings with these 
cognitive enhancers, and ultimately clinical utility, are limited. Last, there is some data from 
DCS enhancement showing that augmentation can also have detrimental effects when 
sessions lack extinction. For safe use in clinical care, it is important to gather more information 
on potential undesirable outcomes. Therefore, we urge authors to report symptom worsening 
in participants as adverse effects and researchers to further investigate process variables that 
affect outcome.
 In the coming years the amount of studies in this exciting new field will expand quickly. 
New enhancers (yohimbine, oxytocin, methylene blue) will be studied, and previously studied 
enhancers will be examined in larger trials. A search in trial registries (www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu) reveals that large(r) clinical trials on DCS (N > 100), hydrocortisone 
(N = 60), and propranolol (N = 50) enhancement in PTSD patients are currently enrolling 
patients. Hopefully, translational designs will additionally provide us with more information 
on the mechanisms of action of exposure therapy (extinction and reconsolidation) and the 
possibility to enhance these processes with diverse pharmacological agents. 
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Table 1. Characteristics and outcome of reviewed enhancement studies
Author, 
year
Cognitive 
enhancer Population Study design Intervention
De Kleine 
et al., 2012
DCS Civilian, 
79% women, 
mixed-trauma
N = 67
RCT; 50 mg DCS or placebo 
60 minutes prior to (max) 9 
prolonged exposure sessions 
Prolonged Exposure; Imaginal exposure (30-
45 minutes) & exposure in vivo; homework 
assignments; 1 psycho-education and 9 
exposure sessions.
Litz et al., 
2012
DCS Veteran, male, 
N = 26
RCT; 50 mg DCS or placebo 30 
minutes prior to 4 exposure 
sessions
Brief exposure therapy; Imaginal exposure 
(50 minutes); 1 psycho-education, 4 
exposure and 1 relapse prevention session.
Bouso et 
al., 2008
MDMA Civilian, 
women, sexual 
assault, N = 6
RCT; 50 mg MDMA, 75 mg 
MDMA or placebo prior to 1 
experimental session
Confrontation with the traumatic event, 
discussion of narrative and new insights, 
experience based (6 hours); 1 session
Mithoefer 
et al. 2011
MDMA Civilian, 
85% women, 
mixed-trauma, 
N = 20
RCT; 125 mg (+ 62.5 mg)
MDMA or placebo prior to 2 
exposure based sessions 
Relaxation, experience based, introspection 
and discussion of experiences (8-10 hours); 
2 introductory sessions, 2 MDMA/placebo 
enhanced sessions, 4 integration sessions 
after each enhanced session (8 in total).* 
Oehen et 
al. 2013
MDMA Civilian, 
83% women, 
mixed-trauma, 
N = 12
RCT; 125 mg + 62.5 mg MDMA 
or active placebo 25 + 12.5 
mg MDMA prior to 3 exposure 
based sessions
Relaxation, experience based, introspection 
and discussion of experiences (8-10 hours); 
2 introductory sessions; 3 MDMA/active 
placebo enhanced sessions, 3 integration 
sessions after each enhanced session (9 in 
total).
Yehuda et 
al., 2010
Hydro-
cortisone
Veteran, male, 
N = 2
Controlled case study; 30 mg 
hydrocortisone or placebo 30 
minutes prior to 8 prolonged 
exposure sessions
Prolonged Exposure; Imaginal exposure (60 
minutes) & exposure in vivo; homework 
assignments; 2 psycho-education and 8 
exposure sessions. 
Suris et al., 
2010
Hydro-
cortisone
Veteran, male, 
N = 20
RCT; 4mg/kg hydrocortisone 
or placebo immediately 
after 1 memory reactivation 
session
Traumatic memory reactivation; written 
account of 2 “worst” traumatic memories; 1 
session.
Brunet et 
al., 2008
Propranolol Civilian, 52% 
women, mixed 
trauma, N = 19
RCT; 40 mg short-acting + 60 
mg long-acting propranolol; 
immediately after 1 traumatic 
reactivation session
Traumatic memory reactivation; written 
description of index trauma (20 minutes); 
1 session.
Brunet et 
al. 2011
Propranolol Civilian, 68% 
women, mixed 
trauma, N = 28
Open label; 0.67 mg/kg short-
acting + 1 mg/kg long-acting 
propranolol (modal dose resp. 
40 and 60 mg), 90 minutes 
prior to 6 sessions
Traumatic memory reactivation; reading 
aloud a written account of the index trauma 
(< 15-20 minutes); 6 sessions.
Propranolol Civilian, 71% 
women, mixed 
trauma, N = 7
Open label; 40 mg short-
acting + 80 mg long acting 
propranolol, 90 minutes prior 
to 6 sessions
Traumatic memory reactivation; renarrating 
an oral account of the index trauma (< 15-20 
minutes); 6 sessions.
Propranolol Civilian, 
71% women, 
disaster 
survivors, 
N = 7 (treated)
Open label; 40 mg short-
acting + 80 mg long acting 
propranolol 90 minutes prior 
to session 1, 80 mg long 
acting propranolol 90 minutes 
prior to sessions 2-6.
Traumatic memory reactivation; reading 
aloud a written account of the index trauma 
(< 15-20 minutes); 6 sessions.
*Additional integration sessions were permitted if needed. 7 participants in the MDMA group received additional sessions 
(20 sessions in total), compared to 1 participant (1session). Abbreviations: DCS: d-cycloserine; MDMA: ±3,4 -methylene-
dioxymethamphetamine; RCT: Randomized clinical trial; CAPS: Clinician Administered PTSD Scale; N/A: Not applicable; 
PSS-SR: Posttraumatic stress-scale Self-report; PCL: PTSD checklist; IES-R: Impact of event scale – revised form.
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Table 1. Characteristics and outcome of reviewed enhancement studies
Author, 
year
Cognitive 
enhancer Population Study design Intervention
De Kleine 
et al., 2012
DCS Civilian, 
79% women, 
mixed-trauma
N = 67
RCT; 50 mg DCS or placebo 
60 minutes prior to (max) 9 
prolonged exposure sessions 
Prolonged Exposure; Imaginal exposure (30-
45 minutes) & exposure in vivo; homework 
assignments; 1 psycho-education and 9 
exposure sessions.
Litz et al., 
2012
DCS Veteran, male, 
N = 26
RCT; 50 mg DCS or placebo 30 
minutes prior to 4 exposure 
sessions
Brief exposure therapy; Imaginal exposure 
(50 minutes); 1 psycho-education, 4 
exposure and 1 relapse prevention session.
Bouso et 
al., 2008
MDMA Civilian, 
women, sexual 
assault, N = 6
RCT; 50 mg MDMA, 75 mg 
MDMA or placebo prior to 1 
experimental session
Confrontation with the traumatic event, 
discussion of narrative and new insights, 
experience based (6 hours); 1 session
Mithoefer 
et al. 2011
MDMA Civilian, 
85% women, 
mixed-trauma, 
N = 20
RCT; 125 mg (+ 62.5 mg)
MDMA or placebo prior to 2 
exposure based sessions 
Relaxation, experience based, introspection 
and discussion of experiences (8-10 hours); 
2 introductory sessions, 2 MDMA/placebo 
enhanced sessions, 4 integration sessions 
after each enhanced session (8 in total).* 
Oehen et 
al. 2013
MDMA Civilian, 
83% women, 
mixed-trauma, 
N = 12
RCT; 125 mg + 62.5 mg MDMA 
or active placebo 25 + 12.5 
mg MDMA prior to 3 exposure 
based sessions
Relaxation, experience based, introspection 
and discussion of experiences (8-10 hours); 
2 introductory sessions; 3 MDMA/active 
placebo enhanced sessions, 3 integration 
sessions after each enhanced session (9 in 
total).
Yehuda et 
al., 2010
Hydro-
cortisone
Veteran, male, 
N = 2
Controlled case study; 30 mg 
hydrocortisone or placebo 30 
minutes prior to 8 prolonged 
exposure sessions
Prolonged Exposure; Imaginal exposure (60 
minutes) & exposure in vivo; homework 
assignments; 2 psycho-education and 8 
exposure sessions. 
Suris et al., 
2010
Hydro-
cortisone
Veteran, male, 
N = 20
RCT; 4mg/kg hydrocortisone 
or placebo immediately 
after 1 memory reactivation 
session
Traumatic memory reactivation; written 
account of 2 “worst” traumatic memories; 1 
session.
Brunet et 
al., 2008
Propranolol Civilian, 52% 
women, mixed 
trauma, N = 19
RCT; 40 mg short-acting + 60 
mg long-acting propranolol; 
immediately after 1 traumatic 
reactivation session
Traumatic memory reactivation; written 
description of index trauma (20 minutes); 
1 session.
Brunet et 
al. 2011
Propranolol Civilian, 68% 
women, mixed 
trauma, N = 28
Open label; 0.67 mg/kg short-
acting + 1 mg/kg long-acting 
propranolol (modal dose resp. 
40 and 60 mg), 90 minutes 
prior to 6 sessions
Traumatic memory reactivation; reading 
aloud a written account of the index trauma 
(< 15-20 minutes); 6 sessions.
Propranolol Civilian, 71% 
women, mixed 
trauma, N = 7
Open label; 40 mg short-
acting + 80 mg long acting 
propranolol, 90 minutes prior 
to 6 sessions
Traumatic memory reactivation; renarrating 
an oral account of the index trauma (< 15-20 
minutes); 6 sessions.
Propranolol Civilian, 
71% women, 
disaster 
survivors, 
N = 7 (treated)
Open label; 40 mg short-
acting + 80 mg long acting 
propranolol 90 minutes prior 
to session 1, 80 mg long 
acting propranolol 90 minutes 
prior to sessions 2-6.
Traumatic memory reactivation; reading 
aloud a written account of the index trauma 
(< 15-20 minutes); 6 sessions.
*Additional integration sessions were permitted if needed. 7 participants in the MDMA group received additional sessions 
(20 sessions in total), compared to 1 participant (1session). Abbreviations: DCS: d-cycloserine; MDMA: ±3,4 -methylene-
dioxymethamphetamine; RCT: Randomized clinical trial; CAPS: Clinician Administered PTSD Scale; N/A: Not applicable; 
PSS-SR: Posttraumatic stress-scale Self-report; PCL: PTSD checklist; IES-R: Impact of event scale – revised form.
Outcome (CAPS) Other outcome measure Comments
No significant time × group effects. 
Pretreatment: DCS: 61.8 Placebo: 73.8
Posttreatment (intent-to-treat; model means): 
DCS: 34.3 Placebo: 53.7 
Self-report (PSS-SR): no time 
× group differences.
Significant time × group effect, in favor of placebo. 
Pretreatment: DCS: 69.9 Placebo: 73.4
Posttreatment(intent-to-treat): DCS: 72.3 Placebo: 53.7
Self report (PCL):
Significant time × group 
effect, in favor of placebo.
No results 
available.
Significant time × group effect, in favor of MDMA. 
Pretreatment: MDMA: 79.2 Placebo: 79.6
Posttreatment: MDMA: 29.3 Placebo: 66.8 
Self-report (IES-R):
Significant time × group 
effect, in favor of MDMA. 
Results were 
maintained 
at follow-up 
(Mithoefer et al., 
2013)
No significant time × group effect.
Pretreatment: MDMA: 66.4 Placebo: 63.4
Posttreatment: MDMA: 50.8 Placebo: 66.5 
Self-report (IES-R):
Significant time × group 
effect, in favor of MDMA. 
Pretreatment: Hydrocortisone: 97.0 Placebo: 94.0
Posttreatment: Hydrocortisone: 43.0 Placebo: 52.0
Self report (PSS-SR):
more symptom decline in 
hydrocortisone treated than 
placebo treated patient.
N/A Self report (IES-R): 
Lower avoidance/
numbing symptoms in 
the hydrocortisone group 
compared to placebo.
N/A Physiological outcome: 
Lower heart rate and skin 
conductance in response to 
trauma script in propranolol 
group.
Pretreatment: Propranolol: 71.8
Posttreatment: Propranolol: 45.8
Self-report (PCL)
Decline of self-reported 
PTSD symptoms.
Pretreatment: Propranolol: 68.4
Posttreatment: Propranolol: 35.6
N/A
Self-report (PCL): More 
symptom decline in treated 
group than non-treated 
group.
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Introduction
This dissertation focused on augmentation of exposure therapy effects in posttraumatic stress 
disorder (PTSD). Prolonged exposure therapy (PE) is an effective treatment strategy for PTSD, 
and recommended as a first-line treatment in guidelines across the world. Notwithstanding 
its efficacy, not all PTSD patients benefit from exposure therapy. Consequently, it is pivotal to 
develop new treatment strategies that might enhance remission rates. Combining exposure 
therapy with other evidence based treatment strategies (i.e. medication or cognitive therapy) 
proved disappointing in augmenting treatment outcome. A novel line of research suggested 
that pharmacological enhancement of the underlying learning mechanisms of exposure 
therapy may be more fruitful in enhancing outcome. Specifically, these pharmacological 
agents are thought to augment extinction learning, which is a crucial mechanism of action of 
exposure therapy. In short, extinction refers to the process wherein a conditioned stimulus (CS; 
i.e., a trauma reminder) is repeatedly presented in absence of the unconditioned stimulus (US; 
i.e., the traumatic experience) thereby leading to reduction of the conditioned response (CR; 
i.e., fear). Importantly, extinction learning is believed to be the learning of a new CS - noUS 
association. We have examined the potential of d-cycloserine (DCS) as an adjunct to exposure 
therapy in PTSD, a drug proposed to enhance the consolidation of extinction learning. Further, 
we investigated for whom and under which conditions DCS augmentation might augment 
treatment effects. Given the centrality of extinction learning processes in this line of research, 
we critically reviewed the most used indicator of successful extinction learning during exposure 
therapy sessions, subjective unit of distress ratings (SUDs), and developed a new indicator 
of session success, harm expectancy violation. Lastly, we reviewed different pharmacological 
enhancers and focused on both their efficacy and clinical utility. In this chapter the results of 
these studies will be summarized and discussed, including their limitations, clinical implications 
and the directions for future work. Also, a general discussion of DCS enhancement of exposure 
therapy is provided.
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1. Summary and discussion of the empirical chapters
d-cycloserine augmentation of exposure therapy for PTSD:    
Does it enhance outcome?
In chapter 2 we reported the results of a randomized clinical trial designed to test the 
augmentation effects of DCS in exposure therapy for PTSD. We were able to include 67 
participants (mostly women and survivors of sexual abuse) and randomly allocated them to 
either DCS (50 mg) or placebo 60 minutes prior to weekly prolonged exposure (PE) sessions. 
In contrast to our expectations, DCS did not lead to better outcome on either self-reported 
or clinician administered PTSD symptoms. We did however find DCS enhancement effects 
in a subgroup of patients. Almost half of our group could end treatment before they had 
received all planned treatment sessions. We labeled this group early completers, and for 
them there were no additional effects of DCS. Arguably, because there was no room for 
enhancement: those who respond well and fast to exposure therapy might simply not need 
any boost. While for those who needed all planned treatment sessions (labeled regular 
completers) DCS augmentation led to superior outcome as compared to placebo. 
 First, let us discuss the lack of overall findings in our RCT. Our study was designed 
to test the additive effects of DCS on a full course of PE therapy. Although outcome is 
not perfect, we know that the dose of PE used in this study is highly effective (Powers et 
al., 2010). If we had established DCS enhancement effects we were safe to say that DCS 
administration could indeed improve this first-line treatment strategy, which would have 
been clinically a highly relevant finding. On the other hand, our full course of PE might 
have limited our chance of finding enhancement effects. We found good treatment 
outcome for exposure therapy regardless of drug condition, suggesting that there might 
have been no room left for DCS enhancement (the so called “ceiling-effect”). Alternatively, 
the full course of PE (1 introductory plus 9 exposure sessions) and matching amount of 
DCS administrations (9 times) might have nullified DCS effects. There is animal evidence to 
suggest that frequent administration of DCS leads to desensitization of the NMDA receptor 
and attenuates DCS effects (Quartermain et al., 1994). This has convinced researchers to 
minimize DCS administrations, either by investigating a truncated exposure protocol (e.g. 5 
sessions, Hofmann et al., 2006) or by administering DCS only to a limited amount of exposure 
sessions within a longer protocol (e.g. Otto et al., 2010). Note however, that up until now, we 
do not know which DCS dosing schedule would be most advantageous. On the one hand, we 
know that chronic, daily administration of DCS attenuates effects, and on the other hand we 
know that isolated (matched) dosing of DCS has the potential to enhance exposure therapy 
effects. But, what the optimal isolated dosing schedule would be remains to be established: 
is that weekly, bi-weekly, maximized to five dosages? Suggestions (e.g. Hofmann, 2014) that 
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too many DCS administrations are responsible for the lack of enhancement effects in clinical 
trials remain speculative, and are also contradicted by our finding of DCS enhancement 
effects in the regular completers subsample (which point more into the direction of the 
before mentioned ceiling effect).
 Our post hoc subgroup analysis provided a clinical valuable hypothesis: DCS might 
enhance treatment effects for those who failed to respond to exposure therapy. Although 
appealing, we cannot safely conclude this from our trial. The subgroups were defined based 
on their response to treatment. Although it appears that the early responders were not in 
need of DCS enhancement, we do not know what the outcome would have been if they had 
not received DCS. A new trial should be set up to investigate this, such that all patients start 
with regular (non-enhanced) PE, and only those who have not responded to treatment after 
a certain amount of exposure sessions are randomly allocated to receive DCS or placebo 
augmentation. Of course, this would require a large sample size, but it would provide 
guidance whether DCS is indeed most helpful for those who fail to respond to treatment. 
To date, only some pilot work suggests that DCS might indeed by especially beneficial to 
treatment non-responders (Farrell et al., 2013; Norberg, Gilliam, Villavicencio, Pearlson, & 
Tolin, 2012). Ideally, we would however be able to identify those who are likely to prosper 
from DCS administration prior to treatment.
d-cycloserine augmentation of exposure therapy for PTSD:    
For whom does it enhance outcome?
Chapter 3 was designed to investigate whether baseline characteristics could predict DCS 
enhancement effects. Besides PTSD symptom severity, we investigated general demographic 
variables, co-morbidity, depressive symptoms, antidepressant use and personality traits. None 
of the demographic variables predicted DCS enhancement effects, and neither did any of the 
clinical variables, including PTSD symptom severity. In fact, we found that two personality traits 
interacted with DCS administration. Specifically, DCS led to superior outcome for those low 
in extraversion and high in conscientiousness. Interestingly, in a large social phobia sample 
(Smits, Hofmann, et al., 2013) it was also found that personality traits (and no other variables) 
predicted DCS effects.
 Our finding that DCS effects are most pronounced in those low in extraversion can 
be related to prior work on the relationship between extraversion and extinction learning 
in healthy subject samples. Low extraverted individuals have been shown to show worse 
extinction learning memory (Rauch et al., 2005) and extraversion has been inversely related 
to brain regions thought crucial for extinction learning (Milad et al., 2005; Milad et al., 2007; 
Rauch et al., 2005). Granted that DCS is thought to enhance extinction learning consolidation, 
our finding might indicate that DCS acts as a rescue medication for those with extinction 
learning deficits.
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 As to why high conscientious patients might profit from DCS administration, there is 
little prior work or theory to guide hypotheses. High conscientious people are thoughtful, 
self-disciplined, dutiful and ordered. While often viewed as a positive trait and related to 
(academic) success, on the more extreme, conscientiousness may lead to cognitive rigidity. 
Although speculative, high conscientiousness individuals may display a more rigid thinking 
style, making people less amenable to new learning experiences. Given that extinction 
learning requires acquisition and stabilizing of a new CS-noUS contingency, tentatively, high 
conscientious people might be poor extinction learners. Our finding that DCS is especially 
beneficial for high conscientious patients might also point into the direction that DCS 
facilitates learning in those with impaired extinction learning capacity. 
 Ideally, we would have assessed individual characteristics more closely related to 
the proposed mechanisms of DCS. Although both extraversion and conscientiousness can 
be linked to extinction learning, they represent multi-faceted personality traits and not 
extinction learning as such. A baseline fear and extinction learning task would have been 
more fitting to assess extinction learning deficits and identify individuals who may merit from 
pharmacological enhancement with DCS. What is more, it would have provided crucial insight 
into the mechanism of action of exposure therapy. Note that, although it has been shown that 
extinction learning in anxiety disordered individuals (including PTSD) is impaired or delayed 
(see Duits et al., 2015 for review), we hardly know what the influence of such impaired 
extinction learning would be on exposure therapy outcome. Recently, it was demonstrated 
that brain activation during an extinction-learning task at pretreatment could successfully 
predict exposure therapy outcome in panic disordered patients (Hahn et al., 2015). But, more 
work should be done to clarify the influence of extinction learning capacity on exposure 
therapy outcome. Are those with extinction learning deficits the patients who do not benefit 
from exposure therapy? And, can we help these patients with cognitive enhancers like DCS? 
The findings of chapter 2 and 3 suggest that indeed those with low extinction learning 
capacity may benefit from DCS enhancement, but more work in this direction has to be done 
to establish personalized treatment indications. 
d-cycloserine augmentation of exposure therapy for PTSD:    
When does it enhance outcome?
While identifying prescriptive variables for DCS enhancement might identify individuals who 
are likely to benefit from DCS, another route to improve DCS efficacy may be to identify the 
optimal conditions for DCS to exert it effects. In other words, focusing on when DCS is likely to 
augment exposure therapy effects. DCS is thought to enhance the consolidation of extinction 
learning, i.e. to facilitate retention of what was learned during exposure sessions (i.e. the CS-no 
US association). Keeping this suggested working mechanism in mind; it makes perfect sense 
to expect DCS effects to be dependent on the amount of extinction learning during sessions. 
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If there is no extinction learning, there is nothing to retain and DCS administration is useless 
or even harmful because it might enhance consolidation of the original fear memory (CS-US 
association; Lee et al., 2006). Indeed, both animal (Bolkan & Lattal, 2014; Bouton et al., 2008; 
Weber et al., 2007) and clinical studies (Smits, Rosenfield, Otto, Marques, et al., 2013; Smits, 
Rosenfield, Otto, Powers, et al., 2013) found DCS effects to be specific for (training) sessions 
marked by succesful extinction learning. In these clinical studies, subjective ratings of distress 
(SUDs) were used to measure the subjective level of anxiety provoked by an exposure session, 
and low SUDs at the end of sessions was hypothesized to indicate successful extinction 
learning.
 In chapter 4, we however did not find evidence that DCS effects in our PTSD trial were 
subject to the degree of extinction learning during exposure sessions, as indexed by (change) 
in subjective fear ratings (SUDs). What might explain our divergent finding? Most likely it can 
be explained in light of the complexity of PTSD and the limitations of subjective fear ratings 
as an index of extinction learning within this population. First, PTSD is a heterogeneous 
disorder and not all symptoms (e.g. emotional numbness or loss of interest in activities) are 
fear-related. This might make it more difficult to establish extinction learning enhancement 
effects on weekly changes in PTSD symptoms. Second, as compared to simple phobia’s 
(acrophobia, speech phobia) SUDs ratings in PTSD are generally high and less likely to change 
within and over sessions (chapter 4; Bluett et al., 2014; van Minnen & Foa, 2006), which 
questions whether SUDs ratings in PTSD are equivalent to those in other anxiety disorders. 
Third, to align with previous studies in this field we used (a change in) SUDs ratings as an 
indicator of extinction learning. The intuitive idea is that a decline in SUDs rating – i.e. fear 
habituation - indicates successful extinction learning. Note however that in experimental 
studies, fear habituation during extinction training proved to be a poor marker of long-
term learning (Baker et al., 2010; Plendl & Wotjak, 2010; Prenoveau et al., 2013), and that 
the evidence for the predictive value of fear habituation for non-enhanced PE outcome is 
unstable (Bluett et al., 2014; Nacasch et al., 2015; van Minnen & Hagenaars, 2002). Although 
a decline in SUDs ratings may point to extinction learning, in essence SUDS measure fear 
expression, which is not equate to extinction learning (i.e. the new learning of a CS - noUS 
contingency). This questions whether SUDs ratings are a good indicator of the extinction 
learning process that is thought to be enhanced with DCS during PE. Perhaps a SUDs rating 
would be a more reliable indicator of extinction learning when completed by other indices of 
corrective learning, such as cognitive changes or physiological responding (e.g. heart rate or 
skin conductance).
 It has been suggested that DCS should be administered post session, and only after 
successful exposure sessions (Hofmann, 2014; Smits, Rosenfield, Otto, Powers, et al., 2013). 
But, up until now, there is no evidence for such a matching strategy in PTSD. An issue further 
complicated by the lack of a good definition of “session success” in exposure therapy for PTSD. 
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What defines “session success” in exposure therapy for PTSD?
If we want to selectively administer DCS to successful sessions only, we need valid indicators 
of exposure success. In chapter 4 we defined session success as a change in SUDs ratings (i.e. 
fear habituation), but given the caveats with this measure, there is a need for other indices of 
session success. Associative learning theories provide alternative ideas on the assessment of 
successful extinction learning during exposure therapy sessions. In short, harm expectancy 
is thought to play a crucial role in extinction learning. Specifically, extinction is thought to 
occur after a mismatch between the expectancy of an aversive event (US) and the absence of 
its occurrence (noUS; Gallistel & Gibbon, 2000; Rescorla & Wagner, 1972). In line, it has been 
suggested that successful learning during exposure therapy is signaled by a violation of harm 
(US) expectancies (instead of fear habituation; Craske et al., 2014; Hofmann, 2008). However, 
there was no clinical evidence that expectancy violation during exposure sessions indeed 
signals positive treatment outcome. Filling this gap, in chapter 5 we developed a measure to 
assess changes in harm expectancies during exposure therapy in PTSD. We examined whether 
exposure therapy leads to expectancy violation and whether these expectancy violations were 
a yardstick of session success. 
 In chapter 5, we demonstrated that harm expectancies were indeed prevalent prior to 
treatment. Patients feared that confrontation with their traumatic memories would lead to 
hazardous outcome, and they were most fearful of their own reactions to imaginal exposure 
(for instance, losing control or going crazy). In line with associative learning theory, harm 
expectancies were violated within and decreased between exposure therapy sessions. 
However, in contrast to recent suggestions, we did not find evidence that expectancy violation 
was related to PTSD symptom reduction following treatment.
 Of note, we developed a new measure to assess harm expectancy violation, and this 
measure may need refinement. Although are open-ended sentence completion task supported 
the relevance of the harm expectancies we assessed, it is well possible that harm expectancies 
changed over the course of treatment, and that personalized harm expectancy measures had 
captured patient’s danger expectancies better. Furthermore, we assessed harm expectancy 
and harm experience prior and post each imaginal exposure session, and these sessions 
were given on consecutive days. This treatment protocol has its advantage over weekly 
delivered exposure sessions in its better control over potential confounding variables (e.g. 
varying adherence to homework or session attendance), but it would also be interesting to 
learn whether harm expectancies change in similar fashion in a more time-spaced treatment 
program. Given that generalization of learning over different contexts and stimuli is an 
important condition for successful treatment outcome, it is highly relevant to examine whether 
patients can generalize their expectancy violation from context A (therapist’s office) to context 
B (their home environment) and from trauma reminder A (e.g. traumatic memory) to trauma 
reminder B (e.g. trauma related pictures). Last, it should be noted that assessment of harm 
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(US) expectancies are known to be subject to demand effects (Boddez et al., 2013), which 
suggests that explicit assessment of harm expectancies might incite patients to underrate their 
actual danger expectancies. Hypothetically, a more objective, physiological index of extinction 
learning (e.g. heart rate variability or fear potentiated startle) might better gauge successful 
extinction learning during exposure therapy, and be more predictive of treatment outcome.
 Fuelled by the unstable evidence for fear habituation as predictor of treatment outcome, 
the critique on the fear habituation model of exposure therapy is growing. Accordingly, it 
has been suggested that clinicians should no longer use fear habituation indices, but rather 
expectancy violation, to guide and evaluate exposure sessions (Craske et al., 2014). However, 
this clinical implication may be premature, and more research is warranted to examine 
expectancy violation as a mechanism of change in exposure therapy for PTSD.
Pharmacological enhancement of exposure therapy for PTSD:   
Is d-cycloserine the most promising candidate?
In chapter 6 we reviewed the clinical data on pharmacological treatment enhancement of 
exposure based therapies in PTSD. We reviewed four different enhancers: d-cycloserine; MDMA; 
hydrocortisone and propranolol. All in all, we concluded that pharmacological enhancement 
shows promise in enhancing treatment efficacy in PTSD, but we also observed challenges for 
future studies and clinical implementation. Since our review, more clinical trials have been 
published and in the following paragraphs the current state of the evidence for these four 
enhancers will be briefly discussed. 
 Focusing on DCS, our RCT was the first trial to examine enhancement effects of DCS when 
given in conjunction with exposure therapy in PTSD patients (chapter 2), and four trials have 
been published since. The results of these studies have been very mixed. The most profound 
enhancement effects were demonstrated by Difede and colleagues (2014), who found faster 
and more symptom decline for those receiving DCS as compared to placebo. In line with our 
findings, Rothbaum and colleagues (2014) failed to find overall enhancement effects of DCS 
compared to placebo and alprazolam, but did show that DCS reduced physiological reactivity to 
trauma relevant cues. In a pediatric sample, Scheeringa and Weems (2014) found no evidence 
of DCS facilitation. Importantly, Litz et al. (2012) actually observed negative effects for DCS 
augmentation of exposure treatment. Thus, at this point, it is difficult to draw any conclusion 
on DCS efficacy in PTSD. 
 As for the other enhancers, empirical studies investigating their efficacy are still scarce. 
While the initial findings of MDMA enhancement appeared promising (see chapter 6), more 
and larger controlled studies on MDMA enhanced treatment are necessary to draw reliable 
conclusions on its efficacy, but have not been conducted yet. At the time of our review, there 
was no empirical evidence for the beneficial effects of hydrocortisone enhancement of 
exposure therapy in PTSD other than a case-report. Since then, a small randomized placebo 
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controlled study (Yehuda et al., 2015) showed that hydrocortisone augmentation was related 
to greater reduction of PTSD symptoms compared to placebo, a finding driven by greater 
patient retention in the hydrocortisone group. Similarly, at the time of our review the evidence 
for propranolol enhancement in PTSD was still sparse. One study has been published since 
(Brunet et al., 2014), which was conducted by the same research group as the previous 
studies on propranolol enhancement in PTSD (see chapter 6). In line with previous findings, 
durable effects of propranolol on physiological responding to trauma related stimuli were 
found. Unfortunately, most studies on propranolol augmentation are not placebo controlled. 
Although the findings thus far are promising, a placebo controlled randomized clinical trial 
on propranolol enhancement in PTSD patients needs to confirm its potential as an effective 
enhancer of treatment effects. 
 With respect to their clinical utility, with the exception of MDMA, the reviewed 
pharmacological agents seem to be safe and well tolerated. When used as a cognitive 
enhancer, the doses of DCS, hydrocortisone, and propranolol are relatively low and infrequent, 
while adverse effects of these pharmacological agents have been related to higher doses 
and frequent use. Thus far, no serious side-effects with any of these enhancers have been 
published in the literature. More knowledge should be gathered on the interaction between 
these cognitive enhancers and psychotropic medication, specifically antidepressants. In DCS, 
animal studies showed that prior exposure to the antidepressant imipramine attenuates DCS 
effects (Werner-Seidler & Richardson, 2007), and a large trial in obsessive compulsive disorder 
found comparable results in humans (Andersson et al., 2015). Note however, that we did not 
find an interaction between antidepressant use and DCS in our PTSD trial (see chapter 3), but 
our study might have been underpowered to detect this effect. A large meta-analysis on this 
topic (including our data) is currently in preparation.
 To conclude, pharmacological enhancement of exposure therapy in PTSD often yields 
promise in enhancing treatment efficacy. Up until now, DCS has been the most studied 
cognitive enhancer, and proven efficacious in several meta-analyses across anxiety disorders, 
but findings in PTSD have been mixed. For the other enhancers the empirical evidence is still 
too limited to draw a conclusion on their efficacy. Consequently, a conclusion about which (if 
any) agent has the most potential to enhance exposure therapy effects in PTSD patients would 
be premature. Pharmacological enhancement of exposure therapy is an emerging research 
field, reflected by the fast growing amount of clinical studies that are being conducted. For 
instance, we await the results of a large scaled, four-armed DCS study comparing DCS and 
placebo in conjunction with either PE or Virtual Reality Exposure therapy (estimated N = 300; 
NCT01188694); a larger randomized controlled clinical trial on hydrocortisone augmentation 
of PE (est. N = 60; NCT01525680); a multi-site placebo controlled trial on propranolol 
enhancement of exposure based treatment (est. N = 56; NCT01713556); and several small 
scale clinical studies on MDMA efficacy and mechanisms in PTSD treatment (est. N = 10 to 
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N = 24; NCT01689740; NCT01793610; NCT01958593; NCT01211405; NCT02102802). In 
addition, new cognitive enhancers are being tested as enhancers of exposure therapy in PTSD. 
For instance, the augmentation effects of the drugs methylene blue and yohimbine (both 
shown to enhance exposure therapy effects in other anxiety disorders (Smits et al., 2014; Telch 
et al., 2014)), are currently being tested in PTSD patients (est. N = 42; NCT01188694; est. N 
= 60; NCT01031979, respectively). Furthermore, a clinical trial on enhancement of Virtual 
Reality Exposure therapy effects with dexamethasone, a cortisol suppressor, is currently being 
conducted (est. N = 60; NCT01031979). We also anxiously await the findings on a trial of 
oxytocin enhancement of exposure therapy in PTSD (est. N = 24; EudraCT 2012-003072-39). 
While there are theoretical grounds for oxytocin enhancement in PTSD (Olff et al., 2010) and 
experimental evidence to suggest that oxytocin might enhance extinction learning (Acheson et 
al., 2013), the first exposure enhancement study on oxytocin actually found impeding effects 
of oxytocin on exposure therapy outcome in specific phobia (Acheson, Feifel, Kamenski, 
McKinney, & Risbrough, 2015). Pharmacological enhancement of exposure therapy is an 
exciting new research field, and the coming years will learn us more about the potential of 
different pharmacological agents. Hopefully, this will provide guidance which agent has the 
most potential to potentiate treatment effects in PTSD. 
2. General discussion of d-cycloserine enhancement   
of exposure therapy
Is d-cycloserine augmentation of exposure therapy truly a translational 
success?
DCS has been often called a translational success: findings on DCS extinction learning 
enhancement effects in rats were relatively swift translated to a clinical application for anxiety-
disordered patients. More than a decade after the first proof-of-principle trial, the question 
arises whether we should still consider DCS augmentation a translational success-story. 
 Across anxiety disorders, multiple meta-analyses (Bontempo et al., 2012; Norberg et al., 
2008; Ori et al., 2015; Rodrigues et al., 2014) have now been conducted on DCS enhancement 
of exposure therapy, and while the first meta-analyses confirmed DCS potentiating effects, 
effect-sizes have declined over time, with the latest meta-analysis (Ori et al., 2015) even 
concluding that DCS does not improve exposure treatment. This faltering of effect may be 
due to the fact that the first studies on DCS enhancement were done in small samples, with 
truncated, well-controlled treatment protocols while later studies enrolled larger, more 
heterogeneous groups of patients over multiple sites, and participants were treated with 
standard (full) protocols. Statistically, small studies are likely to overestimate effects, which 
suggest that the later, bigger studies might better reflect DCS’ “true” effects. Thus, critics may 
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claim that DCS’ large initial effects reflect the novelty advantage: newly developed treatments 
appear highly effective at their introduction, but as time progresses, and the amount of studies 
increases, effect sizes wane. In defense, most studies found advantages for DCS over placebo: 
either overall enhancement, faster decline in symptoms, or effects for specific subgroups of 
patients. Furthermore, several potential moderators have been identified: DCS effects appear 
to be influenced in different patients samples by symptom severity (Siegmund et al., 2011), 
personality traits (this dissertation, chapter 3), antidepressant use (Andersson et al., 2015), and/
or the degree of extinction learning during treatment (Smits, Rosenfield, Otto, Marques, et al., 
2013; Smits, Rosenfield, Otto, Powers, et al., 2013, but note that in chapter 4 we failed to 
establish this moderating effect in PTSD). The moderating effects of these variables need to be 
confirmed in large datasets, preferably across disorders. Drawing the conclusion that DCS does 
not improve exposure therapy outcome, may be throwing out the good with the bad. 
 The quick translation of DCS administration from the animal lab to the clinic appears to 
be both a blessing and a curse, because many questions regarding the effective application 
of DCS in clinical care are yet unanswered. In its swift translation, an intermediate step of 
experimentally examining DCS effects in anxiety-disordered patients was bypassed. For 
instance, it was not systematically investigated whether DCS indeed enhanced extinction 
learning in anxiety disordered patients. Although this question was later addressed in 
reanalyses of clinical trial data (see also chapter 4), clinical trials do not have the optimal 
design to test hypotheses regarding DCS mechanisms. Ideally, the extinction enhancement 
hypothesis would have been tested in human experimental designs prior to testing DCS 
efficacy in clinical trials. An experimental design would allow to experimentally manipulate 
the amount of extinction learning (in analogue to animal studies; Bouton et al., 2008; Lee et al., 
2006), which would provide more direct evidence that DCS exerts its effects by enhancement 
of extinction learning in anxiety disordered patients. Suggestively, this research field could 
benefit from a step backwards in the translational paradigm (i.e. from the clinic back to the lab).
 Recently, attempts have been made to illuminate DCS indications and limitations in the 
clinical field. The successfully introduced clinical assay by Rodebough and colleagues (2013) 
is a noteworthy step in this direction. Given its costs- and time-effective design in comparison 
to clinical trials (2 exposure sessions instead of a full course of therapy), this assay may provide 
a favorable method to test DCS mechanisms. As an alternative to this assay, different research 
groups are currently collaborating on a large four armed clinical trial specifically designed 
to test the effect of dose timing (i.e. before or after exposure sessions) and the moderating 
effect of the amount of extinction learning during sessions (i.e. application based on successful 
extinction learning during sessions; est. N = 156; NCT02066792) on DCS effects in social 
anxiety disorders.
  All in all, DCS enhancement of exposure therapy shows promise in enhancing exposure 
therapy effects, but a decade of research has taught us that DCS enhancement is not a “one size 
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fits all” strategy. More work has to be done to illuminate the mechanisms of action and optimal 
parameters for DCS enhancement, since this may contribute to DCS’ success in enhancing 
exposure therapy outcome. 
Does d-cycloserine enhance extinction learning during exposure therapy 
for the anxiety disorders?
The proposed mechanism of action of DCS is enhancement of extinction learning consolidation. 
Translated to exposure therapy in PTSD, a patient learns that exposure to the feared trauma 
related stimulus (CS), does not lead to the anticipated harmful outcome (noUS) and the 
consolidation of this learning experience is amplified by DCS. Animal studies do indeed provide 
a solid basis for the extinction consolidation enhancement hypothesis of DCS and the central 
role of the amygdala in this (Ledgerwood et al., 2003; Walker et al., 2002). But in humans, 
attempts to enhance extinction learning in a de novo fear conditioning paradigm have failed 
(Guastella, Lovibond, Dadds, Mitchell, & Richardson, 2007; Klumpers et al., 2012). Explaining 
this incongruent findings, it has been argued that fear learning during a fear conditioning 
paradigm in humans is dependent on higher-order cognitive processes, whereas both fear 
conditioning in animals and exposure therapy in humans relies on automatic lower-order 
cognitive processes, and DCS is thought to enhance the latter (Grillon, 2009, see also Otto 
et al. in press). This explanation would however question the validity of the fear-conditioning 
paradigm as an experimental equivalent of exposure therapy, and distract from the translational 
work based on the fear conditioning literature. Another explanation for the null-findings of DCS 
enhancement in de novo fear conditioning might be that DCS might enable extinction learning 
in extinction resistant people (i.e. anxiety disordered patients), but not in healthy individuals 
with intact extinction learning capacities and normal NMDA functioning (Klumpers et al., 2012).
 A different viewpoint is that DCS mechanisms may go beyond extinction learning 
enhancement. Most studies on DCS so far implicate its efficacy as a cognitive enhancer of 
non-declarative fear memory. However, in animals it was shown hat DCS also facilitates 
hippocampal dependent learning tasks (L. T. Thompson, Moskal, & Disterhoft, 1992), and that 
DCS increases hippocampal plasticity (Yamamoto et al., 2008). Subsequently, work in healthy 
subjects suggests that DCS facilitates hippocampus-dependent declarative learning (Onur et 
al., 2010; but see Otto et al., 2009). Underlining DCS’ broader learning facilitating properties, 
DCS enhancement effects were found for non-exposure based therapy in psychotic disorders 
(Cain et al., 2014; Gottlieb et al., 2011), and trials investigating whether DCS can enhance 
cognitive therapy effects by facilitating memory in depressed individuals (NCT02376257) and 
those suffering from schizophrenia or schizophreniform disorder (NCT09181759) are currently 
enrolling participants.
 In parallel to the potential different mechanism of action of DCS, the mechanism of 
action of exposure therapy is not restricted to extinction learning: auxiliary mechanisms, such 
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as cognitive reappraisal, play an important role in exposure therapy effects. Combined, DCS 
augmentation effects of exposure therapy in the anxiety disorders are not necessarily restricted 
to extinction enhancement. The exact mechanisms of DCS in exposure therapy still need to be 
established, and a broader perspective on therapeutic learning could help this juvenile field 
forward. 
Are there non-pharmacological alternatives to d-cycloserine to enhance 
exposure therapy effects?
Although DCS administration is relatively safe, given in (very) small doses, and only matched 
with exposure sessions (i.e. weekly), administration of all pharmacological agents comes with 
disadvantages. Patients might be reluctant to take (yet another) drug, gains may be (falsely) 
attributed to the drug instead of the exposure therapy, and patients with somatic illness, 
substance abuse or concurrent medication use that co-interfere with the agent are excluded 
from treatment. Non-pharmacological interventions with the same mechanism of action – 
enhancement of learning and memory – may also improve exposure therapy effects and bypass 
the limitations of pharmacotherapy.
 The large body of work on experimental extinction learning provides some ideas about 
improving exposure therapy outcome by altering exposure procedures. A complete review of 
all the extinction enhancement procedures is beyond the scope of this discussion, and there 
are some good review articles on this topic available (Craske et al., 2014; Fitzgerald, Seemann, 
& Maren, 2014; Vervliet, Craske, & Hermans, 2013), but two strategies will be briefly discussed: 
massed extinction and deepened extinction. First, augmenting the amount of extinction trials 
(massed extinction) can strengthen the extinction memory and prevent the return of fear in 
rats (Denniston, Chang, & Miller, 2003). Whether, this also accounts for humans needs to be 
established. There is some evidence of a dose-response relationship with PE (Foa et al., 2005), 
but up until now, we do not know what the optimal amount of PE sessions would be. The 
length of the current PE protocol is based on clinical experience and insurance trade-off, but 
the most advantageous treatment length should be established in future work. Related, there 
is clinical evidence in phobic individuals that massed exposure is more effective than a series 
of short exposure of the same total duration (see Craske et al., 2008). This suggests that more 
condensed treatment programs might improve exposure efficacy. Indeed, as shown in chapter 
5, pilot work suggests that intensive exposure treatment can be an effective treatment strategy 
for PTSD (Hendriks, De Kleine, Hendriks, & Van Minnen, In press). But note that there is animal 
work to suggest that massed extinction may lead to superior short-term but inferior long-term 
learning (see for review Fitzgerald et al., 2014). Although this issue may be tackled by the 
inclusion of timely spaced booster sessions, future controlled trials should establish whether 
these massed exposure therapies are equally effective or even superior to the standard 
weekly-based exposure therapy protocols. A second strategy to enhance exposure therapy 
108 |
effects might be deepened extinction (Rescorla, 2000, 2006). In most disorders, fear memories 
are complex and consist elements of multiple sensory modalities. Deepened extinction refers 
to the procedure wherein conditioned stimuli are first extinguished in isolation, and then in 
compound. This has been shown to lead to better long time learning effects (Rescorla, 2006). 
Translated to the treatment of PTSD, this suggests that treatment effects may be augmented by 
compounding different conditioned stimuli within exposure sessions. For instance, to let the 
patient recount the traumatic memory, while concurrently being exposed to trauma-related 
smells or sounds (see for instance Hendriks et al., 2010; Rothbaum et al., 2014)
  Another alternative to pharmacological enhancement of learning may be to combine 
exposure therapy with behavioral interventions that enhance learning and memory. For instance, 
brain-derived neurotrophic factor (BDNF) is a vital protein for learning and memory. Physical 
exercise has been shown to significantly enhance BDNF levels in panic disordered patients 
(Strohle et al., 2010), and in rats, wheel running enhanced extinction learning, hypothetically 
by enhancing BDNF levels (Siette, Reichelt, & Westbrook, 2014). A recent small pilot-study 
wherein PTSD patients ran a treadmill before PE, showed large effects sizes that well exceeded 
previously reported effect sizes of standard PE (Powers et al., 2015). This promising pilot finding 
awaits further replication in a larger, controlled patient trial. In line, sleep is an important 
enhancer of learning and memory (Walker & Stickgold, 2006). Experimental studies showed 
that sleep enhanced the generalization of extinction learning (Pace-Schott et al., 2009) and 
exposure therapy in spider phobic individuals (Pace-Schott, Verga, Bennett, & Spencer, 2012). 
Hypothetically, letting patients sleep following PE session could augment extinction learning 
memory consolidation. However, given the frequent sleeping problems in PTSD patients, it is 
questionable whether this would be a feasible enhancement strategy in the clinical field. 
 In conclusion, the renewed attention for the basic learning principles underlying 
exposure therapy (i.e. extinction learning) opens up some interesting avenues for optimizing 
treatment efficacy. In line with pharmacological enhancement, therapeutic strategies to 
optimize extinction learning or behavioral enhancement may improve treatment efficacy in 
non-respondent PTSD patients.
General conclusion
The motivating force for his dissertation was to enhance exposure therapy efficacy in PTSD. 
Instead of developing new treatment strategies, we argued that it is best to take something 
with shown efficacy (i.e. PE) and attempt to improve efficacy for that treatment strategy. The 
novel paradigm of pharmacological enhancement of exposure therapy’s underlying learning 
mechanisms showed promise in enhancing exposure therapy effects. Given the strong 
preclinical proof and emerging evidence in anxiety disorders, d-cycloserine was the best 
candidate to augment exposure therapy in PTSD. We conducted the first randomized clinical 
trial on DCS enhancement of exposure therapy in PTSD, but did not find overall augmentation 
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effects. We did found DCS enhancement effects in a subgroup of patients that needed longer 
treatment. Furthermore, we found evidence for the influence of personality traits on DCS 
effects. Together these findings point to specific DCS enhancement effects in patients who are 
delayed or impaired in extinction learning. Future work should establish whether identifying 
those with impaired extinction learning at pretreatment enables predicting exposure therapy 
outcome, and whether these patients benefit from DCS augmentation before or after successful 
exposure sessions. Identifying those who are likely to fail to respond to exposure therapy, 
based on the underlying learning mechanisms of exposure therapy, is an important step 
towards personalized treatment, may reduce avoidable suffering, and ultimately enhance PTSD 
treatment efficacy. In addition, judicious application of DCS by restricting the administration to 
successful exposure sessions only is likely to amplify exposure enhancement effects. We did 
not find evidence for a DCS matching strategy based on the commonly used, but hampered 
measure for session success: fear habituation (SUDs). We developed a new indicator of exposure 
session success –harm expectancy validation – and demonstrated that while exposure therapy 
indeed promotes expectancy violation, this was not related to treatment outcome. To be able to 
selectively administer DCS in PTSD patients, more clinical work should be done to establish valid 
indicators of exposure session success. To conclude, there is accumulating evidence for specific 
indications and limitations for successful DCS augmentation. When taken these parameters into 
account, DCS may act as a rescue-medication for poor extinction learners. However, it needs to 
be established whether DCS can truly enhance exposure therapy efficacy in PTSD. 
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PTSS is een ernstige psychische aandoening
Na het meemaken van een traumatische gebeurtenis, zoals seksueel misbruik of fysiek geweld, 
ontwikkelen sommige mensen een posttraumatische stressstoornis (PTSS). Mensen die lijden 
aan PTSS hebben last van terugkerende herbelevingen aan de traumatische gebeurtenis, 
vertonen vermijdingsgedrag, hebben negatieve gedachten en gevoelens, en ervaren 
veranderingen in arousal en reactiviteit. Door deze klachten zijn zij minder goed in staat om 
thuis, op het werk of in hun sociale omgeving te functioneren. 
Exposuretherapie voor PTSS 
Eén van de meest effectieve behandelvormen voor PTSS is exposuretherapie. Exposure 
betekent letterlijk blootstelling. Een exposuretherapie voor PTSS bestaat eruit dat de patiënt 
zich blootstelt aan de herinneringen aan het trauma en aan situaties, plaatsen of dingen die 
hem of haar aan het trauma doen denken. Extinctieleren is een verondersteld onderliggend 
werkingsmechanisme van exposuretherapie. Een patiënt leert daarbij dat hetgeen hij of zij 
vreest niet leidt tot gevaar, maar in wezen ongevaarlijk is.
Een nieuw paradigma: Farmacologische versterking van onderliggende 
werkingsmechanismen 
Ondanks het feit dat exposuretherapie een effectieve behandeling is voor PTSS, is er ruimte 
voor verbetering. Niet alle patiënten knappen op van de behandeling. Door de onderliggende 
werkingsmechanismen van exposuretherapie, zoals extinctieleren, farmacologisch te 
versterken, is een geheel nieuwe manier ontstaan om de behandeleffectiviteit te verbeteren. 
Een medicijn wordt hierbij uitsluitend in combinatie met een exposuresessie gegeven om het 
werkingsmechanisme van de therapie te versterken. Het middel dat in dit kader als eerste 
werd onderzocht was d-cycloserine (DCS). DCS is een partiële agonist (versterker) van de bij 
extinctieleren betrokken N-methyl-d-aspartaat receptor. Het middel bleek al succesvol bij het 
afleren van angst bij dieren en bij het verbeteren van de effecten van exposuretherapie bij 
mensen met andere angststoornissen. Nog niemand had onderzocht of ook PTSS-patiënten 
baat konden hebben bij de combinatie van exposuretherapie en DCS. 
Het proefschrift 
Het doel van dit proefschrift was te onderzoeken of DCS van toegevoegde waarde kan zijn voor 
exposuretherapie bij PTSS-patiënten. In eerste instantie onderzochten wij of DCS de effecten van 
exposuretherapie kan verbeteren (hoofdstuk 2). Vervolgens hebben we onderzocht welke PTSS-
patiënten het meeste baat hebben bij de toevoeging van DCS (hoofdstuk 3). De aanname over 
DCS is dat het de effecten van exposuretherapie verbetert doordat het extinctieleren versterkt. 
In hoofdstuk 4 beschrijven wij ons onderzoek naar de invloed van de mate van extinctieleren 
op de effecten van DCS. Om extinctieleren tijdens de therapiesessie te meten keken wij in deze 
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studie naar een afname in subjectief ervaren angst van de patiënt. Het is echter de vraag of dat 
de meest optimale manier is om extinctieleren te meten. In hoofdstuk 5 beschrijven wij ons 
onderzoek naar een alternatieve manier om extinctieleren tijdens therapiesessies te meten. Tot 
slot, hebben wij in hoofdstuk 6 een overzicht gemaakt van de verschillende farmacologische 
middelen die momenteel worden onderzocht om onderliggende mechanismen van 
exposuretherapie te versterken bij PTSS-patiënten. 
De toegevoegde waarde van DCS aan exposuretherapie voor   
PTSS-patiënten
In de studie beschreven in hoofdstuk 2 onderzochten wij of DCS de effecten van 
exposuretherapie kan vergroten. 67 patiënten met een chronische PTSS werden bij toeval (at 
random) toegewezen aan één van twee behandelcondities: 1) exposuretherapie plus 50 mg 
DCS of 2) exposuretherapie plus placebo. De patiënten slikten een uur voorafgaand aan elke 
therapiesessie de pil. Vervolgens kregen zij exposuretherapie, waarbij zij zich blootstelden aan 
de herinneringen aan het trauma. Uit de resultaten bleek dat er geen significante verschillen in 
effecten waren tussen de groep die DCS kreeg (33 patiënten) en de groep die placebo kreeg 
(34 patiënten). Beide groepen patiënten knapten goed van de therapie op. Wat wij tijdens de 
studie merkten was dat veel patiënten al snel opknapten van de exposuretherapie. Wij hadden 
gepland dat alle patiënten negen exposuresessies zouden krijgen. Een aanzienlijk gedeelte van 
de patiënten kon echter al eerder met de therapie stoppen, omdat er geen klachten meer waren. 
Wij hebben vervolgens de groep patiënten die eerder met de exposuresessies kon stoppen 
vergeleken met de groep patiënten die alle exposuresessies nodig had. Voor de groep die snel 
kon stoppen constateerden wij geen verschil tussen degenen die DCS of placebo kregen. Zij 
werden snel beter, ongeacht of zij voorafgaand aan hun exposuresessie DCS of placebo kregen. 
Voor de groep patiënten die alle sessies nodig had vonden wij wel verschillen tussen DCS en 
placebo. Degenen die DCS kregen hadden aan het eind van de therapie minder klachten dan 
degenen die placebo kregen. Dit wijst erop dat DCS de behandeleffecten verbetert voor de 
PTSS-patiënten die aanvankelijk niet goed op de exposuretherapie reageren. 
Voor welke patiënten werkt de toevoeging van DCS het beste?
Idealiter zou men voorafgaand aan een exposuretherapie kunnen voorspellen of de patiënt 
van de DCS-toevoeging profiteert. Daarom onderzochten wij in een volgende studie 
(hoofdstuk 3) een aantal mogelijk voorspellende factoren. Wij vonden geen aanwijzingen 
dat demografische of klinische variabelen van invloed zijn op DCS-effecten. Wel vonden 
wij dat twee persoonlijkheidskenmerken de effecten van DCS beïnvloedden: naarmate de 
PTSS-patiënten meer consciëntieus en minder extravert waren, profiteerden zij meer van 
de toevoeging van DCS. Dit heeft mogelijk iets te maken met de samenhang tussen deze 
persoonlijkheidskenmerken en het extinctie-leervermogen van patiënten. 
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Beïnvloedt de mate van extinctieleren tijdens een exposuresessie   
het effect van DCS?
In een volgende studie (hoofdstuk 4) onderzochten wij of de mate van extinctieleren de 
effecten van DCS bij PTSS-patiënten beïnvloedt. Of er extinctieleren plaatsvond bepaalden 
wij aan de hand van subjectieve angstscores van de patiënt tijdens de exposuresessies. Een 
afname van angst tijdens de exposuresessie zou wijzen op extinctieleren. Wij vonden geen 
aanwijzingen dat het effect van DCS bij PTSS-patiënten beïnvloed wordt door de mate van 
extinctieleren. Echter, het is de vraag of wij met de afname van de angstscores tijdens de 
exposuresessies daadwerkelijk extinctieleren vaststelden. Aangenomen dat extinctieleren 
vooral gaat over het leren van een nieuwe associatie tussen de gevreesde stimulus enerzijds 
en de uitkomst anderzijds, wordt dit leerproces mogelijk niet goed gemeten door het navragen 
van angst tijdens de blootstelling aan de gevreesde stimulus. 
Het succes van een exposuresessie: Hoe kunnen wij vaststellen   
of er extinctieleren plaatsvindt?
In hoofdstuk 5 beschrijven wij de ontwikkeling van een nieuw instrument om extinctieleren 
tijdens exposuresessies te meten. Wij vroegen patiënten voorafgaand aan een exposuresessie 
waar zij bang voor waren wanneer zij zich bloot zouden stellen aan hun herinnering. Bijna alle 
patiënten vreesden dat zij gek zouden worden, de controle over zichzelf zouden verliezen of 
in paniek zouden raken. Vervolgens lieten wij patiënten voorafgaand aan elke exposuresessie 
aangeven in welke mate zij deze verwachtingen hadden, en na afloop van elke sessie in welke 
mate de gevreesde uitkomsten ook daadwerkelijk hadden plaatsgevonden. Uit deze studie 
bleek zoals verwacht dat patiënten voorafgaand aan de therapie weliswaar sterk verwachtten 
dat blootstelling aan de herinnering tot negatieve uitkomsten zal leiden, maar dat deze 
verwachtingen tijdens de therapie niet uitkwamen. Dit leereffect hing echter niet samen met 
het uiteindelijke behandelresultaat. Er moet daarom meer onderzoek worden gedaan naar 
goede instrumenten om extinctieleren tijdens exposuresessies vast te stellen. 
Alternatieven voor DCS: Zijn er andere middelen om de effecten   
van exposuretherapie bij PTSS-patiënten te vergroten?
Binnen het onderzoeksparadigma van de farmacologische versterking van de 
werkingsmechanismen van exposuretherapie is DCS het eerst onderzochte middel. Sindsdien 
zijn er meer middelen onderzocht, die elk verschillend werken. Al deze middelen worden net 
als DCS gegeven in combinatie met een exposuresessie, met als doel de behandeleffecten 
te vergroten. Wij maakten een overzicht van deze middelen (hoofdstuk 6) en stelden daarbij 
twee vragen: 1) Wat zijn de effecten van de toevoeging van het leerversterkende middel 
aan de behandeling bij PTSS-patiënten en 2) Is het middel toepasbaar in de klinische 
praktijk? In ons overzichtsartikel richtten wij ons op vier middelen: 1) d-cycloserine (DCS); 2) 
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3,4-methylenedioxymethamphetamine (MDMA; ‘ecstacy’); 3) hydrocortison; 4) propranolol.
Sinds onze studie naar de toegevoegde waarde van DCS aan exposuretherapie zijn er drie 
andere DCS-studies bij PTSS gepubliceerd. De effecten wisselden sterk: bij één studie werden 
sterk positieve resultaten gevonden, bij één studie geen resultaten en bij één studie negatieve 
resultaten. Het is op basis van deze studies dus niet vast te stellen of DCS de effecten van 
exposuretherapie bij PTSS kan vergroten. Het onderzoek naar de andere middelen is nog 
beperkt. Experimentele studies of kleine (ongecontroleerde) klinische studies tonen positieve 
effecten aan van MDMA, hydrocortison en propranolol. Maar ook bij deze middelen verschilt de 
effectiviteit per studie. Er is meer placebo-gecontroleerd onderzoek nodig om de werkzaamheid 
van deze middelen vast te kunnen stellen. DCS, hydrocortison en propranolol lijken alle drie 
veilig en goed toepasbaar in de klinische praktijk. Alcoholgebruik tijdens de behandeling is 
daarbij een belangrijk aandachtspunt, omdat veel PTSS patiënten alcohol gebruiken en dit 
in combinatie met de leerversterkende middelen potentieel gevaarlijk is. MDMA is minder 
geschikt voor de klinische praktijk. Los van het feit dat het gebruik van MDMA strafbaar is in de 
meeste landen, zijn er ernstige bijwerkingen van MDMA bekend en is medisch toezicht tijdens 
een met MDMA versterkte behandelsessie noodzakelijk. 
Conclusie 
Het doel van dit proefschrift was te onderzoeken of de effectiviteit van exposuretherapie 
voor PTSS kan worden verbeterd. Hoewel exposuretherapie een effectieve behandeling voor 
PTSS is, is er zeker nog ruimte voor verbetering. Uit dit proefschrift komt naar voren dat het 
leerversterkende middel d-cycloserine (DCS) mogelijk de effecten van exposuretherapie 
kan vergroten. DCS lijkt hierbij vooral van meerwaarde voor patiënten die minder goed 
of minder snel op exposuretherapie reageren. Het is voorstelbaar dat deze patiënten een 
beperkter vermogen tot extinctieleren hebben. Toekomstig onderzoek zal preciezer moeten 
vaststellen of patiënten met een verminderd vermogen tot extinctieleren minder goed van 
exposuretherapie kunnen profiteren én of wij juist die patiënten kunnen helpen met een 
leerversterkend middel als DCS.
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